Furoindazole derivatives

Abstract

The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals.

Description

FUROINDAZOLE DERIVATIVES The present invention covers furoindazole compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type II, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders. BACKGROUND The present invention covers furoindazole compounds of general formula (I) which are antagonists of the G-protein coupled receptor 84 (also known as GPR84). The relevance of GPR84 for human disease has been described and studied in several publications. Medium-chain free fatty acids (MCFFAs) are fatty acids with tails of 6 to 12 carbons and can activate GPR84 (Wang J et al., J. Biol. Chem. 2006 Nov 10, 281(45): 34457-64). There are two sources of FAs for animal metabolism, exogenously-derived (dietary) FAs and endogenously-synthesized FAs. The biosynthesis of the latter is catalysed by FASN. MCFFAs stimulate release of IL6 from fibroblasts (Smith and Tasi, Nat. Prod. Rep. 2007 Oct, 24(5): 1041-72) and myristic acid increases IL6 and IL8 levels in human coronary arterial smooth muscle (HCASM) and endothelial (HCEC) cells (Soto-Vaca A. et al., J. Agric. Food Chem. 2013 Oct 23, 61(42): 10074-9). GPR84 belongs to the group of Free Fatty Acid (FFA) receptors (Wang J. et al., J. Biol. Chem. 2006 Nov 10, 281(45): 34457-64). The group of FFA receptors consists of 4 GPCRs (FFA1-FFA2) and the new members GPR42 and GPR84. FFA receptors are involved in biological processes such as metabolic and immune function receptors (Wang J. etal, J. Biol. Chem. 2006 Nov 10, 281(45): 34457-64). In contrast to all other FFA receptors which have a broader expression pattern, GPR84 has been described to be expressed primarily in various leukocyte populations and adipocytes (Wang J. et al., J. Biol. Chem. 2006 Nov 10, 281(45): 34457-64; Lattin J.E. et al., Immunome Res. 2008 Apr 29, 4: 5; Nagasaki H. et al., FEBS Lett. 2012 Feb 17, 586(4): 368-72). Activation of GPR84 promotes a comprehensive fibrotic and inflammatory cellular response, exerted by enhanced migration of macrophages and neutrophils, promoted pro-inflammatory M1 macrophage polarization and response and secretion of key inflammatory cytokines such as IL1beta and TNFalpha (Gagnon L. et al., Am. J. Pathol. 2018 May, 188(5): 1132-1148; Muredda L. et al., Arch. Physiol. Biochem. 2018 May, 124(2): 97-108; Huang Q. et al., Dev. Comp. Immunol. 2014, 45(2): 252-258). Based on the involvement of GPR&4 in fibrotic and inflammatory cellular response several diseases have been suggested to be GPR84 dependent. GPR84 as microglia-associated protein is expressed in neuroinflammatory conditions and is described as a potential target for the treatment of multiple sclerosis (Bouchard C. etal., Glia 2007 Jun, 55(8): 790-800) and for endometriosis associated and inflammatory pain (Sacher F. et al. 2018, Conference Abstract SRI 2018). Furthermore, inhibition of activity and / or the knockout of GPR84 are also effective in the treatment of neuropathic pain in several preclinical models (Roman et al. 2010, 7th Forum of European Neuroscience (FENS)). The relevance of GPR84 for inflammatory kidney diseases has been shown in experiments using Gpr84-knockout mice or GPR84 antagonist in models of kidney fibrosis and models for inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases (Puengel et al. 2018, 2018 International Liver Congress (ILC) of the European Association for the Study of the Liver (EASL); Thibodeau J.F. et al. 2018, 51st Annual Meeting and Exposition of the American Society of Nephrology (ASN): Kidney Week 2018). As described previously for macrophages and monocytes, inflammatory changes in adipose tissue enhance expression of GPR84 in adipocytes and modulation of GPR84 regulates adipocyte immune response capabilites (Muredda et al, Archives of Physiology and Biochemistry 2017 Aug, 124(2): 1-12) indicating the relevance of GPR84 in metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type Il, and polycystic ovary syndrome (PCOS) through normalization of adipose tissue inflammation. Regulation of neutrophil activity and general inflammation by GPR84 was also described to be relevant for lung diseases like asthma, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (Nguyen et al. 2018; Annual Congress Scientific Sessions of the American Heart Association (AHA 2018); Saniere L. et al. 2019; 2019 International Conference of the American Thoracic Society (ATS)). Few compounds are known as GPR84 antagonists, for example the patent applications W02013092791 and WO2014095798 disclose dihydropyrimidinoisoquinolinones having activity as GPR84 antagonists. Such compounds find utility in several therapeutic applications including inflammatory conditions. The patent applications WO02015197550 and WQ2016169911 disclose related dihydropyridoisoquinolinones as GPR84 antagonists. The patent application W02018161831 discloses dibenzoannulen hydrogen phosphates as GPR84 antagonists. The patent application W02009023773 discloses galactokinase inhibitors that were identified by a high throughput screening approach. Among the identified hits were two furoindazole compounds. The patent application US20090163545 discloses compounds for altering the lifespan of eukaryotic organisms that were identified by a cell-based phenotypic high throughput screening approach. Among the identified hits were two furoindazole compounds. The patent applications US6245796B1, W02001083487 and W02011071136 disclose aromatic tricyclic pyrrole or pyrazole derivatives as 5-HT2c ligands. The patent application WO2016085990 discloses compounds inhibiting serine hydroxy- methyltransferase 2 activity that were identified by a high throughput screening approach. Among the identified hits were nine furoindazole compounds. The patent application WO2019084271 discloses compounds inhibiting the non- canonical poly(A) RNA polymerase associated domain containing protein 5 (PAPD5) originating from diverse compound classes that were identified by a high throughput screening approach. Among the identified hits were eight furcindazole compounds. However, the state of the art does not describe the furoindazole compounds of general formula (I) of the present invention as described and defined herein. It has now been found, and this constitutes the basis of the present invention, that the compounds of the present invention have surprising and advantageous properties. In particular, the compounds of the present invention have surprisingly been found to be effective antagonists of human GPR84 and may be used for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type Il, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders. DESCRIPTION In accordance with a first aspect, the present invention covers compounds of general formula (1): R72 R" 4 R Rk N—N rR? l 4 N—R rR N N 4 \ ¥ \ 0 1 I R 0 N- R R? I in which: R! represents hydrogen, Ci-Cs-alkyl or C4-Cq-haloalkyl: R? represents hydrogen, C1-C4-alkyl or Ci-Cs-haloalkyl: or R' and R? together with the carbon atom to which they are attached form a 3- to B6-membered cycloalkyl or heterocycloalkyl ring; R? represents Ci-Ce-cycloalkyl, 3- to 6-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or R? represents phenyl, which is optionally substituted, one or more times, independently of each other, with R®, and additionally R? and R represent deuterium; R* represents hydrogen, C+-Cs-alkyl, C4-Cs-haloalkyl or Cs-Ce-cycloalkyl; RS, R® represent, independently of each other, hydrogen, C-Cs-alkyl, C2-Ce- hydroxyalkyl, (C1-Ca-alkoxy)-(C2-Ca-alkyl)-, Cas-Ce-cycloalkyl, Cs-Cs-haloalkyl, Ca- Ce-halocycloalkyl, 3- to 8-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, heterocycloalkyl fused with phenyl or heteroaryl, 3- to 6- membered heterocycloalkyl-(C1-Ca-alkyl)-, heterospirocycloalkyl-(C-Ca-alkyl)-, (heterocycloalkyl fused with phenyl or heteroaryl)-(C+-Cs-alkyl)-, phenyl-(C1-Ca- alkyl)- or heteroaryl-(C-Ca-alkyl)-, wherein said 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R®, or RS and R® together with the nitrogen atom to which they are attached form a 3- to B6-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom or heteroatom containing group selected from O, NH and S, and which may be optionally substituted, one or more times, independently of each other, with R®: R™ represents hydrogen, deuterium, or Cs-Ce-alkyl: R™ represents hydrogen, deuterium, or Ci-Cs-alkyl; R® represents halogen, cyano, Ci-Cs-alkyl, C1-Cs-haloalkyl, C+-Ca-alkoxy, C1-Cs-haloalkoxy, Cs-Ce-cycloalkyl, Ca-Cs-cycloalkyl-(Ci-Cs-alkyl)-, R'3-(C=0)-, R'"-0-(C=0)-, R"-NH-(C=0)-, or R'2-(SO5)-; R® represents halogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, HoN-C1-Cs-alkyl, C1-Cs-alkoxy, Ci-Ca-haloalkoxy, Ca-Cs-cycloalkyl, R'°-O-(C=0)-, oxo, 5- to 6- membered heterocycloalkyl-, 5- to 8-membered heterocycloalkyl-(C1-Ca-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, C+- Cs-alkyl, C4-Cq-haloalkyl, C1-Cs-alkoxy, or C+-Cs-haloalkoxy: R'® represents hydrogen, C+-Cs-alkyl, or phenyl-CHa-; R" represents hydrogen, C1-Cs-alkyl, or 5- to 6-membered heterocycloalkyl-(C-Ca- alkyl)-; R'2 represents Ci-Cs-alkyl or phenyl: R™® represents Ci-Cs-alkyl, C1-Cs-haloalkyl, (C1-Cs-alkoxy)-(C1-Cs-alkyl)-, C1-Ca- alkyl-(C=0)-, Ca-Ce-cycloalkyl, or phenyl, wherein said Ca-Ce-cycloalkyl group is optionally substituted with C1-C4-alkyl or hydroxy and said phenyl group is optionally substituted, one or more times, independently of each other, with halogen, Ci-Cs-alkyl, C+-Cs-haloalkyl, Ci-Cs-alkoxy, or Ci-Ca-haloalkoxy; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. DEFINITIONS The term “substituted” means that one or more hydrogen atoms on the designated atom or group are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded. Combinations of substituents and / or variables are permissible. The term “optionally substituted” means that the number of substituents can be equal to or different from zero. Unless otherwise indicated, it is possible that optionally substituted groups are substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Commonly, it is possible for the number of optional substituents, when present, to be 1, 2, 3, 4 or 5, in particular 1, 2 or 3. As used herein, the term “one or more”, e.g. in the definition of the substituents of the compounds of general formula (I) of the present invention, means 1, 2, 3, 4 or 5, particularly 1, 2, 3 or 4, more particularly 1, 2 or 3, even more particularly 1 or 2. As used herein, an oxo substituent represents an oxygen atom, which is bound to a carbon atom via a double bond. Should a composite substituent be composed of more than one parts, e.g. (C4-Cs-alkoxy)-(C-Ca-alkyl)-, it is possible for the position of a given part to be at any suitable position of said composite substituent, i.e. the C1-Cs-alkoxy part can be attached to any carbon atom of the C+-Cqs-alkyl part of said (C+-Cs-alkoxy)-(C1-Ce-alkyl)- group. A hyphen at the beginning or at the end of such a composite substituent indicates the point of attachment of said composite substituent to the rest of the molecule. Should a ring, comprising carbon atoms and optionally one or more heteroatoms, such as nitrogen, oxygen or sulphur atoms for example, be substituted with a substituent, it is possible for said substituent to be bound at any suitable position of said ring, be it bound to a suitable carbon atom and / or to a suitable heteroatom. The term “comprising” when used in the specification includes “consisting of”. If within the present text any item is referred to as “as mentioned herein”, it means that it may be mentioned anywhere in the present text. The terms as mentioned in the present text have the following meanings: The term “halogen atom” means a fluorine, chlorine, bromine or iodine atom, particularly a fluorine, chlorine or bromine atom. The term “C+-Cq-alkyl” means a linear or branched, saturated, monovalent hydrocarbon group having 1, 2, 3, or 4 carbon atoms, e.g. a methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, isobutyl, tert-butyl. Particularly, said group has 1, 2, or 3 carbon atoms (“C4-Cs-alkyl”), e.g. a methyl, ethyl, propyl, or isopropyl group, more particularly 1 or 2 carbon atoms (“C1-Cz-alkyl”), e.g. a methyl or ethyl group. The term “C2-Cs-hydroxyalkyl” means a linear or branched, saturated, monovalent hydrocarbon group in which the term “Co-Cs-alkyl” is defined supra, and in which one hydrogen atom is replaced with a hydroxy group, e.g. a 1-hydroxyethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropan-2-yl, 2-hydroxypropan-2-yl, 3-hydroxy-2-methyl-propyl, 2-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl group. The term “Ci-Cs-haloalkyl” means a linear or branched, saturated, monovalent hydrocarbon group in which the term “C+-Cy-alkyl” is as defined supra, and in which one or more of the hydrogen atoms are replaced, identically or differently, with a halogen atom. Particularly, said halogen atom is a fluorine atom. Said Cs-Cs-haloalkyl group is, for example, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl or 1,3-difluoropropan-2-yl. The term “C4-Cs-alkoxy” means a linear or branched, saturated, monovalent group of formula (C+-Cs-alkyl)-O-, in which the term “Cs-Cs-alkyl” is as defined supra, e.g. a methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, or tert-butoxy group. The term “Cs-Cs-haloalkoxy” means a linear or branched, saturated, monovalent C+-Cq-alkoxy group, as defined supra, in which one or more of the hydrogen atoms is replaced, identically or differently, with a halogen atom. Particularly, said halogen atom is a fluorine atom. Said C+-Cs-haloalkoxy group is, for example, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy or pentafluoroethoxy. The term “Cs-Ce-cycloalkyl” means a saturated, monovalent, monocyclic hydrocarbon ring which contains 3, 4, 5, or 6 carbon atoms (‘Cs-Ce-cycloalkyl”). Said Ca-Ce-cycloalkyl group is for example, e.g. a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl group. The term “Cs-Ce-halocycloalkyl” means a saturated, monovalent, monocyclic hydrocarbon ring in which the term “Cs-Ce-halocycloalkyl” is as defined supra, and in which one or more of the hydrogen atoms are replaced, identically or differently, with a halogen atom. Particularly, said halogen atom is a fluorine atom. The term “4- to 6-membered heterocycloalkyl” means a monocyclic, saturated heterocycle with 4, 5 or 6 ring atoms in total, which contains one or two identical or different ring heteroatoms from the series N, O and S, it being possible for said heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, a nitrogen atom. Said heterocycloalkyl group, without being limited thereto, can be a 4-membered ring, such as azetidinyl, oxetanyl or thietanyl, for example; or a 5-membered ring, such as tetrahydrofuranyl, 1,3-dioxolanyl, thiolanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1,1-dioxidothiolanyl, 1,2-oxazolidinyl, 1,3-oxazolidinyl or 1,3-thiazolidinyl, for example; or a 6-membered ring, such as tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, 1,3-dioxanyl, 1,4-dioxanyl or 1,2-oxazinanyl, for example. Particularly, “4- to 6-membered heterocycloalkyl” means a 4- to 6-membered heterocycloalkyl as defined supra containing one ring nitrogen or oxygen atom and optionally one further ring heteroatom from the series: N, O, S. More particularly, “5- or 6-membered heterocycloalkyl” means a monocyclic, saturated heterocycle with 5 or 6 ring atoms in total, containing one ring nitrogen or oxygen atom and optionally one further ring heteroatom from the series: N, O. The term “heterocycloalkyl fused with phenyl or heteroaryl” means a bicyclic heterocycle with 8, 9 or 10 ring atoms in total, in which the two rings share two adjacent ring atoms, and in which the “heterocycloalkyl” part contains one or two identical or different ring heteroatoms from the series: N, O and / or S, and the term “heteroaryl” means a monocyclic aromatic ring having 5 or 6 ring atoms (a “5- to 6-membered heteroaryl” group), which contains at least one ring heteroatom and optionally one, two or three further ring heteroatoms from the series N, O and / or S; it being possible for said fused heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, a nitrogen atom. The term “heterospirocycloalkyl” means a bicyclic, saturated heterocycle with 6, 7, 8, 9, 10 or 11 ring atoms in total, in which the two rings share one common ring carbon atom, which “heterospirocycloalkyl” contains one or two identical or different ring heteroatoms from the series: N, O, S; it being possible for said heterospirocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms, except the spiro carbon atom, or, if present, a nitrogen atom. Said heterospirocycloalkyl group is, for example, azaspiro[2.3]hexyl, azaspiro[3.3]heptyl, oxaazaspiro[3.3]heptyl, thiaazaspiro[3.3]heptyl, oxaspiro[3.3]heptyl, oxazaspiro[5.3]nonyl, oxazaspiro[4.3]octyl, azaspiro[4,5]decyl, oxazaspiro [5.5]undecyl, diazaspiro[3.3]heptyl, thiazaspiro[3.3]heptyl, thiazaspiro[4.3]octyl, azaspiro[5.5]undecyl, or one of the further homologous scaffolds such as spiro[3.4]-, spiro[4.4]-, spiro[2.4]-, spiro[2.5]-, spiro[2.6]-, spiro[3.5]-, spiro[3.6]-, spiro[4.5]- and spiro[4.6]-. The term “heteroaryl” means a monovalent, monocyclic, bicyclic or tricyclic aromatic ring having 5, 6, 8, 9, or 10 ring atoms (a “5- to 10-membered heteroaryl” group), particularly 5, 8, 9 or 10 ring atoms, which contains at least one ring heteroatom and optionally one, two or three further ring heteroatoms from the series: N, O and / or S, and which is bound via a ring carbon atom or optionally via a ring nitrogen atom (if allowed by valency). Said heteroaryl group can be a 5-membered heteroaryl group, such as, for example, thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl or tetrazolyl; or a 6-membered heteroaryl group, such as, for example, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl; or a tricyclic heteroaryl group, such as, for example, carbazolyl, acridinyl or phenazinyl; or a 9- membered heteroaryl group, such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzothiazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl, indolizinyl or purinyl; or a 10-membered heteroaryl group, such as, for example, quinolinyl, quinazolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinoxalinyl or pteridinyl. In general, and unless otherwise mentioned, the heteroaryl groups include all possible isomeric forms thereof, e.g.: tautomers and positional isomers with respect to the point of linkage to the rest of the molecule. Thus, for some illustrative non-restricting examples, the term pyridinyl includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; or the term thienyl includes thien-2-yl and thien-3-yl. Particularly, the heteroaryl group is a pyridinyl group. The term “C-Cs”, as used in the present text, e.g. in the context of the definition of “Ci-Ce-alkyl”, “C4-Ce-haloalkyl”, “C4-Ce-hydroxyalkyl”, “C4-Ce-alkoxy” or “C1-Ce-haloalkoxy” means an alkyl group having a finite number of carbon atoms of 1 to 8, ie. 1,2 3, 4, 5o0r6 carbon atoms. Further, as used herein, the term “Ca-Cs”, as used in the present text, e.g. in the context of the definition of “Cs-Ce-cycloalkyl”, means a cycloalkyl group having a finite number of carbon atoms of 3to 8, i.e. 3, 4, 5, 8, 7 or 8 carbon atoms. When a range of values is given, said range encompasses each value and sub-range within said range. For example: "C+-Ce" encompasses C+, Cz, Cs, Cs, Cs, Cs, C1-Cs, C+-Cs, C1-C4, C1-Cs, C+-Cz, C2-Ce, Co- Cs, C2-Cs, C2-Cs, Ca-Cs, C3-Cs, Ca-C4, C4-Cs, C4-Cs, and Cs-Cs; "C2-Ce" encompasses Cz, Ci, Cs Cs, Cs, C2-Cs, C2-Cs, C2-Cs, C2-Cs, C3-Cs, Cs-Cs, Ca-C4, C4-Cs, Cs-Cs, and Cs-Ce: "Cs-C10" encompasses Cs, C4, Cs, Cs, C7, Cs, Co, Cio, Ca-Cio, Ca-Cs, Cs-Cs, Ca-Cy, Cs-Cs, C3-Cs, Ca-C4, C4-Cio, C4-Cs, C4-Cs, C4-C7, C4-Cs, C4-Cs, Cs-C1o, Cs-Co, Cs-Cs, Cs-C7, Cs-Cs, Ce-C1o, Ce-Co, Ce-Ce, Ce-C7, C7-C1o, Cr7-Co, C7-Cs, Cs-C10, Ce-Co and Co-Cio; "Cs-Cg" encompasses Cs, C4, Cs, Cs, C7, Cs, C3-Cs, C3-C7, C3-Cs, C3-Cs, Ca-Ca, C4-Cs, Ca C7, C4-Cs, C4-Cs, Cs-Cs, Cs-C7, Cs-Cs, Cs-Cs, Ce-C7 and C7-Cg: "Ca-Ce" encompasses Cs, C4, Cs, Cs, Ca-Cs, C3-Cs, Ca-Cs, C4-Cs, C4-Cs, and Cs-Ce; "C4-Ce" encompasses Cs, Cs, Cs, C7, Cs, C4-Cs, C4-C7, C4-Cs, C4-Cs, Cs-Cs, Cs-Cr, Cs-Cs, Cs-Cs, Ce-C7 and C+-Cs; "C4-C7" encompasses Cs, Cs, Cs, C7, C4-C7, C4-Co, C4-Cs, Cs-C7, C5-Cs and Ce-Cr; "C4-Cs" encompasses Cs, Cs, Cs, C4-Cs, C4-Cs and Cs-Ce: "Cs-C10" encompasses Cs, Ce, C7, Cg, Co, C10, Cs-Cio, Cs5-Co, C5-Cs, Cs-C7, C5-Cs, Ce-Cro, Ce-Cg, Cs-Cs, Ce-C7, C7-C1o, C7-Cg, C7-Cs, Ce-C1o, Ce-Co and Cg-Cio: "Ce-C10" encompasses Cs, Cr, Cs, Co, C10, Ce-Co, Ce-Ce, Ce-Cs, Co-C7, C7-Cio, Cr-Ce, Cr- Cs, Cs-C10, Ce-Cg and Ce-Cio. As used herein, the term “leaving group” means an atom or a group of atoms that is displaced in a chemical reaction as stable species taking with it the bonding electrons. In particular, such a leaving group is selected from the group comprising: halide, in particular fluoride, chloride, bromide or iodide, (methylsulfonyl)oxy, [(trifluoromethyl)sulfonylloxy, [(nonafluorobutyl)sulfonyl]oxy, (phenylsulfonyl)oxy, [(4-methylphenyl)sulfonyl]oxy, [(4-bromophenyl)sulfonyl]oxy, [(4-nitrophenyl)sulfonyl]oxy, [(2-nitrophenyl)sulfonyl]oxy, [(4-isopropylphenyl)sulfonylJoxy, [(2,4,6-triisopropylphenyl)sulfonyl]oxy, [(2,4,6-trimethylphenyl)sulfonyl]oxy, [(4-tert-butylphenyl)sulfonylloxy and [(4-methoxyphenyl)sulfonyl]oxy. Itis possible for the compounds of general formula (1) to exist as isotopic variants. The invention therefore includes one or more isotopic variant(s) of the compounds of general formula (I), particularly deuterium-containing compounds of general formula (1). The term “Isotopic variant” of a compound or a reagent is defined as a compound exhibiting an unnatural proportion of one or more of the isotopes that constitute such a compound. The term “Isotopic variant of the compound of general formula (I)’ is defined as a compound of general formula (I) exhibiting an unnatural proportion of one or more of the isotopes that constitute such a compound. The expression “unnatural proportion” means a proportion of such isotope which is higher than its natural abundance. The natural abundances of isotopes to be applied in this context are described in “Isotopic Compositions of the Elements 1997", Pure Appl. Chem., 70(1), 217-235, 1998. Examples of such isotopes include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2H (deuterium), *H (tritium), 11C, °C, C, ®N, 170, 80, 3p, ¥p, ¥g, #5, 3g, Bg, 18F 3¥C|, s2gy 129) 124) 125) 128] gng 131 respectively. With respect to the treatment and / or prophylaxis of the disorders specified herein the isotopic variant(s) of the compounds of general formula (I) preferably contain deuterium (“deuterium-containing compounds of general formula (I)"). Isotopic variants of the compounds of general formula (I) in which one or more radioactive isotopes, such as *H or '*C, are incorporated are useful e.g. in drug and / or substrate tissue distribution studies. These isotopes are particularly preferred for the ease of their incorporation and detectability. Positron emitting isotopes such as '8F or ''C may be incorporated into a compound of general formula (I). These isotopic variants of the compounds of general formula (I) are useful for in vivo imaging applications. Deuterium-containing and '*C- containing compounds of general formula (I) can be used in mass spectrometry analyses in the context of preclinical or clinical studies. Isotopic variants of the compounds of general formula (I) can generally be prepared by methods known to a person skilled in the art, such as those described in the schemes and / or examples herein, by substituting a reagent for an isotopic variant of said reagent, preferably for a deuterium-containing reagent. Depending on the desired sites of deuteration, in some cases deuterium from DO can be incorporated either directly into the compounds or into reagents that are useful for synthesizing such compounds. Deuterium gas is also a useful reagent for incorporating deuterium into molecules. Catalytic deuteration of olefinic bonds and acetylenic bonds is a rapid route for incorporation of deuterium. Metal catalysts (i.e. Pd, Pt and Rh) in the presence of deuterium gas can be used to directly exchange deuterium for hydrogen in functional groups containing hydrocarbons. A variety of deuterated reagents and synthetic building blocks are commercially available from companies such as for example C / D / N Isotopes, Quebec, Canada; Cambridge Isotope Laboratories Inc., Andover, MA, USA; and CombiPhos Catalysts, Inc., Princeton, NJ, USA. The term “deuterium-containing compound of general formula (I)’ is defined as a compound of general formula (1), in which one or more hydrogen atom(s) is / are replaced by one or more deuterium atom(s) and in which the abundance of deuterium at each deuterated position of the compound of general formula (1) is higher than the natural abundance of deuterium, which is about 0.015%. Particularly, in a deuterium-containing compound of general formula (1) the abundance of deuterium at each deuterated position of the compound of general formula (1) is higher than 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80%, preferably higher than 90%, 95%, 96% or 97%, even more preferably higher than 98% or 99% at said position(s). It is understood that the abundance of deuterium at each deuterated position is independent of the abundance of deuterium at other deuterated position(s). The selective incorporation of one or more deuterium atom(s) into a compound of general formula (I) may alter the physicochemical properties (such as for example acidity [C. L. Perrin, et al., J. Am. Chem. Soc., 2007, 129, 4490], basicity [C. L. Perrin et al., J. Am. Chem. Soc., 2005, 127, 9641], lipophilicity [B. Testa et al., Int. J. Pharm., 1984, 19(3), 271]) and / or the metabolic profile of the molecule and may result in changes in the ratio of parent compound to metabolites or in the amounts of metabolites formed. Such changes may result in certain therapeutic advantages and hence may be preferred in some circumstances. Reduced rates of metabolism and metabolic switching, where the ratio of metabolites is changed, have been reported (A. E. Mutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102). These changes in the exposure to parent drug and metabolites can have important consequences with respect to the pharmacodynamics, tolerability and efficacy of a deuterium-containing compound of general formula (I). In some cases, deuterium substitution reduces or eliminates the formation of an undesired or toxic metabolite and enhances the formation of a desired metabolite (e.g. Nevirapine: A. M. Sharma et al., Chem. Res. Toxicol., 2013, 26, 410; Efavirenz: A. E. Mutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102). In other cases, the major effect of deuteration is to reduce the rate of systemic clearance. As a result, the biological half-life of the compound is increased. The potential clinical benefits would include the ability to maintain similar systemic exposure with decreased peak levels and increased trough levels. This could result in lower side effects and enhanced efficacy, depending on the particular compound's pharmacokinetic / pharmacodynamic relationship. ML-337 (C. J. Wenthur et al, J. Med. Chem. 2013, 56, 5208) and Odanacatib (K. Kassahun et al, W02012 / 112363) are examples for this deuterium effect. Still other cases have been reported in which reduced rates of metabolism result in an increase in exposure of the drug without changing the rate of systemic clearance (e.g. Rofecoxib: F. Schneider et al., Arzneim. Forsch. / Drug. Res., 2006, 56, 295; Telaprevir: F. Maltais et al., J. Med. Chem., 2009, 52, 7993). Deuterated drugs showing this effect may have reduced dosing requirements (e.g. lower number of doses or lower dosage to achieve the desired effect) and / or may produce lower metabolite loads. A compound of general formula (I) may have multiple potential sites of attack for metabolism. To optimize the above-described effects on physicochemical properties and metabolic profile, deuterium-containing compounds of general formula (I) having a certain pattern of one or more deuterium-hydrogen exchange(s) can be selected. Particularly, the deuterium atom(s) of deuterium-containing compound(s) of general formula (I) is / are attached to a carbon atom and / or is / are located at those positions of the compound of general formula (1), which are sites of attack for metabolizing enzymes such as e.g. cytochrome Paso. Where the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like. By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The compounds of the present invention optionally contain one or more asymmetric centres, depending upon the location and nature of the various substituents desired. It is possible that one or more asymmetric carbon atoms are present in the (R) or (S) configuration, which can result in racemic mixtures in the case of a single asymmetric centre, and in diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, it is possible that asymmetry also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds. Preferred compounds are those which produce the more desirable biological activity. Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of the present invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art. Preferred isomers are those which produce the more desirable biological activity. These separated, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and / or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., HPLC columns using a chiral phase), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable HPLC columns using a chiral phase are commercially available, such as those manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ, for example, among many others, which are all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of the present invention can likewise be obtained by chiral syntheses utilizing optically active starting materials. In order to distinguish different types of isomers from each other reference is made to IUPAC Rules Section E (Pure Appl Chem 45, 11-30, 1976). The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g. (R)- or (S)- isomers, in any ratio. Isolation of a single stereocisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention is achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example. Further, it is possible for the compounds of the present invention to exist as tautomers. For example, any compound of the present invention which contains an indazole moiety can exist as a 1H tautomer, or a 2H tautomer, or even a mixture in any amount of the two tautomers, namely: H H 1H tautomer 2H tautomer The present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio. Further, the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides. The present invention also covers useful forms of the compounds of the present invention, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and / or co-precipitates. The compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example, as structural element of the crystal lattice of the compounds. It is possible for the amount of polar solvents, in particular water, to exist in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- efc. solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates. Further, it is possible for the compounds of the present invention to exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or to exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, which is customarily used in pharmacy, or which is used, for example, for isolating or purifying the compounds of the present invention. The term “pharmaceutically acceptable salt” refers to an inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19. A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, or “mineral acid’, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfamic, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic, 3-phenylpropionic, pivalic, 2-hydroxyethanesulfonic, itaconic, trifluoromethanesulfonic, dodecylsulfuric, ethanesulfonic, benzenesulfonic, para-toluenesulfonic, methanesulfonic, 2-naphthalenesulfonic, naphthalinedisulfonic, camphorsulfonic acid, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric, D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, or thiocyanic acid, for example. Further, another suitably pharmaceutically acceptable salt of a compound of the present invention which is sufficiently acidic, is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium, magnesium or strontium salt, or an aluminium or a zinc salt, or an ammonium salt derived from ammonia or from an organic primary, secondary or tertiary amine having 1 to 20 carbon atoms, such as ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, diethylaminoethanol, tris(hydroxymethyl)aminomethane, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, 1,2-ethylenediamine, N- methylpiperidine, N-methyl-glucamine, N,N-dimethyl-glucamine, N-ethyl-glucamine, 1,6- hexanediamine, glucosamine, sarcosine, serinol, 2-amino-1,3-propanediol, 3-amino-1,2- propanediol, 4-amino-1,2,3-butanetriol, or a salt with a quarternary ammonium ion having 1 to 20 carbon atoms, such as tetramethylammonium, tetraethylammonium, tetra(n- propyl)ammonium, tetra(n-butyl)ammonium, N-benzyl-N,N,N-trimethylammonium, choline or benzalkonium. Those skilled in the art will further recognise that it is possible for acid addition salts of the claimed compounds to be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the present invention are prepared by reacting the compounds of the present invention with the appropriate base via a variety of known methods. The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio. In the present text, in particular in the Experimental Section, for the synthesis of intermediates and of examples of the present invention, when a compound is mentioned as a salt form with the corresponding base or acid, the exact stoichiometric composition of said salt form, as obtained by the respective preparation and / or purification process, is, in most cases, unknown. Unless specified otherwise, suffixes to chemical names or structural formulae relating to salts, such as "hydrochloride", "trifluoroacetate”, "sodium salt", or "x HCI", "x CFsCOOH", "x Na*", for example, mean a salt form, the stoichiometry of which salt form not being specified. This applies analogously to cases in which synthesis intermediates or example compounds or salts thereof have been obtained, by the preparation and / or purification processes described, as solvates, such as hydrates, with (if defined) unknown stoichiometric composition. Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorph, or as a mixture of more than one polymorph, in any ratio. Moreover, the present invention also includes prodrugs of the compounds according to the invention. The term “prodrugs” here designates compounds which themselves can be biologically active or inactive but are converted (for example metabolically or hydrolytically) into compounds according to the invention during their residence time in the body. In accordance with a second embodiment of the first aspect, the present invention covers compounds of general formula (1), supra, in which: R! represents hydrogen, Ci-Cs-alkyl or C4-Cq-haloalkyl: R? represents hydrogen, C1-Cs-alkyl or C1-Cs-haloalkyl: or R' and R? together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl ring; R? represents Ci-Ce-cycloalkyl, 3- to 6-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or R? represents phenyl, which is optionally substituted, one or more times, independently of each other, with R®, and additionally R? and R represent deuterium; R* represents hydrogen, C+-Cs-alkyl, C4-Cs-haloalkyl or Cs-Ce-cycloalkyl; RS, R® represent, independently of each other, hydrogen, C-Cs-alkyl, C2-Ce- hydroxyalkyl, (C1-Ca-alkoxy)-(C2-Ca-alkyl)-, Cas-Ce-cycloalkyl, Cs-Cs-haloalkyl, Ca- Ce-halocycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, heteroaryl, heterocycloalkyl fused with phenyl or heteroaryl, 3- to 6-membered heterocycloalkyl-(C-Ca-alkyl)-, (heterocycloalkyl fused with phenyl or heteroaryl)-(C1-Ca-alkyl)-, phenyl-(C1-Ca-alkyl)- or heteroaryl-(Ci-Ca-alkyl)-, wherein said 3- to 8-membered heterocycloalkyl, phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with R?, or R® and R® together with the nitrogen atom to which they are attached form a 3- to B6-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom or heteroatom containing group selected from O, NH and S, and which may be optionally substituted, one or more times, independently of each other, with R%: R™ represents hydrogen, deuterium, or Ci-Cs-alkyl; R™ represents hydrogen, deuterium, or Ci-Cs-alkyl: R® represents halogen, cyano, Ci-Cs-alkyl, C1-Cs-haloalkyl, C+-Ca-alkoxy, C4-Ca-haloalkoxy, Cas-Ce-cycloalkyl, Ci-Cs-alkyl-(C=0)-, R'%-0-(C=0)-, R'"-NH- (C=0)-, or R'2(S0,)-; R® represents halogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, HaN-C4-Ce-alkyl, C4-Cs-alkoxy, C-Ca-haloalkoxy, Ca-Ce-cycloalkyl, R'%-O-(C=0)-, oxo, 5- to 6- membered heterocycloalkyl-, 5- to 6-membered heterocycloalkyl-(C1-Ca-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, Ci- Cq-alkyl, C1-Cs-haloalkyl, C4-Cs-alkoxy, or C+-Cs-haloalkoxy; R'® represents hydrogen, C+-Cs-alkyl, or phenyl-CHa-; R™ represents hydrogen, C+-Cs-alkyl, or 5- to 6-membered heterocycloalkyl-(C1-Cs- alkyl)-: R'2 represents Ci-C4-alkyl or phenyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In accordance with a third embodiment of the first aspect, the present invention covers compounds of general formula (1), supra, in which: R! represents hydrogen, Ci-Cs-alkyl or C4-Cq-haloalkyl: R? represents hydrogen or Ci-Cs-alkyl: or R' and R? together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl or heterocycloalkyl ring; R? represents Ci-Ce-cycloalkyl, 4- to 6-membered heterocycloalkyl, heterocycloalkyl fused with heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R®, or R? represents phenyl, which is optionally substituted, one or more times, independently of each other, with R®, and additionally R? and R represent deuterium; R* represents hydrogen, C+-Cs-alkyl, C4-Cs-haloalkyl or Cs-Ce-cycloalkyl; RS, R® represent, independently of each other, hydrogen, C2-Cs-hydroxyalkyl, (C1-Cs-alkoxy)-(C2-Cs-alkyl)-, 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, 4- to 6-membered heterocycloalkyl- (C4-Ca-alkyl)-, heterospirocycloalkyl-(C1-Ca-alkyl)-, (heterocycloalkyl fused with heteroaryl)-(C-Ca-alkyl)-, or heteroaryl-(C1-Cs-alkyl)-, wherein said 3- to 6- membered heterocycloalkyl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R®, or RS and R® together with the nitrogen atom to which they are attached form a 5-membered nitrogen containing heterocyclic ring, which may be optionally substituted, once with R®: R7 represents hydrogen, deuterium, or methyl: R™ represents hydrogen, deuterium, or methyl: R® represents halogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, C4-Ca-alkoxy, Ca-Ce- cycloalkyl, Ca-Cs-cycloalkyl-(C-Cs-alkyl)-, R'3-(C=0)-, R'%-0-(C=0)-, R''-NH- (C=0)-, or R'2(S0y)-; R® represents halogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, HoN-C1-Cs-alkyl, Ca-Ce- cycloalkyl, R'°-O-(C=0)-, oxo, 6-membered heterocycloalkyl-(C-Ca-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, Ci- Ca-haloalkyl, or Ci-Ca-alkoxy; R'® represents hydrogen, C+-Cs-alkyl, or phenyl-CHa-; R' represents 5- to 6-membered heterocycloalkyl-(C-Ca-alkyl)-; R'2 represents Ci-Cs-alkyl: R™ represents Ci-Cq-alkyl, (Ci-Cs-alkoxy)-(C1-Cs-alkyl)-, C+-Cs-alkyl-(C=0)-, Ca-Ce- cycloalkyl, or phenyl, wherein said Ca-Cs-cycloalkyl group is optionally substituted with methyl or hydroxy; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In accordance with a fourth embodiment of the first aspect, the present invention covers compounds of general formula (1), supra, in which: R! represents hydrogen, methyl or trifluoromethyl; R? represents hydrogen or methyl: or R' and R? together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; R?® represents cyclopropyl, 4- to 6-membered heterocycloalkyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R®, or R? represents phenyl, which is optionally substituted, one or more times, independently of each other, with R8, and additionally R? and R™ represent deuterium; R* represents hydrogen, methyl, Ci-haloalkyl or cyclopropyl; RS represents hydrogen; R® represents methoxy-ethyl, 5-membered heteroaryl, 4- to 6-membered heterocycloalkyl-(C-Cz-alkyl)-, heterospirocycloalkyl-methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yimethyl, or 5- to 6-membered heteroaryl-(C+- Cz-alkyl)-, wherein said 4- to 6-membered heterocycloalkyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R®: R™ represents hydrogen, deuterium, or methyl; R™ represents hydrogen, deuterium, or methyl; Re represents fluoro, chloro, Ci-Cz-alkyl, trifluoromethyl, C1-Cs-alkoxy, cyclopropyl, cyclopropylmethyl, R'*-(C=0)-, R'*-0-(C=0)-, R""-NH-(C=0)-, or R'-(SO)-; R® represents fluoro, chloro, C-Ca-alkyl, trifluoromethyl, cyclopropyl, or oxo; R'™ represents C-Cs-alkyl, or phenyl-CHaz-; RM represents 5- to 6-membered heterocycloalkyl-methyl; R'2 represents methyl: R™ represents methyl, methoxymethyl, ethyl-(C=0)-, cyclopropyl, or phenyl, wherein said cyclopropyl group is optionally substituted with methyl or hydroxy; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In accordance with a fifth embodiment of the first aspect, the present invention covers compounds of general formula (1), supra, in which: R! represents hydrogen or methyl; R? represents hydrogen or methyl: or and R? together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; represents cyclopropyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, oxetan-3-yl, oxolan-3-yl, oxolan-2-yl, 3-methyloxetan-3-yl, 3-fluorooxetan-3-yl, pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, oxan-4-yl, 1,4-dioxan-2-yl, 6-methylpyridin-3-yl, 5- methylpyridin-2-yl, 3-methylpyridin-2-yl, 2-methylpyridin-4-yl, 6-methylpyridin-2- yl, 3-chloropyridin-2-yl, 6-ethylpyridin-3-yl, 1-acetylpiperidin-4-yl, 3-chloro-5- ethoxypyridin-2-yl, 1-benzoylpiperidin-4-yl, or a group selected from: De I \ \, N bof oN HN: CHs 7 gs oe CH, 3 £5 CHy a AN PNG oO N. NN F A TNA SN | 1 fF _ dF 2 HC CHgy eof A Sp° © oy AN SN ~~ 1 L 2K" T HO AL CL A SN O° AN ~N ~~ J © i ZN " o HN ne Po AN Ly 0 , or ~~ , or R® represents phenyl, and additionally R7 and R™ represent deuterium; R* represents methyl, difluoromethyl, trifluoromethyl, or cyclopropyl; RS represents hydrogen; R® represents (oxolan-2-yl)methyl, (1,3-oxazol-4-yl)methyl, (1,2-oxazol-3-yl)methyl, (4-methyloxolan-2-yl)methyl, (pyrimidin-2-yl)methyl, (pyrazin-2-yl)methyl, (5- methyloxolan-2-yl)methyl, (5-methyloxolan-2-yl)methyl, (1,4-dioxan-2-yl)methyl, (4-methylphenyl)methyl, (5-methylpyrimidin-2-yl)methyl, (5-methylpyrazin-2- yl)methyl, (5-chloropyrazin-2-yl)methyl, (5-cyclopropyl-pyrazin-2-yl)methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl, 1,3-oxazol-2-ylmethyl, 1,3-thiazol-2- ylmethyl, (1-methyl-1H-pyrazol-3-yl)methyl, (1-methyl-1H-imidazol-4-yl)methyl, (5-isopropyl-1,2-oxazol-3-yl)methyl, (5-cyclopropyl-1,2-oxazol-3-yl)methyl, (5,5- dimethyltetrahydrofuran-2-yl)methyl, (4,4-difluorotetrahydrofuran-2-yl)methyl, (6,6-dimethyl-1,4-dioxan-2-yl)methyl, 5-oxaspiro[2.4]heptan-6-ylmethyl, or 2,6- dioxaspiro[3.4]octan-7-yimethyl; R™ represents hydrogen; R™ represents hydrogen; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. Further embodiments of the first aspect of the present invention: In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R! represents hydrogen, C1-Cs-alkyl or C1-Cs-haloalkyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R! represents hydrogen, methyl or trifluoromethyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R! represents hydrogen or C-Cs-alkyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R! represents hydrogen or C-Ca-alkyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R! represents hydrogen or methyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R? represents hydrogen, C1-Cs-alkyl or C1-Cs-haloalkyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R? represents hydrogen or C-Cs-alkyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R? represents hydrogen or C-Ca-alkyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R2 represents hydrogen or methyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R' and R? together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl ring; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R' and R? together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl ring; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R' and R? together with the carbon atom to which they are attached form a 3- to 5-membered cycloalkyl ring; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R' and R? together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: rR? represents Cs-Ce-cycloalkyl, 3- to 8-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with RE; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents Cs-Ce-cycloalkyl, 4- to 6-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or 5- to 6-membered heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R®; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents Cs-Ce-cycloalkyl, 4- to 6-membered heterocycloalkyl, heterocycloalkyl fused with heteroaryl, or 5- to 6-membered heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with RE; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents cyclopropyl, 4- to 6-membered heterocycloalkyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, or 5- to 6-membered heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with RS: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents Ca-Ce-cycloalkyl, 4- to 6-membered heterocycloalkyl, heterocycloalkyl fused with heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R®; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: rR? represents cyclopropyl, 4- to 68-membered heterocycloalkyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R®; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents cyclopropyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, oxetan-3-yl, oxolan-3-yl, oxolan-2-yl, 3-methyloxetan-3-yl, 3-fluorooxetan-3-yl, pyridin-4-yl, pyridin-3- yl, pyridin-2-yl, oxan-4-yl, 1,4-dioxan-2-yl, 8-methylpyridin-3-yl, 5-methylpyridin-2-yl, 3- methylpyridin-2-yl, 2-methylpyridin-4-yl, 6-methylpyridin-2-yl, 3-chloropyridin-2-yl, 6- ethylpyridin-3-yl, 1-acetylpiperidin-4-yl, 3-chloro-5-ethoxypyridin-2-yl, 1- benzoylpiperidin-4-yl, or a group selected from: de Il — NL N df I ¥ > oN HN CH V4 Le he, CHa 3 CH, A T po Na LW F A A F NN | 1 F = JF o HC. Ho > 1 AL yw CHy retort SN op° 1 NA A N ~~ £1 pL NT $2 CHy T HOS, A CL Ap p° N\, y N A ~~ ah: < #4 3 ZN XN © HN mm Po AN A hg , or and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents phenyl, which is optionally substituted, one or more times, independently of each other, with R®, and additionally R and R” represent deuterium; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents phenyl, which is optionally substituted, one or two times, independently of each other, with R®, and additionally R7 and R™ represent deuterium; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents phenyl, and additionally R7 and R™ represent deuterium; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R* represents hydrogen, Ci-Cs-alkyl, C4-Cy-haloalkyl or Ci-Ce-cycloalkyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R* represents hydrogen, C+-Cs-alkyl, C+-Ca-haloalkyl or Ca-Ce-cycloalkyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R* represents hydrogen, C+-Cs-alkyl, C+-Ca-haloalkyl or Ca-Cs-cycloalkyl and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R* represents hydrogen, methyl, C4-haloalkyl or cyclopropyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R* represents hydrogen, methyl, trifluoromethyl, or cyclopropyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R®, R® represent, independently of each other, hydrogen, C1-Cs-alkyl, C2-Cs- hydroxyalkyl, (C1-Cs-alkoxy)-(C2-Cs-alkyl)-, Cs-Ce-cycloalkyl, Ci-Cs-haloalkyl, Ca-Ce- halocycloalkyl, 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, heterocycloalkyl fused with phenyl or heteroaryl, 3- to 6-membered heterocycloalkyl-(C+-Cs-alkyl)-, heterospirocycloalkyl-(C:-Ca-alkyl)-, (heterocycloalkyl fused with phenyl or heteroaryl)-(C1-Cs-alkyl)-, phenyl-(C+-Cs-alkyl)- or heteroaryl-(C- Ca-alkyl)-, wherein said 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R®; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: RS, R® represent, independently of each other, hydrogen, C>-Cs-hydroxyalkyl, (C4-Cs-alkoxy)-(C2-Cs-alkyl)-, 3- to 8-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, 4- to 8-membered heterocycloalkyl-(C-Ca-alkyl)-, heterospirocycloalkyl-(C+-Cs-alkyl)-, (heterocycloalkyl fused with heteroaryl)-(C1-Ca- alkyl)-, or heteroaryl-(C+-Cs-alkyl)-, wherein said 3- to 6-membered heterocycloalkyl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R®: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R®, R® represent, independently of each other, hydrogen, Ci-Cs-alkyl, Co-Cs- hydroxyalkyl, (C+-Cs-alkoxy)-(C2-Cs-alkyl)-, Cs-Ce-cycloalkyl, Ci-Cs-haloalkyl, Ci-Ce- halocycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, heteroaryl, heterocycloalkyl fused with phenyl or heteroaryl, 3- to 6-membered heterocycloalkyl-(C:-Cs-alkyl)-, (heterocycloalkyl fused with phenyl or heteroaryl)-(C1-Cs-alkyl)-, phenyl-(C+-Cs-alkyl)- or heteroaryl-(C1-Cs-alkyl)-, wherein said 3- to 6-membered heterocycloalkyl, phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with R%: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® and R® together with the nitrogen atom to which they are attached form a 3- to 6-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom or heteroatom containing group selected from O, NH and S, and which may be optionally substituted, one or more times, independently of each other, with R®; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® and R® together with the nitrogen atom to which they are attached form a 5- to 6-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom or heteroatom containing group selected from O, NH and S, and which may be optionally substituted, one or more times, independently of each other, with R®; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® and R® together with the nitrogen atom to which they are attached form a 5- to 6-membered nitrogen containing heterocyclic ring, which may be optionally substituted, one or more times, independently of each other, with R®: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® and R® together with the nitrogen atom to which they are attached form a 5-membered nitrogen containing heterocyclic ring, which is substituted with aminomethyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents hydrogen; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents methoxy-ethyl, 5-membered heteroaryl, 4- to 5-membered heterocycloalkyl-(C-Cz-alkyl)-, heterospirocycloalkyl-methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl, or 5- to 6-membered heteroaryl-(C+-C2- alkyl)-, wherein said 4- to 5-membered heterocycloalkyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R®; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents (oxolan-2-yl)methyl, (1,3-oxazol-4-yl)methyl, (1,2-oxazol-3-yl)methyl, (4-methyloxolan-2-yl)methyl, (pyrimidin-2-yl)methyl, (pyrazin-2-yl)methyl, (5- methyloxolan-2-ylmethyl, (5-methyloxolan-2-yl)methyl, (1,4-dioxan-2-yl)methyl, (4- methylphenyl)methyl, (5-methylpyrimidin-2-ylmethyl, (5-methylpyrazin-2-yl)methyl, (5- chloropyrazin-2-yl)methyl, (5-cyclopropyl-pyrazin-2-yl)methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl, 1,3-oxazol-2-ylmethyl, 1,3-thiazol-2- ylmethyl, (1-methyl-1H-pyrazol-3-yl)methyl, (1-methyl-1H-imidazol-4-yl)methyl, (5- isopropyl-1,2-oxazol-3-yl)methyl, (5-cyclopropyl-1,2-oxazol-3-yl)methyl, (5,5- dimethyltetrahydrofuran-2-yl)methyl, (4,4-difluoroetrahydrofuran-2-yl)methyl, (6,6- dimethyl-1,4-dioxan-2-yl)methyl, 5-oxaspiro[2.4]heptan-6-yImethyl, or 2,6- dioxaspiro[3.4]octan-7-yimethyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents Ci-Cy-alkyl, Co-Cs-hydroxyalkyl, (C1-Cs-alkoxy)-(C2-Cs-alkyl)-, Cs-Ce- cycloalkyl, Ci-Cs-haloalkyl, Ca-Cs-halocycloalkyl, 3- to 8-membered heterocycloalkyl, phenyl, heteroaryl, heterocycloalkyl fused with phenyl or heteroaryl, 3- to 6-membered heterocycloalkyl-(C+-Ca-alkyl)-, (heterocycloalkyl fused with phenyl or heteroaryl)-(C+-Ca- alkyl)-, phenyl-(C+-Cs-alkyl)- or heteroaryl-(C+-Cs-alkyl)-, wherein said 3- to 8-membered heterocycloalkyl, phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with R®; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents Ci-Ca-alkyl, C2-Cs-hydroxyalkyl, (Ci-Ca-alkoxy)-(C2-Cs-alkyl)-, C-Cs- cycloalkyl, Ci-Ca-haloalkyl, 4- to 8-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl, heterocycloalkyl fused with heteroaryl, 4- to 6-membered heterocycloalkyl-(C+-Ca-alkyl)-, (heterocycloalkyl fused with heteroaryl)-(C+-Ca-alkyl)-, phenyl-(C+-Cs-alkyl)- or 5- to 8-membered heteroaryl-(C+-Cs-alkyl)-, wherein said 4- to 6-membered heterocycloalkyl, phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with R®: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents C,-C4-hydroxyalkyl, methoxy-(C2-Ce-alkyl)-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocycloalkyl-(C+-Cz-alkyl)-, (2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yl)-methyl, phenyl-(C+-C2-alkyl)- or 5- to 6-membered heteroaryl-methyl, wherein said 4- to 6-membered heterocycloalkyl, phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with R®; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R’ represents hydrogen, deuterium, or Ci-Cs-alkyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R™ represents hydrogen, deuterium, or Ci-Cs-alkyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R™ represents hydrogen, deuterium, or methyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R™ represents hydrogen, deuterium, or methyl: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R™ represents hydrogen or deuterium; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R™ represents hydrogen or deuterium; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R™ represents hydrogen; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R™ represents hydrogen; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents halogen, cyano, Ci-Cs-alkyl, C1-Cs-haloalkyl, Ci-Cs-alkoxy, C+-Ca-haloalkoxy, Cs-Ce-cycloalkyl, Cs-Cs-cycloalkyl-(Ci-Ca-alkyl)-, R™*-(C=0)-, R'%-0- (C=0)-, R""-NH-(C=0)-, or R'2-(S0»)-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents halogen, cyano, C+-Cs-alkyl, C+-Cs-haloalkyl, Cs-Cs-alkoxy, Ca-Ce- cycloalkyl, Ca-Ce-cycloalkyl-(C+-Cs-alkyl)-, R™*-(C=0)-, R'%-0-(C=0)-, R"-NH-(C=0)-, or R'2(S0y)-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents fluoro, chloro, C+-Cz-alkyl, trifluoromethyl, C4-Cs-alkoxy, cyclopropyl, cyclopropylmethyl, R®-(C=0)-, R'*-0-(C=0)-, R"-NH-(C=0)-, or R'-(SO,)-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents halogen, cyano, Ci-Ce-alkyl, Ci-Cs-haloalkyl, Ci-Cs-alkoxy, C+-Ca-haloalkoxy, Ca-Ce-cycloalkyl, Ci-Cs-alkyl-(C=0)-, R'%-0-(C=0)-, R"-NH-(C=0)-, or R'2-(SO.)-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents halogen, C-Cs-alkyl, C-Ca-haloalkyl, C1-Cs-alkoxy, Cs-Cs-cycloalkyl, C1-Cs-alkyl-(C=0)-, R'°-O-(C=0)-, R''-NH-(C=0)-, or R'2-(SO5)-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents fluoro, chloro, methyl, trifluoromethyl, ethoxy, cyclopropyl, methyl (C=0)-, R'%-0O-(C=0)-, R"-NH-(C=0)-, or R'2-(SO2)-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents halogen, cyano, Ci-Csalkyl, C+-Cs-haloalkyl, HzN-Ci-Ce-alkyl, Ci-Cs-alkoxy, Ci-Ca-haloalkoxy, Ca-Cs-cycloalkyl, R'%-O-(C=0)-, oxo, 5- to 6-membered heterocycloalkyl-, 5- to 6-membered heterocycloalkyl-(Ci-Ca-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, Ci-Cs-alkyl, Ci-Cs-haloalkyl, C+-Cs-alkoxy, or Ci-Ca-haloalkoxy; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents halogen, cyano, C+-Cs-alkyl, C+-Cs-haloalkyl, HoN-C1-Cys-alkyl, Cs-Ce- cycloalkyl, R'%-O-(C=0)-, oxo, 6-membered heterocycloalkyl-(C1-Cs-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, C+-Cs-haloalkyl, or C+-Ca-alkoxy; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents halogen, cyano, C+-Cs-alkyl, C4-Cs-haloalkyl, H2N-C+-Cs-alkyl, C+-Ca-alkoxy, Cs-Ce-cycloalkyl, R'*-O-(C=0)-, oxo, 5- to 6-membered heterocycloalkyl-, 5- to 6-membered heterocycloalkyl-(Ci-Cz-alkyl)-, phenyl, or 5- to 6-membered heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, Ci-Cs-alkyl, Ci-Cs-haloalkyl, or C+-Cs-alkoxy and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents fluoro, cyano, Ci-Cs-alkyl, trifluoromethyl, aminomethyl, ethoxy, cyclopropyl, R-0-(C=0)-, oxo, 6-membered heterocycloalkyl-methyl, phenyl, or 5- to 6-membered heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted with chloro, trifluoromethyl, or methoxy: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R® represents fluoro, chloro, C+-Cs-alkyl, trifluoromethyl, cyclopropyl, or oxo; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R'® represents hydrogen, C+-Cs-alkyl, or phenyl-CHa-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R'™ represents C-Cs-alkyl, or phenyl-CHaz-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R'" represents hydrogen, Cs-Cs-alkyl, or 5- to 6-membered heterocycloalkyl-(C1-Ca- alkyl)-: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R" represents Ci-Cs-alkyl, or 5- to 8-membered heterocycloalkyl-(C+-Ca-alkyl)-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R" represents Ci-Ca-alkyl, or 5- to 8-membered heterocycloalkyl-(C-Cz-alkyl)- and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R" represents C+-Ca-alkyl, or 5- to 8-membered heterocycloalkyl-methyl and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R" represents 5- to 68-membered heterocycloalkyl-(C4-Ca-alkyl)-; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: RM represents 5- to 6-membered heterocycloalkyl-methyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: RM represents tetrahydrofuran-2-yl-methyl, or 1,4-dioxan-2-yl-methyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R'2 represents Ci-C4-alkyl or phenyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R'2 represents Ci-Ca-alkyl or phenyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R'2 represents Ci-Cs-alkyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R'2 represents methyl; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R™ represents Ci-Cs-alkyl, Ci-Ce-haloalkyl, (Ci-Cs-alkoxy)-(C1-Cs-alkyl)-, C1-Ca- alkyl-(C=0)-, Cs-Ce-cycloalkyl, or phenyl, wherein said Cs-Ce-cycloalkyl group is optionally substituted with C+-Ca-alkyl or hydroxy and said phenyl group is optionally substituted, one or more times, independently of each other, with halogen, C+-Cs-alkyl, C+-Cs-haloalkyl, C+-Cs-alkoxy, or C4-Cs-haloalkoxy: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R'® represents Ci-Cs-alkyl, (C+-Cs-alkoxy)-(C+-Cs-alkyl)-, Ci-Cs-alkyl-(C=0)-, Cs-Ce- cycloalkyl, or phenyl, wherein said Ca-Cs-cycloalkyl group is optionally substituted with methyl or hydroxy; and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a further embodiment of the first aspect, the present invention covers compounds of formula (1), supra, in which: R™ represents methyl, methoxymethyl, ethyl-(C=0)-, cyclopropyl, or phenyl, wherein said cyclopropyl group is optionally substituted with methyl or hydroxy: and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same. In a particular further embodiment of the first aspect, the present invention covers combinations of two or more of the above-mentioned embodiments under the heading “further embodiments of the first aspect of the present invention”. The present invention covers any sub-combination within any embodiment or aspect of the present invention of compounds of general formula (1), supra. The present invention covers any sub-combination within any embodiment or aspect of the present invention of intermediate compounds of general formula (11). The present invention covers the compounds of general formula (I) which are disclosed in the Example Section of this text, infra. The compounds according to the invention of general formula (I) can be prepared according to the following schemes 1, 2, 3 and 4. The schemes and procedures described below illustrate synthetic routes to the compounds of general formula (1) of the invention and are not intended to be limiting. It is clear to the person skilled in the art that the order of transformations as exemplified in schemes 1, 2, 3 and 4 can be modified in various ways. The order of transformations exemplified in these schemes is therefore not intended to be limiting. In addition, interconversion of any of the substituents R', R?, R®, R* R®, R® Ror R" can be achieved before and / or after the exemplified transformations. These modifications can be such as the introduction of protecting groups, cleavage of protecting groups, reduction or oxidation of functional groups, halogenation, metallation, substitution or other reactions known to the person skilled in the art. These transformations include those which introduce a functionality which allows for further interconversion of substituents. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art. Specific examples are described in the subsequent paragraphs. Routes for the preparation of compounds of general formula (I) and corresponding intermediates are described in schemes 1, 2, 3 and 4. Scheme 1 xR HaC(-CHa N ] -R Rl LD >~0" 0 Oo 0 4a or 2 r* -R RE LD o” Yo Re a3 Ho Rr -R RL DS 0 o 12 4b or OH x 6 H I ’ -R FZ : 1) Ro" R’ MOF NN O-R Mey R o” Yo rR? 5 8 Hs N-R 8 . N ~| Rr? J 1 L \ R ib ~N 4 H ; [ R® LD ) (iy / > oo ® 5 rR o ol” 9 >< re ]° (I) Scheme 1: Route for the preparation of compounds of general formula (1) in which X is a leaving group, R is methyl, ethyl or tert-butyl and R', R?, R?, R*, R%, R®, R® and R™ have the meaning as given for general formula (1), supra. Tetrahydrobenzofuranes of general formula (3) can be obtained via aldol condensation of (1) and (2) followed by intramolecular cyclisation according to the procedures described by Stetter at al. (Chem. Ber. 1960, 93, 603-607) as depicted in Scheme 1. Compounds (1) and (2) are either commercially available or can be prepared according to procedures available from the public domain, as understandable to the person skilled in the art. Depending on the reactivity of the involved centers the regioisomer of (3) can be obtained [i.e. in cases where nucleophilic displacement of the leaving group of (2) by the acidic methylene unit of (1) is taking place prior to intramolecular condensation with the ketone moiety of (2)]. In general, 1,3-diketones of formula (1) can be reacted with alpha-carbonylesters of general formula (2) in the presence of inorganic bases like sodium hydroxide or potassium hydroxide, preferably potassium hydroxide, in protic solvents such as for example methanol, ethanol or water or mixtures thereof, preferably a mixture of the alcohol incorporated in ester (2) and water, at temperatures between 0 °C and the boiling point of the solvent (mixture), preferably between room temperature and 50 °C. The reaction times vary between 15 hours and several days. It is usually necessary to isomerize the primary formed cyclisation products to the tetrahydrobenzofuranes of general formula (3) by treatment with acids such as aqueous hydrochloric acid at pH 1-4 at temperatures between 0 °C and the boiling point of the solvent (mixture), preferably at room temperature, for 1-6 hours. Alternatively, (1) and (2) may be reacted in the presence of organic bases like triethylamine in aprotic solvents like dichloromethane, dichloroethane or tetrahydrofuran, preferably dichloromethane or dichloroethane, at temperatures between room temperature and the boiling point of the solvent, preferably at 40-60 °C (pressure tube), for 12-72 h followed by treatment with acids such as aqueous hydrochloric acid at pH 1- 4 at temperatures between 0 °C and the boiling point of the solvent (mixture), preferably at room temperature, for 3-24 hours. Alternatively, (1) and (2) may be reacted without further additives in toluene at temperatures between room temperature and 120 °C, preferably at 80-120 °C for 12- 20 hours. Enamines of general formula (4a) can be synthesized from tetrahydrobenzofuranes of general formula (3) by alpha-methylation with electrophiles like 1-tert-butoxy-N,N,N',N*- tetramethylmethanediamine (Bredereck’s reagent) or 1,1-dimethoxy-N,N- dimethylmethanamine, preferably 1-tert-butoxy-N, N,N’ N-tetramethylmethanediamine, in aprotic solvents like benzene, toluene or dioxane, preferably toluene, at temperatures between room temperature and the boiling point of the solvent, preferably at 100-110 °C, for 15 hours or up to several days. Alternatively, tetrahydrobenzofuranes of general formula (3) can be transferred to alpha- hydroxymethyleneketones of general formula (4b) by formylation with formic acid derivatives such as ethyl formate or methyl formate in the presence of bases such as sodium methylate, sodium ethylate, potassium tert-butoxide or sodium hydride in solvents such as methanol, ethanol, toluene or tetrahydrofuran or mixtures thereof at temperatures between 0 °C and the boiling point of the solvent (mixture), preferably between room temperature and 50 °C, for 1-18 hours. Furoindazoles of general formula (5) can be obtained starting from either enamines of general formula (4a) or alpha-hydroxymethyleneketones of general formula (4b) by reacting (4a) or (4b) with hydrazine or hydrazine derivatives such as hydrazine hydrates or hydrazine salts, preferably hydrazine hydrate or hydrazine dihydrochloride, in polar protic solvents like ethanol or water or mixtures thereof, preferably ethanol / water mixtures, at temperatures between room temperature and the boiling point of the solvent (mixture), preferably at 70-80 °C, for 4-18 hours. 2-Substituted furoindazole esters of general formula (8) can be synthesized from furoindazoles of general formula (5) either by Mitsunobu reaction with alcohols of general formula (6) in the presence of activating reagents such as diisopropyl azodicarboxylate (DIAD) or N,N,N’ N'-tetramethylazodicarboxamide (TMAD) and a tertiary posphine such as triphenylphosphine or tri-n-butylphosphine, preferably a combination of TMAD and tri- n-butylphosphine, in aprotic solvents such as tetrahydrofuran or toluene, preferably toluene, at temperatures between room temperature and the boiling point of the solvent, preferably at room temperature, for 12-48 hours. Alternatively, 2-substituted furoindazoles of general formula (8) can be synthesized from furoindazoles of general formula (5) by reaction with electrophiles of general formula (7) such as alkyl halides or alkyl tosylates or alkyl mesylates, preferably alkyl bromides, in the presence of an inorganic base such as potassium carbonate or in the presence of an organic base such as triethylamine or N,N-diisopropylethylamine, preferably potassium carbonate, in a polar, aprotic solvent such as acetonitrile or ethyl acetate, preferably acetonitrile, at temperatures between room temperature and the boiling point of the solvent, preferably at 60-75 °C. It can be benefical to add a catalyst like 4-dimethylaminopyridine (DMAP) to the mixture. Generally, depending on the reactivity of the involved centers the 1- substituted regioisomer of (8) can be obtained in certain cases as well. Carboxylic acids of general formula (9) may be obtained from carboxylic esters of formula (8) by saponification with inorganic bases such as lithium hydroxide, potassium hydroxide or sodium hydroxide, preferably lithium hydroxide, in a suitable solvent such as methanol, ethanol, tetrahydrofuran, water or mixtures thereof, preferably a mixture of the alcohol incorporated in ester (8), THF and water, at temperatures between 0 °C and the boiling point of the solvent (mixture), typically at 70 °C, for 4-48 hours. Furoindazoles of general formula (I) may be synthesized from suitably functionalized carboxylic acids of general formula (9) by reaction with appropriate amines HN(R®)(R®) (Il). For amide formation, however, all processes that are known from peptide chemistry to the person skilled in the art may be applied. The acids of general formula (9) can be reacted with an appropriate amine in aprotic polar solvents, such as for example DMF, acetonitrile or N-methylpyrrolid-2-one via an activated acid derivative, which is obtainable for example with hydroxybenzotriazole and a carbodiimide such as for example diisopropylcarbodiimide, or else with preformed reagents, such as for example O-(7- azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (see for example Chem. Comm. 1994, 201 203), or else with activating agents such as dicyclohexylcarbodiimide N,N-dimethylaminopyridine or N-ethyl-N’,N*- dimethylaminopropylcarbodiimide / N,N-dimethylaminopyridine. The addition of a suitable base such as for example N-methylmorpholine, triethylamine or DIPEA may be necessary. In certain cases, the activated acid derivative might be isolated prior to reaction with the appropriate amine. Amide formation may also be accomplished via the acid halide (which can be formed from a carboxylic acid by reaction with e.g. oxalyl chloride, thionyl chloride or sulfuryl chloride), mixed acid anhydride (which can be formed from a carboxylic acid by reaction with e.g. isobutylchloroformate), imidazolide (which can be formed from a carboxylic acid by reaction with e.g. carbonyldiimidazole) or azide (which can be formed from a carboxylic acid by reaction with e.g. diphenylphosphorylazide). Scheme 2 oO Oo Laz vv oO Oo R Ao HCP J AN Nz O-R —- z —- A ]! ]! i” ]! | Ao I o > 0 0 Lr R 0 2 o 0- ‘ D R 0” o 2 13 — QO a og O-R O- 1 7 - 1 BR R R 2 co © > 0 0 R R’ 14 3 Scheme 2: Alternative route for the preparation of intermediates of general formula (3) in which Hal is a halogen atom, R is methyl, ethyl or tert-butyl and R', R?, and R* have the meaning as given for general formula (1), supra. An alternative route for the preparation of tetrahydrobenzofurane intermediates of general formula (3) is depicted in Scheme 2. 1,3-Diketones of general formula (1) may be converted to diazodicarbonyl compounds of general formula (11) by diazo transfer as described in Synthesis 2011, 16, 2549-2552 or Synlett 2009, 18, 2943-2944. Bicyclic furane esters of general formula (13) can be synthesized in a [3+2] cycloaddition from diazodicarbonyl compounds of general formula (11) and terminal alkynes of general formula (12) in the presence of a metal catalyst such as Ru(PPhs)sCl2 according to the procedures described by Lee at al. (Eur. J. Org. Chem. 2014, 3430-3442). Halogenated furanes of general formula (14) may be obtained from furanes of general formula (13) by any aromatic halogenation reaction known to the person skilled in the art. For example, compounds of formula (13) may be reacted with halogen electrophiles such as N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS), preferably NBS, in polar solvents such as pyridine or N,N-dimethylformamide, preferably pyridine, at temperatures between 0 °C and the bailing point of the solvent, preferably at room temperature. The reaction times vary between 2 hours and several days. Tetrahydrobenzofurane intermediates of general formula (3) in turn may be obtained from halogenated furanes of general formula (14) by Suzuki reaction or radical processes like light-induced reactions applying photocatalysts. An alternative route for the preparation of 8-methyl-furcindazoles of general formula (la) is depicted in Scheme 3. 3-Methyl-tetrahydrobenzofuranes of general formula (16) can be synthesized from 1,3-dicarbonyls of general formula (1) by a two-step procedure involving reaction of the enolate of (1) with allenic sulfonium salt (15) [prepared in situ by reaction of propargyl bromide with dimethyl sulfide] and subsequent acid catalysed isomerization to (16) according to the procedures described by Kanematsu et al. (J. Org. Chem. 1993, 58, 3960-3968 and Heterocycles 1990, 31, 8, 1003-1006). Brominated furanes of general formula (17) may be obtained from furanes of general formula (16) by any aromatic bromination reaction known to the person skilled in the art. For example, compounds of formula (16) may be reacted with bromo electrophiles such as N-bromosuccinimide (NBS) in polar solvents such as pyridine or N,N- dimethylformamide, preferably pyridine, at temperatures between 0 °C and the boiling point of the solvent, preferably at room temperature. The reaction times vary between 2 hours and several days. Enamines of general formula (18a) and alpha-hydroxymethyleneketones of general formula (18b) can be synthesized starting from compounds of general formula (17) according to the procedures described for (4a) and (4b) in Scheme 1. 8-Methyl-furoindazoles of general formula (19) can be obtained from either (18a) or (18b) by reaction with hydrazine derivatives as described for the synthesis of (5) in Scheme 1. Scheme 3 Act LCA SICH oF SICH; C7 dui pe A gr- CHa 15 = Hs 1 R R. > 0 Hs 1 B Br R o 2 16 17 C.-CHs HCl i . 7 br R o 2 R 7 Rm R75 RAR or Rk! RR OH xX 8 u Hg > ZZ i 7 D—sr ~0 oe OH X Ne! 18a or — { nn —~ i Hs 1 7 )—sr \ LL” Rho 6 of sr oO TT \_n rR? H Ha Rl | N—ar > 0 ~~ 19 20 18b H H os N-R RY 10 Hs N-R 8 {any / —\ ia r® R® 7a ed” | He S, 2 Re 21 (la) Scheme 3: Alternative route for the preparation of compounds of general formula (la) in which R* = CH; and R', R?, R?, R®, R®, R7 and R”™ have the meaning as given for general formula (1), supra. 2-Substituted furoindazoles of general formula (20) can be synthesized from compounds of general formula (19) and alcohols (6) or electrophiles (7) as described for the synthesis of (8) from (5) in Scheme 1. Carboxylic acids of general formula (21) may be obtained from bromo-furoindazoles (20) by carbonylation reactions. Bromides of general formula (20) can be reacted in the presence of a carbon monoxide source such as for example molybdenum hexacarbonyl or under a carbon monoxide atmosphere at pressures between 1 and 20 bar (autoclave), preferably under a carbon monoxide atmosphere at 15 bar (autoclave), and in the presence of a suitable palladium catalyst such as palladium actetate or bis(triphenylphosphine) palladium(ll) dichloride, preferably palladium acetate, and in the presence of a ligand such as 1,1'-bis(diphenylphosphino)ferrocene and a suitable base such as potassium acetate in a polar solvent such as dimethylsulfoxide at temperatures between room temperature and 180 °C, preferably at 100 °C, for 12-24 h. 8-Methyl-furoindazoles of general formula (la) can be synthesized from suitably functionalized carboxylic acids of general formula (21) by amide coupling reactions with appropriate amines HN(R®)(R®) (III) as described for the synthesis of furcindazoles of general formula (1) from (9) in Scheme 1. Alternatively, 8-methyl-furoindazoles of general formula (la) may be directly synthesized from aryl bromides of general formula (20) by reaction with appropriate amines HN(R®)(R®) (lll) under palladium catalyzed carbonylation conditions. For this carbonylation all processes that are known to the person skilled in the art may be applied. Bromides of formula (20) can be reacted with an appropriate amine (III) in the presence of a carbon monoxide source such as for example molybdenum hexacarbonyl or under a carbon monoxide atmosphere at pressures between 1 and 20 bar (autoclave) and in the presence of a palladium catalyst such as for example palladium(ll) acetate and a base such as sodium carbonate in a polar aprotic solvent such as for example dioxane at temperatures between room temperature and the boiling point of the solvent, preferably at 110-140 °C (pressure tube). It might be necessary to add a ligand such as tri-tert- butylphosphonium tetrafluoroborate to the mixture. An alternative approach to 8-methyl-furoindazoles of general formula (la) is depicted in Scheme 4. 8-Methyl-furcindazoles of general formula (24) can be obtained starting from 1,3-dicarbonyl compounds of general formula (1) in four steps via (16) and (22a) or (22b) and (23) according to the corresponding procedures described in Scheme 1 and Scheme 3. Compounds of general formula (24) in turn can be formylated to give aldehydes of general formula (25) by all formylation processes that are known to the person skilled in the art. Furanes of general formula (24) can be reacted under Vilsmeier-Haack conditions with mixtures of N,N-dimethylformamide and phosphoryl chloride at temperatures between 0 °C and room temperature for 1-18 hours. Carboxamides of general formula (la) can be directly obtained from aldehydes of general formula (24) similar to the procedures described in Synthesis 2003, 7, 1055-1064. Aldehydes of general formula (24) can be reacted with an appropriate amine (III) in the presence of cyanide salts like sodium cyanide or potassium cyanide and in the presence of oxidizing agents like manganese(lV) dioxide in solvents like tetrahydrofuran, dichloromethane or dimethylsulfoxide, preferably tetrahydrofuran, at temperatures between 0 °C and the boiling point of the solvent, preferably at room temperature for 24- 96 hours. Scheme 4 CA st Hac” Y. ote i a Cin: H3C CHa No Hs 1 BR R > 0 oo ~ gr~ CHa J REA, Tag JD — 22a or hoo hd Mo ‘ R R Oo Re 16 TH 4 Hs N\ 1 | R 3 lo} a 22b or OH xX 8 y = CH, & { ! | rR 5 R N=N He SY RL 0 RR 23 24 H 5 N-R <8 _ — qn N=N Ha a) RL D3 oo’ Yo rR? » 2) CHa \ o R® [LD 2 © 2 R > Ca 25 (la) Scheme 4. Alternative route for the preparation of compounds of general formula (1a) in which R* = CHs and R', R? R?, R®, R®, R and R™ have the meaning as given for general formula (1), supra. Specific examples are described in the Experimental Section. In accordance with a second aspect, the present invention covers methods of preparing compounds of general formula (1) as defined supra, said methods comprising the step of allowing an intermediate compound of general formula (1): ra R” 7 R Rk NaN RY Il oN N—N Rr? \ ! 0 R! > Oo R R (0), in which R is H or OH or OMe or OEt and R', R?, R?, R*, R™ and R™ are as defined for the compound of general formula (I) as defined supra, to react with a compound of general formula (lI): H mn N—R® re (10, in which R® and R® are as defined for the compound of general formula (I) as defined supra, thereby giving a compound of general formula (I): R72 R™ 2 R Rk Ne—N rR? 1] 4 N—R RY N 4 ~N | R \ 0 s [1 R 7 0 \- R Rr? [OR in which R', R?, R?, R%, R®, R7 and R™ are as defined supra. In accordance with a third aspect, the present invention covers methods of preparing compounds of general formula (1) as defined supra, said methods comprising the step of allowing an intermediate compound of general formula (11): Rr’ R” 2 R rR Neen Rr ! oN N—N Rr? \ ! 0 \ I R 0° Rr rR? in which R is H, OH, OMe, or OEt and R', R?, R?, R*, R™ and R™ are as defined for the compound of general formula (I) as defined supra, to react with a compound of general formula (lI): H mn N—R® re (10, in which R® and R® are as defined for the compound of general formula (I) as defined supra, thereby giving a compound of general formula (I): R72 R" 4 R Rk N—N rR? l 4 N—R rR N N 4 \ ¥ \ 0 Rl 3 Oo N- R Re [OR in which R', R?, R?, R%, R®, R7 and R™ are as defined supra, then optionally converting said compound into solvates, salts and / or solvates of such salts using the corresponding (i) solvents and / or (ii) bases or acids. The present invention covers methods of preparing compounds of the present invention of general formula (I), said methods comprising the steps as described in the Experimental Section herein. In accordance with a fourth aspect, the present invention covers intermediate compounds which are useful for the preparation of the compounds of general formula (1), supra. Particularly, the invention covers the intermediate compounds of general formula (11): Rr’ R” 2 R rR Neen Rr ! oN N—N Rr? \ ! 0 \ I R 0° Rr rR? (Nn, in which R is H or OH or OMe or OEt and R', R2, R?, R*, R and R™ are as defined for the compound of general formula (1) supra. In accordance with a fifth aspect, the present invention covers the use of said intermediate compounds for the preparation of a compound of general formula (I) as defined supra. Particularly, the invention covers the use of intermediate compounds of general formula an: Rr’ R” 2 R rR Neen Rr ! oN N—N Rr? \ ! 0 \ I R 0° Rr rR? (0), in which R is H or OH or OMe or OEt and R', R?, R?, R*, R™ and R™ are as defined for the compound of general formula (I) supra, for the preparation of a compound of general formula (1) as defined supra. The present invention covers the intermediate compounds which are disclosed in the Example Section of this text, infra. The present invention covers any sub-combination within any embodiment or aspect of the present invention of intermediate compounds of general formula (II), supra. The compounds of general formula (I) of the present invention can be converted to any salt, preferably pharmaceutically acceptable salts, as described herein, by any method which is known to the person skilled in the art. Similarly, any salt of a compound of general formula (I) of the present invention can be converted into the free compound, by any method which is known to the person skilled in the art. Compounds of general formula (I) of the present invention demonstrate a valuable pharmacological spectrum of action which could not have been predicted. Compounds of the present invention have surprisingly been found to be effective antagonists of GPR84 and it is possible therefore that said compounds be used for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type Il, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals. Compounds of the present invention can be utilized to inhibit, antagonize, block, reduce, decrease GPR84 signal transduction, activity and cellular function. This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; which is effective to treat the disorder. In particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type II, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals. The present invention also provides methods of treating PCOS and symptoms These disorders have been well characterized in humans, but also exist with a similar aetiology in other mammals and can be treated by administering pharmaceutical compositions of the present invention. The term “treating”, or “treatment” as used in the present text is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as PCOS or IPF. The compounds of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis and treatment of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type Il, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals. In accordance with a further aspect, the present invention covers compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for use in the treatment or prophylaxis of diseases, in particular autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type II, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals. The pharmaceutical activity of the compounds according to the invention can be explained by their activity as GPR84 antagonists. In accordance with a further aspect, the present invention covers the use of compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for the treatment or prophylaxis of diseases, in particular autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type II, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals. In accordance with a further aspect, the present invention covers the use of a compound of formula (I), described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of diseases, in particular autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type II, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals In accordance with a further aspect, the present invention covers the use of compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, in a method of treatment or prophylaxis of diseases, in particular autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non- alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic- endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type Il, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals. In accordance with a further aspect, the present invention covers use of a compound of general formula (1), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for the preparation of a pharmaceutical composition, preferably a medicament, for the prophylaxis or treatment of diseases, in particular autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type II, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals In accordance with a further aspect, the present invention covers a method of treatment or prophylaxis of diseases, in particular autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type | and type Il, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals, using an effective amount of a compound of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same. In accordance with a further aspect, the present invention covers pharmaceutical compositions, in particular a medicament, comprising a compound of general formula (1), as described supra, or a stereocisomer, a tautomer, an N-oxide, a hydrate, a solvate, a salt thereof, particularly a pharmaceutically acceptable salt, or a mixture of same, and one or more excipients), in particular one or more pharmaceutically acceptable excipient(s). Conventional procedures for preparing such pharmaceutical compositions in appropriate dosage forms can be utilized. The present invention furthermore covers pharmaceutical compositions, in particular medicaments, which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipients, and to their use for the above-mentioned purposes. Itis possible for the compounds according to the invention to have systemic and / or local activity. For this purpose, they can be administered in a suitable manner, such as, for example, via the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic route or as an implant or stent. For these administration routes, it is possible for the compounds according to the invention to be administered in suitable administration forms. For oral administration, it is possible to formulate the compounds according to the invention to dosage forms known in the art that deliver the compounds of the invention rapidly and / or in a modified manner, such as, for example, tablets (uncoated or coated tablets, for example with enteric or controlled release coatings that dissolve with a delay or are insoluble), orally-disintegrating tablets, films / wafers, films / lyophilizates, capsules (for example hard or soft gelatine capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. It is possible to incorporate the compounds according to the invention in crystalline and / or amorphized and / or dissolved form into said dosage forms. Parenteral administration can be effected with avoidance of an absorption step (for example intravenous, intraarterial, intracardial, intraspinal or intralumbal) or with inclusion of absorption (for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal). Administration forms which are suitable for parenteral administration are, inter alia, preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilizates or sterile powders. Examples which are suitable for other administration routes are pharmaceutical forms for inhalation [inter alia powder inhalers, nebulizers], nasal drops, nasal solutions, nasal sprays; tablets / films / wafers / capsules for lingual, sublingual or buccal administration; suppositories; eye drops, eye ointments, eye baths, ocular inserts, ear drops, ear sprays, ear powders, ear-rinses, ear tampons; vaginal capsules, aqueous suspensions (lotions, mixturae agitandae), lipophilic suspensions, emulsions, ointments, creams, transdermal therapeutic systems (such as, for example, patches), milk, pastes, foams, dusting powders, implants or stents. The compounds according to the invention can be incorporated into the stated administration forms. This can be effected in a manner known per se by mixing with pharmaceutically suitable excipients. Pharmaceutically suitable excipients include, inter alia, fillers and carriers (for example cellulose, microcrystalline cellulose (such as, for example, Avicel®), lactose, mannitol, starch, calcium phosphate (such as, for example, Di-Cafos®)), ointment bases (for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols), bases for suppositories (for example polyethylene glycols, cacao butter, hard fat), solvents (for example water, ethanol, isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatty oils, liquid polyethylene glycols, paraffins), surfactants, emulsifiers, dispersants or wetters (for example sodium dodecyl sulfate), lecithin, phospholipids, fatty alcohols (such as, for example, Lanette®), sorbitan fatty acid esters (such as, for example, Span®), polyoxyethylene sorbitan fatty acid esters (such as, for example, Tween®), polyoxyethylene fatty acid glycerides (such as, for example, Cremophor®), polyoxethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers (such as, for example, Pluronic®), buffers, acids and bases (for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine), isotonicity agents (for example glucose, sodium chloride), adsorbents (for example highly-disperse silicas), viscosity-increasing agents, gel formers, thickeners and / or binders (for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, carboxymethylcellulose-sodium, starch, carbomers, polyacrylic acids (such as, for example, Carbopol®): alginates, gelatine), disintegrants (for example modified starch, carboxymethylcellulose-sodium, sodium starch glycolate (such as, for example, Explotab®), cross- linked polyvinylpyrrolidone, croscarmellose-sodium (such as, for example, AcDiSol®)), flow regulators, lubricants, glidants and mould release agents (for example magnesium stearate, stearic acid, talc, highly-disperse silicas (such as, for example, Aerosil®)), coating materials (for example sugar, shellac) and film formers for films or diffusion membranes which dissolve rapidly or in a modified manner (for example polyvinylpyrrolidones (such as, for example, Kollidon®), polyvinyl alcohol, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as, for example, Eudragit®), capsule materials (for example gelatine, hydroxypropylmethylcellulose), synthetic polymers (for example polylactides, polyglycolides, polyacrylates, polymethacrylates (such as, for example, Eudragit®), polyvinylpyrrolidones (such as, for example, Kollidon®), polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and blockcopolymers), plasticizers (for example polyethylene glycols, propylene glycol, glycerol, triacetine, triacetyl citrate, dibutyl phthalate), penetration enhancers, stabilisers (for example antioxidants such as, for example, ascorbic acid, ascorbyl! palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate), preservatives (for example parabens, sorbic acid, thiomersal, benzalkonium chloride, chlorhexidine acetate, sodium benzoate), colourants (for example inorganic pigments such as, for example, iron oxides, titanium dioxide), flavourings, sweeteners, flavour- and / or odour-masking agents. The present invention furthermore relates to a pharmaceutical composition which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipient(s), and to their use according to the present invention. EXPERIMENTAL SECTION NMR peak forms are stated as they appear in the spectra, possible higher order effects have not been considered. The "H-NMR data of selected compounds are listed in the form of "H-NMR peaklists. Therein, for each signal peak the 5 value in ppm is given, followed by the signal intensity, reported in round brackets. The & value-signal intensity pairs from different peaks are separated by commas. Therefore, a peaklist is described by the general form: d+ (intensity+), 82 (intensity,), ... , &i (intensity), ... , dn (intensityy). The intensity of a sharp signal correlates with the height (in cm) of the signal in a printed NMR spectrum. When compared with other signals, this data can be correlated to the real ratios of the signal intensities. In the case of broad signals, more than one peak, or the center of the signal along with their relative intensity, compared to the most intense signal displayed in the spectrum, are shown. A "H-NMR peaklist is similar to a classical "H-NMR readout, and thus usually contains all the peaks listed in a classical NMR interpretation. Moreover, similar to classical "H-NMR printouts, peaklists can show solvent signals, signals derived from stereoisomers of the particular target compound, peaks of impurities, °C satellite peaks, and / or spinning sidebands. The peaks of stereoisomers, and / or peaks of impurities are typically displayed with a lower intensity compared to the peaks of the target compound (e.g., with a purity of >90%). Such stereoisomers and / or impurities may be typical for the particular manufacturing process, and therefore their peaks may help to identify a reproduction of the manufacturing process on the basis of "by-product fingerprints”. An expert who calculates the peaks of the target compound by known methods (MestReC, ACD simulation, or by use of empirically evaluated expectation values), can isolate the peaks of the target compound as required, optionally using additional intensity filters. Such an operation would be similar to peak-picking in classical "H-NMR interpretation. A detailed description of the reporting of NMR data in the form of peaklists can be found in the publication “Citation of NMR Peaklist Data within Patent Applications” (cf. http: / / www.researchdisclosure.com / searching-disclosures, Research Disclosure Database Number 605005, 2014, 01 Aug 2014). In the peak picking routine, as described in the Research Disclosure Database Number 605005, the parameter "MinimumHeight" can be adjusted between 1% and 4%. However, depending on the chemical structure and / or depending on the concentration of the measured compound it may be reasonable to set the parameter "MinimumHeight" <1%. Chemical names were generated using the ACD / Name software from ACD / Labs. In some cases, generally accepted names of commercially available reagents were used in place of ACD / Name generated names. The following Table 1 lists the abbreviations used in this paragraph and in the Examples section as far as they are not explained within the text body. Other abbreviations have their meanings customary per se to the skilled person. The following table lists the abbreviations used herein. Table 1: Abbreviations Abbreviation | Meaning br. broad signal in NMR br.s. broad singlet CDI di-1H-imidazol-1-ylmethanone conc. concentrated CPME cyclopentyl methyl ether fa “doublet dd doublet of doublets ddd doublet of doublet of doublets dt doublet of triplets DCM dichloromethane DEA diethylamine DIPEA N,N-diisopropylethyl amine DMAP N,N-dimethylpyridin-4-amine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide EDC N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride ESI electrospray ionization ESlpos Positive electrospray ionization ESineg Negative electrospray ionization EtOAc ethyl acetate [EOH [ethanol Abbreviation |Meaning eq. equivalent GP General procedure mo “Thour® HATU O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HCI hydrochloric acid HCOOH formic acid HPLC, LC high performance liquid chromatography LC-MS / LCMS | Liquid chromatography mass spectrometry m multiplet min minute(s) MS mass spectroscopy MeCN acetonitrile MeOH methanol NMR nuclear magnetic resonance “Tauintet quint Rt retention time rt room temperature [s singlet sept septet TFA trifluoroacetic acid THF tetrahydrofuran TMAD N,N,N’ N'tetramethylazodicarboxamide UPLC ultra performance liquid chromatography UPLC-MS ultra performance liquid chromatography mass spectrometry The various aspects of the invention described in this application are illustrated by the following examples which are not meant to limit the invention in any way. The example testing experiments described herein serve to illustrate the present invention and the invention is not limited to the examples given. EXPERIMENTAL SECTION - GENERAL PART All reagents, for which the synthesis is not described in the experimental part, are either commercially available, or are known compounds or may be formed from known compounds by known methods by a person skilled in the art. The compounds and intermediates produced according to the methods of the invention may require purification. Purification of organic compounds is well known to the person skilled in the art and there may be several ways of purifying the same compound. In some cases, no purification may be necessary. In some cases, the compounds may be purified by crystallization. In some cases, impurities may be stirred out using a suitable solvent. In some cases, the compounds may be purified by chromatography, particularly flash column chromatography, using for example prepacked silica gel cartridges, e.g. Biotage SNAP cartidges KP-Sil® or KP-NH® in combination with a Biotage autopurifier system (SP4® or Isolera Four®) and eluents such as gradients of hexane / ethyl acetate or DCM / methanol. In some cases, the compounds may be purified by preparative HPLC using for example a Waters autopurifier equipped with a diode array detector and / or on- line electrospray ionization mass spectrometer in combination with a suitable prepacked reverse phase column and eluents such as gradients of water and acetonitrile which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia. In some cases, purification methods as described above can provide those compounds of the present invention which possess a sufficiently basic or acidic functionality in the form of a salt, such as, in the case of a compound of the present invention which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present invention which is sufficiently acidic, an ammonium salt for example. A salt of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art or be used as salts in subsequent biological assays. It is to be understood that the specific form (e.g. salt, free base etc.) of a compound of the present invention as isolated and as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity. UPLC-MS Standard Procedures Analytical UPLC-MS was performed as described below. The masses (m / z) are reported from the positive mode electrospray ionisation unless the negative mode is indicated (ESI-). In most of the cases method 1 is used. If not, it is indicated. Method 1: Instrument: Waters Acquity UPLC-MS SQD 3001; Column: Acquity UPLC BEH C18 1.7 um, 50x2.1 mm; Eluent A: water + 0.2 vol % ammonia, Eluent B: acetonitrile; Gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; Flow rate: 0.8 mL / min; Temperature: 60 °C: Injection: 2 uL; DAD scan: 210-400 nm; ELSD. Method 2: Instrument: Waters Acquity UPLC-MS SQD 3001; Column: Acquity UPLC BEH C18 1.7 um, 50x2.1 mm; Eluent A: water + 0.1 vol % formic acid , Eluent B: acetonitrile; Gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; Flow rate: 0.8 mL / min; Temperature: 60 °C: Injection: 2 uL; DAD scan: 210-400 nm. LC-MS Standard Procedures Method A: Instrument: Waters Acquity UPLCMS SingleQuad; Colum: Acquity UPLC BEH C18 1.7 pum, 50x2.1 mm; Eluent A: water + 0.2 vol % aqueous ammonia (32%), Eluent B: acetonitrile; Gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; Flow: 0.8 mL / min; Temperature: 60 °C; DAD scan: 210-400 nm. Method B:5-95AB, Shimadzu Instrument: SHIMADZU LCMS-2020 SingleQuad; Column: Chromolith@Flash RP-18E 25-2 MM; Eluent A: water + 0.0375 vol % trifluoroacetic acid, Eluent B: acetonitrile + 0.01875 vol % trifluoroacetic acid; Gradient: 0-0.8 min, 5-95% B, 0.8-1.2 min 95% B; Flow: 1.5 mL / min; Temperature: 50 °C; PDA: 220 nm & 254 nm. Method C:5-95AB, Agilent Instrument: Agilent 1100\G1956A SingleQuad; Column: Kinetex@ 5 um EVO C18 30*2.1 mm; Eluent A: water + 0.0375 vol % trifluoroacetic acid, Eluent B: acetonitrile + 0.01875 vol % trifluoroacetic acid; Gradient: 0-0.8 min 5-95% B, 0.8-1.2 min 95% B; Flow: 1.5 mL / min; Temperature: 50 °C; PDA: 220 nm & 254 nm. Method D:5-95CD, Shimadzu Instrument: SHIMADZU LCMS-2020 SingleQuad; Column: Kinetex EVO C18 2.1*30 mm, 5 pm; Eluent A: water + 0.025 vol % ammonium hydroxide, Eluent B: acetonitrile; gradient: 0-0.8 min, 5-95% B, 0.8-1.2 min 95% B; Flow: 1.5 mL / min; Temperature: 40 °C; PDA: 220 nm & 254 nm. Method E:5-95CD, Shimadzu Instrument: SHIMADZU LCMS-2020 SingleQuad; Column: Kinetex EVO C18 2.1*30 mm, 5um; eluent A: water + 0.025 vol % ammonium hydroxide, eluent B: acetonitrile; gradient: 0-0.8 min, 5-95% B, 0.8-1.2 min, 95% B; flow 1.5 ml / min; temperature: 40 °C; PDA: 220 nm & 254 nm. Analytical characterization of enantiomers was performed by analytical chiral HPLC. In the description of the individual examples is referred to the applied HPLC procedure. Purification Methods: Biotage Isolera™ chromatography system (http: / / www.biotage.com / product-area / flash- purification) using pre-packed silica and pre-packed modified silica cartridges. Preparative HPLC, Method A: Instrument: pump: Labomatic HD-5000 or HD-3000, head HDK 280, lowpressure gradient module ND-B1000; manual injection valve: Rheodyne 3725i038; detector: Knauer Azura UVD 2.15; collector: Labomatic Labocol Vario-4000; column: Chromatorex RP C-18 10 um, 125x30mm; eluent A: water + 0.2 vol-% ammonia (32%), eluent B: acetonitrile; gradient A: 0 - 15 min 1 — 25% B; flow: 60 ml / min; gradient B: 0 - 15 min 10 — 50% B: flow: 60 ml / min; gradient C: 0 - 15 min 15 — 55% B: flow: 60 ml / min; gradient D: 0 - 15 min 30 — 70% B; flow: 60 ml / min: gradient E: 0 - 15 min 40 — 80% B; flow: 60 ml / min; gradient F: 0 - 15 min 65 — 100% B: flow: 60 ml / min; temperature: 25 °C; solution: max. 250 mg / 2ml dimethyl sulfoxide; injection: 1 x 2 ml; Detection: UV 254 nm: Software: SCPA PrepCon5. Preparative HPLC, Method B: Instrument: pump: Labomatic HD-5000 or HD-3000, head HDK 280, lowpressure gradient module ND-B1000; manual injection valve: Rheodyne 3725i038; detector: Knauer Azura UVD 2.15; collector: Labomatic Labocol Vario-4000; column: Chromatorex RP C-18 10 pm, 125x30mm; eluent A: water + 0.1 vol % formic acid (99%), eluent B: acetonitrile; gradient A: 0 - 15 min 1 = 25% B; flow: 60 ml / min; gradient B: 0 - 15 min 10 — 50% B; flow: 60 ml / min; gradient C: 0 - 15 min 15 — 55% B; flow: 60 ml / min: gradient D: 0 - 15 min 30 — 70% B; flow: 60 ml / min; gradient E: 0 - 15 min 40 — 80% B: flow: 60 ml / min; gradient F: 0 - 15 min 65 — 100% B; flow: 60 ml / min; temperature: 25 °C; solution: max. 250 mg / 2ml dimethyl sulfoxide; injection: 1 x 2 ml; Detection: UV 254 nm; Software: SCPA PrepCon5. EXPERIMENTAL SECTION - GENERAL PROCEDURES General procedure A (GP A): Alpha-formylation reaction (3 — 4af / b, Scheme 1 or 17 — 18a / b, Scheme 3 or 16 — 22a / b, Scheme 4) (conditions A: enamine formation); similar to H.Bredereck et al., Liebigs Ann. Chem. 1980, 3, 344-357 and WO2010 / 078427, p. 222. To a solution of the respective ketone (1 eq.) in toluene at r.t. is added 1-tert-butoxy- N,N,N’, N'tetramethylmethanediamine (Bredereck’s reagent, CAS No. [5815-08-7]; 1.2 — 5 eq.) or 1,1-dimethoxy-N,N-dimethylmethanamine (1.2 — 5 eq.) and the reaction mixture is stirred at 100 - 120 °C until TLC and / or LCMS indicate complete consumption of the starting material (overnight or up to 6 days). The reaction mixture is concentrated under reduced pressure and used in the subsequent reaction without further purification steps. Alpha-formylation reaction (3 — 4a / b, Scheme 1 or 17 — 18a / b, Scheme 3 or 16 — 22a / b, Scheme 4) (conditions B: enol formation); similar to M.L.Hammond et a / ., J. Med. Chem. 1989, 32, 1006-1020 and D.J.Goldsmith et al, J. Org. Chem. 1980, 45, 3989-3993 and G.Grandolini et al., Gazzetta Chimica Italiana 1978, 1086, 1083-1094. To a solution of ethyl formate (CAS No. [109-94-4]; 2.0 — 6.0 eq.) in toluene is added sodium hydride (3.0 eq., 60 % purity) at 0 °C. After stirring for 0.5 hours, a solution of the respective ketone (1.0 eq.) in toluene is added to the above mixture. The reaction mixture is stirred at room temperature or 45°C until TLC and / or LCMS indicate complete consumption of the starting material (typically 2 h or up to overnight). The reaction mixture is quenched with 2 N aqueous hydrochloric acid and the phases separated. The aqueous phase is extracted with ethyl acetate and the combined organic phases are washed with brine, dried with anhydrous sodium sulfate, filtrated and concentrated under reduced pressure. The obtained crude desired product is used in the subsequent reaction without further purification steps. General procedure B (GP B): Furoindazole formation (4a / b — 5, Scheme 1 or 18a / b — 19, Scheme 3 or 22a / b — 23, Scheme 4); similar to G.Grandolini et al., Gazzetta Chimica Italiana 1976, 106, 1083- 1094 and W.A.Remers et al., J. Heterocycl. Chem. 1975, 12, 421-422. To a solution of the respective enamine or enol (1.0 eq.) in ethanol is added a solution of hydrazine hydrate 1:1 (CAS No. [7803-57-8]; 5.0 eq.) or hydrazine dihydrochloride (CAS No. [56341-61-7]; 2.0 eq.) in water or ethanol at room temperature. The reaction mixture is stirred at 60 — 70 °C until TLC and / or LCMS indicate complete consumption of the starting material (typically 2h or up to overnight). After quenching with sodium hypochlorite at 0 °C, the biphasic mixture is concentrated under reduced pressure. The residue is either directly submitted to column chromatography (SiOz) or partitioned between water and ethyl acetate. The aqueous layer is extracted with ethyl acetate and the combined organic layers are washed brine, filtrated and concentrated under reduced pressure to give the crude title compound which is purified via column chromatography (SiO2) where appropriate. General procedure C (GP C): Furoindazole alkylation (5 — 8, Scheme 1 or 19 — 20, Scheme 3 or 23 — 24, Scheme 4) (conditions A: Mitsunobu reaction; in analogy to D.L.Selwoed et al., J. Med. Chem. 2009, 52, 2694-2707) To a solution of the respective furoindazole (1.0 eq.) and alcohol (1-2 eq.) in toluene at rt is added tri-n-butylphosphine (CAS No. [998-40-3]; 1.5-3eq.) and N,N N'N- tetramethylazodicarboxamide (TMAD, CAS No. [10465-78-8]; 1.5-3eq.) and the reaction mixture is stirred at rt until TLC and / or LCMS indicate complete consumption of the starting material (typically overnight). The reaction mixture is diluted with water and the phases separated. The aqueous phase is extracted with dichloromethane (two to three times), the combined organic phases dried with MgSOs4 or NazSOs, filtrated and concentrated. The obtained crude material is subjected to column chromatography (SiOz) to give the desired alkylation product. Usually, the 2-substituted indazoles are obtained as major products. Furoindazole alkylation (5 — 8, Scheme 1 or 19 — 20, Scheme 3 or 23 — 24, Scheme 4) (conditions B: reaction with alkyl (pseudo)halides) A solution of the respective furoindazole (1.0 eq.) and alkyl (pseudo)halide (1.5 - 3 eq.) in acetonitrile or ethyl acetate at rt is treated with potassium carbonate (5 —- 15 eq.) and N,N-dimethylpyridin-4-amine (DMAP, CAS No. [1122-58-3]; 2.5 mol%). The reaction mixture is stirred at 60 — 70 °C until TLC and / or LCMS indicate complete consumption of the starting material (typically overnight or up to several days). The reaction mixture is cooled to rt and filtrated. The filtrate is concentrated under reduced pressure and the residue subjected to column chromatography (SiOz) to give the desired alkylation product. General procedure D (GP D): Saponification of furcindazole ester (8 — 9, Scheme 1) A solution of the respective furoindazole ester (1.0 eq.) in a mixture of tetrahydrofuran and ethanol (1:1) at rt is treated with aqueous lithium hydroxide (2 M, 15 eq.). In some cases, aqueous sodium hydroxide (30 eq.) in THF is used instead. The reaction mixture is stirred at 60 — 70 °C until TLC and / or LCMS indicate complete consumption of the starting material (typically overnight). The reaction mixture is cooled to rt, acidified with aqueous hydrochloric acid to pH 3 — 5 and extracted with ethyl acetate. The desired carboxylic acid either precipitates in the aqueous phase (potentially as HCI salt) and can be isolated by filtration and drying and is used in the subsequent reaction without further purification steps. Alternatively, the phases are separated, the organic phase washed with brine, dried over Na.SO, filtrated and concentrated under reduced pressure to give the desired carboxylic acid which is used in the subsequent reaction without further purification steps. General procedure E (GP E): Carboxylation of furoindazole bromide (20 — 21, Scheme 3) The furoindazole bromide (1.0 eq.) is placed into a steel autoclave under argon atmosphere and dissolved in dimethyl sulfoxide (ca. 15 mL / mmol). Palladium(ll) acetate (5.0 mol%), 1,1-bis(diphenylphosphino)ferrocene (CAS No. [12150-46-8]; 0.20 eq.) and potassium acetate (4.0 eq.) are added and the mixture is purged 3 times with carbon monoxide. The mixture is stirred for 30 min at 20°C under a carbon monoxide pressure of ca. 11 bar. The autoclave is set under vacuum again, then a carbon monoxide pressure of ca. 15 bar is applied, and the mixture heated to 100 °C until TLC and / or LCMS indicate complete consumption of the starting material (usually 23 h), yielding a maximum pressure of ca. 18 bar. The reaction is cooled to rt, the pressure released, and the reaction mixture added to ice-water. The mixture is acidified with aqueous 1 M HCI (pH ca 2.5), stirred for 20 min and diluted with dichloromethane or ethyl acetate. The phases are separated, and the aqueous phase extracted with dichloromethane or ethyl acetate. The combined organic phases are dried, filtrated and concentrated under reduced pressure. The obtained crude carboxylic acid is taken to the next step without further purification. General procedure F (GP F): Vilsmeier-Haack formylation of furoindazoles (24 — 25, Scheme 4) Phosphorylchloride (10eq.) is dropwise added under ice cooling to N,A- dimethylformamide (10 eq.) and stirred for 15 minutes. A solution of the furoindazole (1.0 eq.) in N,N-dimethylformamide is dropwise added, the mixture warmed to rt and stirred until TLC and / or LCMS indicate complete consumption of the starting material (usually 1 — 2 hours). The reaction mixture is added to ice-water and the pH adjusted to ca 9 by addition of aqueous sodium hydroxide (4 M). The mixture is extracted with dichloromethane, the phases separated, and the combined organic phases are dried, filtrated and concentrated under reduced pressure. The obtained crude aldehyde is purified via column chromatography (SiOz) where appropriate. General procedure G (GP G): Amide formation (9 — (1), Scheme 1 or 21 — (la), Scheme 3) (conditions A: amide coupling) A solution of the carboxylic acid or corresponding salt (1.0 eq.) in DMF is treated with HATU (1.5 eq.) and DIPEA (3.0 eq.) and stirred for a couple of minutes at rt upon which the amine component (1 - 1.5 eq.) is added and stirring at rt continued until TLC and / or LCMS indicate complete consumption of the starting material (usually overnight). In most cases the reaction mixture is filtrated and purified by preparative HPLC to give the desired amide. In some cases, the reaction mixture is diluted with water and extracted with ethyl acetate. The organic phase is dried, filtered and purified by column chromatography (SiO.) to give the desired amide. Alternatively, a solution of the carboxylic acid or corresponding salt (1.0 eq.) in DMF is treated with 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (T3P, 50wt% solution in DMF, 1.5-3 eq.), DIPEA (3-5 eq.) and the amine component (1 — 1.5 eq.) and the reaction mixture stirred at rt until TLC and / or LCMS indicate complete consumption of the starting material (usually overnight). The reaction mixture is filtrated and purified by preparative HPLC to give the desired amide. Amide formation (20 — (la), Scheme 3) (conditions B: carbonylation of bromides to yield amides directly) A solution of the furoindazole bromide (1.0 eq.) in 1,4-dioxane (containing ca. 1% water) is treated with the corresponding amine (3-5 eq.), molybdenum hexacarbonyl (CAS No. [13939-06-5]; 2.0 eq.), sodium carbonate (CAS No. [497-19-8]; 3.0eq.), tri-tert- butylphosphonium tetrafiuoroborate (CAS No. [131274-22-1]; 0.10 eq.) and palladium(Il) acetate (CAS No. [3375-31-3]; 0.20 eq.) The reaction mixture is vigorously stirred at 120 — 140 °C until TLC and / or LCMS indicate complete consumption of the starting material (usually 18 h). The mixture is cooled to rt, solids are filtered off over Celite and rinsed with ethyl acetate. The filtrate is concentrated under reduced pressure and the obtained crude product purified by preparative HPLC. Amide formation (25 — (la), Scheme 4) (conditions C: conversion of aldehydes to amides); similar to J.K. Taylor et a / ., Synthesis 2003, 7, 1055-1064. A solution of the furoindazole aldehyde (1.0 eq.) in DMSO or THF is treated with the corresponding amine (5.0 eq.), sodium cyanide (1.0 eq.) and manganese(lV) dioxide (15 eq.) and stirred at rt for 30 minutes. Another amount of manganese(lV) dioxide (15 eq.) is added and stirring at rt continued until TLC and / or LCMS indicate complete consumption of the starting material (24 hours or up to several days.). The reaction mixture is filtered over Celite, the filtrate concentrated under reduced pressure and the obtained crude product purified by preparative HPLC to give the desired amide. General procedure H (GP H): Amide formation (9 — (1), Scheme 1 or 21 — (la), Scheme 3) (conditions A: amide coupling) A solution of the carboxylic acid or corresponding salt (1.0 eq.) in DMF is treated with HATU (1.5 eq.) and DIPEA (3-6 eq.) and stirred for a couple of minutes at rt upon which the amine component (1 — 1.5 eq.) is added and stirring at rt continued until TLC and / or LCMS indicate complete consumption of the starting material (usually overnight). In most cases the reaction mixture is diluted with saturated ammonium chloride and extracted with ethyl acetate. The combined organic phase is washed with water, dried by hydrophobic filtration and purified by preparative HPLC to give the desired amide. In some cases the reaction mixture is filtrated and purified by preparative HPLC to give the desired amide. Amide formation (9 — (1), Scheme 1 or 21 — (la), Scheme 3) (conditions B: amide coupling) A solution of the carboxylic acid or corresponding salt (1.0 eq.) in DMF is treated with HATU (1.5 eq.) and DIPEA (3-6 eq.) and stirred for a couple of minutes at rt upon which the amine component (1-2 eq.) is added and stirring at rt continued until TLC and / or LCMS indicate complete consumption of the starting material (usually overnight). In most cases the reaction mixture is diluted with ethyl acetate and water. The water phase is extracted with ethyl acetate. The combined organic phase is washed with brine, dried over NazSOq, and filtrated or hydrophobic filtration and purified by preparative HPLC to give the desired amide. In some cases the reaction mixture is filtrated and purified by preparative HPLC to give the desired amide. (conditions C: amide coupling) A solution of the carboxylic acid or corresponding salt (1.0 eq.) in THF (and sometimes DMF to dissolve) is treated with HATU (1.5 eq.) and DIPEA (3-6 eq.) and stirred for a couple of minutes at rt upon which the amine component (1 — 2 eq.) is added and stirring at rt continued until TLC and / or LCMS indicate complete consumption of the starting material (usually 72 hours). In most cases the reaction mixture is diluted with sat. NaHCOs / water (1:5) and ethyl acetate and stirred for 30 minutes. The phases were separated and the ethyl acetate phase is extracted with water. The combined organic phase was dried over Na2SQOs, and filtrated or hydrophobic filtration and purified by preparative HPLC to give the desired amide. In some cases the reaction mixture is filtrated and purified by preparative HPLC to give the desired amide. (conditions D: amide coupling) A solution of the carboxylic acid or corresponding salt (1.0 eq.) in DMF or THF is treated with HATU (1.5 eq.) and DIPEA (3-6 eq.) and stirred for a couple of minutes at rt upon which the amine component (1 — 1.5 eq.) is added and stirring at rt continued until TLC and / or LCMS indicate complete consumption of the starting material (usually overnight). In most cases the reaction mixture is diluted with saturated sodium bicarbonate / water and extracted with ethyl acetate. The combined organic phase is washed with brine, dried by hydrophobic filtration or over sodium sulfate and purified by preparative HPLC to give the desired amide. In some cases the reaction mixture is filtrated and purified by preparative HPLC to give the desired amide. EXPERIMENTAL SECTION - INTERMEDIATES Intermediate 1: Step 1 (5E / 2)-5-[(dimethylamino)methylidene]-6,7-dihydro-1-benzofuran-4(5H)-one oO HaCoy A QO Eh, According to GP A (conditions A) 6,7-dihydro-1-benzofuran-4(5H)-one (commercially available, CAS No. [16806-93-2]; 5.00 g, 36.7 mmol) was reacted with 1-tert-butoxy- N,N,N’, N'tetramethylmethanediamine (Bredereck's reagent, CAS No. [5815-08-7]; 1.20 eq., 7.68 g, 44.1 mmol) in toluene (100 mL) at 100 °C for 2 h. Another amount of 1- tert-butoxy-N,N,N',N-tetramethylmethanediamine (1.20 eq., 7.689, 44.1 mmol) was added and stirring at 100 °C continued for another 6 h. The reaction mixture was concentrated under reduced pressure and the obtained crude title compound used in the subsequent reaction without further purification steps. UPLC-MS (Method 1): Ry = 0.83 min; MS (ESIpos): m / z = 192 [M+H]*. Step 2 4,5-dihydro-1H-furo[2,3-glindazole H N~N { “0 Oo According to GP B crude (5E / 2)-5-[(dimethylamino)methylidene]-6,7-dihydro-1- benzofuran-4(5H)-one (1.0 eq., 7.0 g, 37 mmol) from step 1 was reacted with hydrazine hydrate 1:1 (5.0 eq., 8.9 mL, 180 mmol) in ethanol (100 mL) at 70 °C for 3 h to give upon column chromatography (SiOz, DCM / MeOH) the title compound (5.6 g, 35% over two steps). UPLC-MS (Method 1): Ry = 0.80 min; MS (ESIpos): m / z = 161 [M+H]*. Step 3 2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-gJindazole \ a \ Yo 0 According to GP C (conditions B) 4,5-dihydro-1H-furo[2,3-glindazole (1.0eq., 5.6 g, 35 mmol) from step2 was reacted with 2-(bromomethyl)pyridine (1.2eq., 7.2, 42 mmol), potassium carbonate (15 eq., 73 g, 530 mmol) and DMAP (2.5 mol%, 110 mg, 880 pmol) in EtOAc (150 mL) at 75 °C for 3 days to give upon column chromatography (SiO, DCM / MeOH) the title compound (6.0 g, 52%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 2.86 (s, 4H), 5.34 (s, 2H), 6.62 (d, 1H), 7.03-7.05 (m, 1H), 7.27-7.31 (m, 1H), 7.57-7.60 (m, 2H), 7.76 (dt, 1H), 8.52-8.53 (m, 1H). UPLC-MS (Method 1): Ry = 0.96 min; MS (ESIpos): m / z = 252 [M+H]". Step 4 2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carbaldehyde \ NN IN -iy §) o \ oH According to GP F 2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-gJindazole (1.00 eq, 1.00 g, 3.98 mmol) from step 3 was reacted with phosphoric trichloride (CAS No. [10025- 87-3]; 5.0 eq., 1.9 mL, 20 mmol) and DMF (5.0 eq., 1.5 mL, 20 mmol) at rt for 1 h to give upon column chromatography (SiOz, DCM / MeOH) and subsequent preparative HPLC the title compound (63 mg, 5%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 2.91-2.95 (m, 2H), 3.00-3.04 (m, 2H), 5.39 (s, 2H), 7.09 (d, 1H), 7.31 (ddd, 1H), 7.67 (s, 1H), 7.70 (s, 1H), 7.77 (dt, 1H), 8.52-8.54 (m, 1H), 9.52 (s, TH). UPLC-MS (Method 1): Ry = 0.83 min; MS (ESIpos): m / z = 280 [M+H]". Intermediate 2* Step 1 ethyl 8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate \ N—=N CH, CHjy ra of CD 31s CH WV I #- N oo According to GP C (conditions B) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.0 eq., 3.09, 12 mmol) was reacted with 2- (bromomethyl)pyridine (1.6 eq., 3.4 g, 20 mmol), potassium carbonate (15.0 eq., 25.3 g, 183 mmol) and DMAP (2.5 mol%, 37 mg, 300 pmol) in EtOAc (200 mL) at 75 °C for 44 h. Another amount of 2-(bromomethyl)pyridine (1.3 eq., 2.7g, 16 mmol) and DMAP (2.5 mol%, 37 mg, 300 pymol) was added and stirring at 75 °C continued for another 3 days to give upon column chromatography (SiOz, hexane / DCM) the title compound (3.79, 71%). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.46 (s, 3H), 2.85-2.95 (m, 4H), 4.26 (@ 2H), 5.39 (s, 2H), 7.07 (d, 1H), 7.31 (ddd, 1H), 7.65 (s, 1H), 7.77 (dt, 1H), 8.53-8.55 (m, 1H). UPLC-MS (Method 1): Rt = 1.15 min; MS (ESIpos): m / z = 338 [M+H]*. Step 2 8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxylic acid 2 Ne | PN CH, ra / nw CHa §! { or BB oo According to GP D ethyl 8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (3.68 g, 10.9 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 82 mL, 160 mmol) in a 1:1 mixture of ethanol and THF (40 mL) at 70 °C overnight. Upon acidification (pH 2-3) with 6 N aqueous hydrochloric acid and dilution with EtOAc a precipitate was formed which was isolated by filtration. The precipitate was taken up with EtOAc, dried with Na2SOx, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (1.9 g, 54%). "H NMR (400 MHz, DMSO-d6) 5 [ppm]: 2.44 (s, 3H), 2.84-2.93 (m, 4H), 5.39 (s, 2H), 7.07 (d, 1H), 7.32 (dd, 1H), 7.65 (s, 1H), 7.78 (dt, 1H), 8.53-8.55 (m, 1H), 12.80 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.50 min; MS (ESIpos): m / z = 310 [M+H]". Intermediate 3: Step 1 ethyl 8-methyl-2-[(pyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]Jindazole-7- carboxylate =\ $A N—=N CH, CHjy ra of CD 31s CH WV I #- N oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.0 eq., 1.0 g, 4.1 mmol) was reacted with (pyridin- 3-yl)methanol (1.10 eq., 487 mg, 4.47 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 1.6 mL, 6.5 mmol) and TMAD (CAS No. [10465-78-8]; 1.6 eq., 1.1 g, 6.5 mmol) in toluene (30 mL) at rt overnight to give upon column chromatography (Si-NH SiOz, DCM / MeCOH) and trituration with hexane the title compound (1.6 g, 75% purity, 70%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 2.48 (s, 3H), 2.83-2.93 (m, 4H), 4.26 (9, 2H), 5.35 (s, 2H), 7.36-7.39 (m, 1H), 7.64 (t, 1H), 7.66 (s, 1H), 8.50 (dd, 1H), 8.52 (d, 1H). UPLC-MS (Method 1): Ry = 1.10 min; MS (ESIpos): m / z = 338 [M+H]*. Step 2 8-methyl-2-[(pyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxylic acid =\ \ NN CH4 1! OH / “Ha J) { ol I oo “o According to GP D ethyl 8-methyl-2-[(pyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.50 g, 75% purity, 3.33 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 82 mL, 160 mmol) in a 1:1 mixture of ethanol and THF (20 mL) at 70 °C overnight. Upon acidification (pH 4) with 4 N aqueous hydrochloric acid a precipitate was formed which was isolated by filtration and dried to give the desired carboxylic acid (331 mg, 77% purity, 25%). H NMR (400 MHz, DMSO-d6) 8 [ppm]: 2.46 (s, 3H), 2.82-2.91 (m, 4H), 5.34 (s, 2H), 7.38 (ddd, 1H), 7.64-7.67 (m, 2H), 8.50 (dd, 1H), 8.52 (d, 1H), 12.83 (br. s., 1H). UPLC-MS (Method 1): Rt = 0.47 min; MS (ESIpos): m / z = 310 [M+H]". Intermediate 4: Step 1 ethyl 8-methyl-2-[(pyridin-4-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]Jindazole-7- carboxylate \ NN CH, CH, o—’ NN O- ony oO Oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.0 eq., 1.0 g, 4.1 mmol) was reacted with (pyridin- 4-yl)methanol (1.10 eq., 487 mg, 4.47 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 1.6 mL, 6.5 mmol) and TMAD (CAS No. [10465-78-8]; 1.6 eq., 1.1 g, 6.5 mmol) in toluene (30 mL) at rt overnight. Another amount of (pyridin-4-yl)methanol (0.40 eq., 175 mg, 1.6 mmol), tri-n-butylphosphine (0.4 eq., 0.4 mL, 1.6 mmol) and TMAD (0.4 eq., 0.39, 1.6 mmol) were added and stirring continued for 2 days to give upon column chromatography (Si-NH SiOz, DCM / MeOH) the title compound (3 g, 20% purity, 44%). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.47 (s, 3H), 2.87-2.97 (m, 4H), 4.26 (9, 2H), 5.37 (s, 2H), 7.13-7.15 (m, 2H), 7.68 (s, 1H), 8.52-8.53 (m, 2H). UPLC-MS (Method 1): Ry = 1.09 min; MS (ESIpos): m / z = 338 [M+H]". Step 2 8-methyl-2-[(pyridin-4-yl)methyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxylic acid \ Ne | Ne CH, / ww CH J) [7 or BR 0" To According to GP D ethyl 8-methyl-2-[(pyridin-4-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (3 g, 20% purity, 4 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 31 mL, 61 mmol) in a 1:1 mixture of ethanol and THF (22 mL) at 70 °C overnight. Upon acidification with 4 N aqueous hydrochloric acid (pH 4) a precipitate was formed which was isolated by filtration and dried to give the desired carboxylic acid (467 mg, 35%). H NMR (400 MHz, DMSO-d) 8 [ppm]: 2.45 (s, 3H), 2.85-2.94 (m, 4H), 5.37 (s, 2H), 7.13-7.15 (m, 2H), 7.67 (s, 1H), 8.52-8.53 (m, 2H), 12.81 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.50 min; MS (ESIpos): m / z = 310 [M+H]". Intermediate 5: Step 1 ethyl 2-(cyclopropylmethyl)-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate Pp N—~N CH, CH, / i NN O-— rd 0 Oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.0eq., 1.09, 4.1mmol) was reacted with cyclopropylmethanol (1.5 eq., 490 pL, 6.1 mmol), tri-n-butylphosphine (CAS No. [998-40- 3]; 1.6eq, 1.6mL, 6.5mmol) and TMAD (CAS No. [10465-78-8]; 1.6eq., 1.1g, 6.5 mmol) in toluene (20 mL) at rt overnight to give upon column chromatography (Si-HP SiO;, hexane / EtOAc) the title compound (957 mg, 75%) along with the corresponding N1-isomer (155 mg, 12%). "H NMR (400 MHz, DMSO-d6) 8 [ppm]: 0.33-0.37 (m, 2H), 0.49-0.54 (m, 2H), 1.18-1.26 (m, 1H), 1.30 (t, 3H), 2.83-2.93 (m, 4H), 3.92 (d, 2H), 4.27 (q, 2H), 7.56 (s, TH). UPLC-MS (Method 1): Rt = 1.31 min; MS (ESIpos): m / z = 301 [M+H]". Step 2 2-(cyclopropylmethyl)-8-methyl-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxylic acid Pp N—| NN CH, sg IN CHa $$ { of \ lo] 0 According to GP D ethyl 2-(cyclopropylmethyl)-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.00 eq., 955 mg, 3.18 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 24 mL, 48 mmol) in a 1:1 mixture of ethanol and THF (22 mL) at 70 °C overnight. Upon acidification with 6 N aqueous hydrochloric acid (pH 4) a precipitate was formed which was isolated by filtration, washed with water and dried to give the desired carboxylic acid (945 mg, 100%). H NMR (400 MHz, DMSO-d6) 3 [ppm]: 0.33-0.37 (m, 2H), 0.49-0.54 (m, 2H), 1.17-1.27 (m, 1H), 2.48 (s, 3H), 2.82-2.91 (m, 4H), 3.91 (d, 2H), 7.54 (s, 1H), 12.81 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.55 min; MS (ESIpos): m / z = 273 [M+H]". Intermediate 6: Step 1 ethyl 2-{[(2R / S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylJmethyl}-8-methyl-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxylate oo J a) —0 N—=N CH, CH, Fe O— / CHa S$ { o- IR 0 © According to GP C (conditions B) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.0 eq., 930 mg, 3.78 mmol) was reacted with [(2R / S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylimethyl ~~ 4-methylbenzene-1-sulfonate (preparation described in: G.Guillaumet ef al., Tetrahedron 2004, 60, 6461-6473, cpd. 16B; 1.5 eq., 1.8 g, 5.7 mmol), potassium carbonate (15 eq., 7.8 g, 57 mmol) and DMAP (0.30 eq., 140 mg, 1.1 mmol) in MeCN (50 mL) at 60 °C for 9 days to give upon 2-fold column chromatography (Si-HP SiOz, hexane / EtOAc) the title compound (443 mg, 28%). "H NMR (400 MHz, DMSO-d) & [ppm]: 1.29 (t, 3H), 2.84-2.94 (m, 4H), 4.18-4.29 (m, 3H), 4.36-4.48 (m, 2H), 4.53 (dd, 1H), 4.62-4.66 (m, 1H), 6.96 (dd, 1H), 7.31 (dd, 1H), 7.56 (s, 1H), 7.77 (dd, 1H). UPLC-MS (Method 1): Ry = 1.17 min; MS (ESIpos): m / z = 396 [M+H]". Step 2 2-{[(2R / S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yl]methyl}-8-methyl-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxylic acid o— / 7 Ny 7 —0 \ NeN OH Ch CHy NN Ol oY 0 0 In a modification of GP D ethyl 2-{[(2R / S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2- yllmethyl}-8-methyl-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxylate (1.00 eq., 418 mg, 1.06 mmol) from step 1 was reacted with aqueous sodium hydroxide (4 M; 30 eq., 7.9 mL, 32 mmol) in THF (6 mL) at 70 °C overnight. Upon acidification with 6 N aqueous hydrochloric acid (pH 2) and dilution with EtOAc a precipitate was formed which was isolated by filtration. The filtrate was kept. The precipitate was taken up with EtOAc, dried with NazSOx, filtrated and concentrated under reduced pressure to give a first crop of the desired carboxylic acid (190 mg, 47%). The above obtained filtrate was separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOs;, filtrated and concentrated under reduced pressure to give a second crop of the desired carboxylic acid (160 mg, 39%). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 2.48 (s, 3H), 2.83-2.92 (m, 4H), 4.20 (dd, 1H), 4.36-4.47 (m, 2H), 4.52 (dd, 1H), 4.62-4.67 (m, 1H), 6.96 (dd, 1H), 7.31 (dd, 1H), 7.55 (s, 1H), 7.76 (dd, 1H), 12.83 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.51 min; MS (ESIpos): m / z = 368 [M+H]* Intermediate 7: Step 1 ethyl 8-methyl-2-{[6-(trifluoromethyl)pyridin-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate F NL F \ \ NN CH; ~~ CH, o—’ YN Ap TN oo According to GP C (conditions B) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 500 mg, 2.03 mmol) was reacted with 2- (chloromethyl)-6-(trifluoromethyl)pyridine (1.5 eq., 596 mg, 3.05 mmol), potassium carbonate (15.0 eq., 4.21 g, 30.5 mmol) in MeCN (10 mL) at 60 °C for 3 days to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (493 mg, 57%). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.46 (s, 3H), 2.87-2.96 (m, 4H), 4.26 (q, 2H), 5.52 (s, 2H), 7.27 (d, 1H), 7.72 (s, 1H), 7.84 (d, 1H), 8.08 (t, 1H). UPLC-MS (Method 1): Ri = 1.36 min; MS (ESIpos): m / z = 406 [M+H]*. Step 2 8-methyl-2-{[6-(trifluoromethyl)pyridin-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid F TH Cr F 7 AY Ne | NN CH, / ww hj ) { or \ oo According to GP D ethyl 8-methyl-2-{[6-(trifluoromethyl)pyridin-2-ylJmethyl}-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxylate (438 mg, 1.19 mmol) from step 1 was reacted with aqueous lithium hydroxide (1 M; 15 eq., 18 mL, 18 mmol) in a 1:1 mixture of ethanol and THF (35 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOy, filtrated and concentrated under reduced pressure to the desired carboxylic acid (405 mg, 87%). H NMR (400 MHz, DMSO-d6) & [ppm]: 2.44 (s, 3H), 2.86-2.94 (m, 4H), 5.51 (s, 2H), 7.26 (d, 1H), 7.71 (s, 1H), 7.84 (d, 1H), 8.08 (t, 1H), 12.84 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.66 min; MS (ESIpos): m / z = 378 [M+H]". Intermediate 8: Step 1 ethyl 8-methyl-2-{[5-(trifluoromethyl)pyridin-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate FF Yr WW Ne=N CH, CHy rc Ei Ol’ sg ¥ CHa OW) { ~ o- N oO © In a modification of GP C (conditions B) an ice-cooled solution of ethyl 8-methyl-4,5- dihydro-1H-furo[2,3-glindazole-7-carboxylate (commercially available; 1.00 eq., 171 mg, 694 umol) in DMF (6 mL) was treated with sodium hydride (CAS No. [7646-69-7]; 55% purity, 1.2 eq., 36 mg, 830 pmol) for 30 minutes upon which 2-(bromomethyl)-5- (trifluoromethyl)pyridine (1.20 eq., 200 mg, 833 pmol) was added, the reaction mixture warmed to rt and stirring continued for 45 minutes. The reaction mixture was diluted with sat. aqueous ammonium chloride and EtOAc, the phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were dried with NazSOs, filtrated, concentrated under reduced pressure and the obtained material subjected to column chromatography (Si-NH SiO2, DCM / MeOH) to give the title compound (81 mg, 24%). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.46 (s, 3H), 2.87-2.96 (m, 4H), 4.26 (a, 2H), 5.54 (s, 2H), 7.25 (d, 1H), 7.71 (s, 1H), 8.21 (dd, 1H), 8.95 (d, 1H). UPLC-MS (Method 1): Ry = 1.34 min; MS (ESIpos): m / z = 406 [M+H]". Step 2 8-methyl-2-{[5-(trifluoromethyl)pyridin-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid FF Vr TY 7 N~N CH, 1 OH [I 1 wr WJ [of BR QO 0 According to GP D ethyl 8-methyl-2-{[5-(trifluoromethyl)pyridin-2-ylJmethyl}-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxylate (76.0 mg, 187 umol) from step 1 was reacted with aqueous lithium hydroxide (1 M; 30 eq., 5.6 mL, 5.6 mmol) in a 1:1 mixture of ethanol and THF (20 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSO, filtrated and concentrated under reduced pressure to the desired carboxylic acid (71 mg, 84%). H NMR (400 MHz, DMSO-d6) & [ppm]: 2.44 (s, 3H), 2.86-2.94 (m, 4H), 5.53 (s, 2H), 7.25 (d, 1H), 7.70 (s, 1H), 8.21 (d, 1H), 8.95 (d, 1H), 12.80 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.62 min; MS (ESIpos): m / z = 378 [M+H]". Intermediates 9-1 and 9-2: Step 1 ethyl 2-[(3-chloro-5-fluoropyridin-2-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate F = ly N=N CH, CH, 7° 7 CY — WAP IR o ‘oo According to GP C (conditions B) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 500 mg, 2.03 mmol) was reacted with 2- (bromomethyl)-3-chloro-5-fluoropyridine (1.5eq., 684 mg, 3.05mmol), potassium carbonate (15.0 eq., 4.21 g, 30.5 mmol) in MeCN (10 mL) at 60 °C for 3 days to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (364 mg, 44%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 2.44 (s, 3H), 2.83-2.93 (m, 4H), 4.26 (a, 2H), 5.51 (s, 2H), 7.56 (s, 1H), 8.16 (dd, 1H), 8.58 (d, 1H). UPLC-MS (Method 1): Ry = 1.33 min; MS (ESIpos): m / z = 390 / 392 [M+H]* (Cl isotope pattern). Step 2 2-[(3-chloro-5-fluoropyridin-2-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid (Intermediate 9-1) and 2-[(3-chloro-5-ethoxypyridin-2-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid (Intermediate 9-2) CH, J \ F 0 Va oy Vs od J \ ‘N— Ne N=N CH, N-N CH, WY ss ¥ XX ! Fe OH XX } ye OH [3 0 0 0 o According to GP D ethyl 2-[(3-chloro-5-fluoropyridin-2-yl)methyl]-8-methyl-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxylate (1.00 eq, 355 mg, 911 umol) from step 1 was reacted with aqueous lithium hydroxide (1 M; 15 eq., 14 mL, 14 mmol) in a 1:1 mixture of ethanol and THF (27 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOs, filtrated and concentrated under reduced pressure to give a 1:1 mixture of the title compounds (405 mg). 9-1: UPLC-MS (Method 1): R= 0.60 min; MS (ESIpos): m / z = 362 / 364 [M+H]* (Cl isotope pattern). 9-2: UPLC-MS (Method 1): R= 0.67 min; MS (ESIpos): m / z = 388 / 390 [M+H]* (Cl isotope pattern). Intermediate 10: Step 1 ethyl 2-[(3-chloropyridin-2-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-gJindazole- 7-carboxylate ol NN CH CH, 1c ie / Ww CHj $ { o- IR oo According to GP C (conditions B) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 250 mg, 1.02 mmol) was reacted with 3- chloro-2-(chloromethyl)pyridine (1.50 eq., 247 mg, 1.52 mmol), potassium carbonate (15eq., 2.1g, 15 mmol) in MeCN (5 mL) at 60 °C overnight to give after filtration the crude title compound (388 mg, 95%) which was not further purified. "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 2.44 (s, 3H), 2.84-2.94 (m, 4H), 4.26 (q, 2H), 5.53 (s, 2H), 7.42 (dd, 1H), 7.56 (s, 1H), 7.98 (dd, 1H), 8.50 (dd, 1H). UPLC-MS (Method 1): Ry = 1.29 min; MS (ESIpos): m / z = 372 / 374 [M+H]* (Cl isotope pattern). Step 2 2-[(3-chloropyridin-2-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-gJindazole-7- carboxylic acid = Ne N=N CH, 1 / ww CH3 OW { or IR oo According to GP D ethyl 2-[(3-chloropyridin-2-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 382 mg, 1.03 mmol) from step 1 was reacted with aqueous lithium hydroxide (1 M; 15 eq., 7.7 mL, 15 mmol) in a 1:1 mixture of ethanol and THF (10 mL) at 70 °C for 3 days. Upon acidification with 4 N aqueous hydrochloric acid (pH 4) and dilution with EtOAc a precipitate was formed which was isolated by filtration, washed with water and dried to give a first crop of the desired carboxylic acid (204 mg, 57%). The filtrate was separated, and the aqueous phase extracted with EtOAc. The combined organic phases were dried with Na>SOy, filtrated and concentrated under reduced pressure to give a second crop of the desired carboxylic acid (123 mg, 31%). TH NMR (400 MHz, DMSO-d6) 8 [ppm]: 2.42 (s, 3H), 2.83-2.91 (m, 4H), 5.52 (s, 2H), 7.42 (dd, 1H), 7.55 (s, 1H), 7.98 (dd, 1H), 8.50 (dd, 1H), 12.81 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.56 min; MS (ESIpos): m / z = 344 / 346 [M+H]* (Cl isotope pattern). Intermediate 11: Step 1 ethyl 8-methyl-2-[(3-methylpyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate HC N~N CH; CHj fe a oO / 1 CH J) [™o BR o ‘o According to GP C (conditions B) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 264 mg, 1.07 mmol) was reacted with 2- (chloromethyl)-3-methylpyridine hydrogen chloride (1 / 1) (1.50 eq., 286 mg, 1.61 mmol), potassium carbonate (15 eq., 2.2 g, 16 mmol) in MeCN (5 mL) at 60 °C for two days to give after filtration the crude title compound (413 mg, 100%) which was not further purified. H NMR (400 MHz, DMSO-d6) 8 [ppm]: 1.29 (t, 3H), 2.39 (s, 3H), 2.46 (s, 3H), 2.82-2.92 (m, 4H), 4.26 (q, 2H), 5.39 (s, 2H), 7.25 (dd, 1H), 7.47 (s, 1H), 7.62 (dd, 1H), 8.35 (dd, 1H). UPLC-MS (Method 1): Ry = 1.23 min; MS (ESIpos): m / z = 352 [M+H]*. Step 2 8-methyl-2-[(3-methylpyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid ) HC Ne | NN CH4 ! / ww Cha $ { or BR 0” To According to GP D ethyl 8-methyl-2-[(3-methylpyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 400 mg, 1.14 mmol) from step 1 was reacted with aqueous lithium hydroxide (1 M; 15 eq., 17 mL, 17 mmol) in a 1:1 mixture of ethanol and THF (10 mL) at 70 °C overnight. Upon acidification with 4 N aqueous hydrochloric acid (pH 4) and dilution with EtOAc a precipitate was formed which was isolated by filtration, washed with water and dried to give a first crop of the desired carboxylic acid (209 mg, 56%). The filtrate was separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOs, filtrated and concentrated under reduced pressure to give a second crop of the desired carboxylic acid (54 mg, 12%). H NMR (400 MHz, DMSO-d6) 8 [ppm]: 2.39 (s, 3H), 2.44 (s, 3H), 2.81-2.90 (m, 4H), 5.38 (s, 2H), 7.25 (dd, 1H), 7.46 (s, 1H), 7.62 (dd, 1H), 8.35 (dd, 1H), 12.79 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.50 min; MS (ESIpos): m / z = 324 [M+H]". Intermediate 12: Step 1 ethyl 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate CH, 7 = \ 7 N—~N CH, CH, 71° 7 Lo” / Ww cn ) {7 on TN oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (5- methylpyridin-2-ylymethanol (1.50 eq., 225 mg, 1.83 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 pL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336mg, 1.95mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (395 mg, 88%). "H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.27 (s, 3H), 2.46 (s, 3H), 2.84-2.94 (m, 4H), 4.26 (q, 2H), 5.34 (s, 2H), 7.01 (dd, 1H), 7.58 (dd, 1H), 7.62 (s, 1H), 8.37 (dd, 1H). UPLC-MS (Method 1): Ry = 1.18 min; MS (ESIpos): m / z = 352 [M+H]*. Step 2 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid CH, 7 = 7 Ne N=-N CH, 1 OH / Ww “Ra §! { ol BB o “o According to GP D ethyl 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 388 mg, 1.10 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 8.3 mL, 17 mmol) in a 1:1 mixture of ethanol and THF (16 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 6 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na,SOs, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (328 mg, 85%). H NMR (400 MHz, DMSO-d6) 8 [ppm]: 2.27 (s, 3H), 2.44 (s, 3H), 2.83-2.92 (m, 4H), 5.33 (s, 2H), 7.01 (dd, 1H), 7.59 (dd, 1H), 7.61 (s, 1H), 8.37 (dd, 1H), 12.78 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.54 min; MS (ESIpos): m / z = 324 [M+H]". Intermediate 13: Step 1 methyl (5E / Z)-5-[(dimethylamino)methylidene]-3-methyl-4-oxo0-4,5,6,7-tetrahydro- 1-benzofuran-2-carboxylate Q cH, O—CHjy 1 CHs | re o. N HC C 0 CHa According to GP A (conditions A) methyl 3-methyl-4-oxo-4,5,6,7-tetrahydro-1- benzofuran-2-carboxylate (commercially available, CAS No. [40200-70-2]; 10.0g, 48.0 mmol) was reacted with 1-fert-butoxy-N,N,N'N-tetramethylmethanediamine (Bredereck’s reagent, CAS No. [5815-08-7]; 1.2eq., 12mL, 58 mmol) in toluene (100 mL) at 100°C overnight. Another amount of 1-tert-butoxy-N,N,N'N*- tetramethylmethanediamine (0.50 eq., 5.0 mL, 24 mmol) was added and stirring at 100 °C continued for another 5 days. The reaction mixture was concentrated under reduced pressure and the obtained crude title compound used in the subsequent reaction without further purification steps. UPLC-MS (Method 1): Ry = 0.95 / 1.01 min; MS (ESIpos): m / z = 264 [M+H]*. Step 2 methyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7-carboxylate H NN Nei CHg4 O-CHjy ge Cha { / o BB o 0 According to GP B crude methyl (5E / Z)-5-[(dimethylamino)methylidene]-3-methyl-4-oxo- 4,5,6,7-tetrahydro-1-benzofuran-2-carboxylate (1.0 eq., 13 g, 48 mmol) from step 1 was reacted with hydrazine hydrate 1:1 (4.0 eq., 9.5 mL, 195 mmol) in ethanol (150 mL) at 70°C for 4h and at rt overnight to give upon column chromatography (SiOz, hexane / EtOAC) the title compound (771 mg, 7% over 2 steps). 'H NMR (400 MHz, DMSO-d6) & [ppm]: 2.51 (s, 3H; partially covered by solvent peak), 2.84-2.93 (m, 4H), 3.80 (s, 3H), 7.52 (s, 1H), 12.49 (s, 1H). UPLC-MS (Method 1): Ry = 0.88 min; MS (ESIpos): m / z = 233 [M+H]". Step 3 methyl 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate TNcH, \ ‘Nee N=N CH, l O-CHj, / ChHj; OW { ~o- IR oo According to GP C (conditions B) methyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (1.0 eq., 770 mg, 3.3 mmol) from step 2 was reacted with 2-(bromomethyl)- 6-methylpyridine (1.50 eq., 926 mg, 4.98 mmol), potassium carbonate (10 eq., 46g, 33 mmol) in MeCN (10 mL) at 60 °C overnight to give after filtration the crude title compound (1.27 g, 100%) which was not further purified. H NMR (400 MHz, DMSO-d8) 5 [ppm]: 2.46-2.46 (m, 6H), 2.85-2.94 (m, 4H), 3.79 (s, 3H), 5.33 (s, 2H), 6.79 (d, 1H), 7.16 (d, 1H), 7.62-7.66 (m, 2H). UPLC-MS (Method 1): Rt = 1.14 min; MS (ESIpos): m / z = 338 [M+H]". Step 4 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid TN cH, 0 NN CHy 1 OH / oR §! [7 ol BB oo “o In a modification of GP D methyl 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxylate (1.0 eq., 1.2 g, 2.2 mmol) from step 3 was reacted with aqueous sodium hydroxide (4 M; 30 eq., 17 mL, 66 mmol) in THF (14 mL) at 70 °C for two days. The reaction mixture was acidified with aqueous 2 N HCI (pH 4-5) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NaSOa, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (980 mg, 85% purity, 100%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 2.45-2.46 (m, 6H), 2.84-2.92 (m, 4H), 5.33 (s, 2H), 6.79 (d, 1H), 7.16 (d, 1H), 7.62-7.66 (m, 2H)., 12.52 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.55 min; MS (ESIpos): m / z = 324 [M+H]*. Intermediates 14-1 and 14-2: Step 1 ethyl 8-methyl-2-[(2-methylpyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate =\ $¢ CH, N—~N CH; ~~ CHj Aq o—" / Ww on WV [7 o N oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (2- methylpyridin-3-yl)methanol (1.50 eq., 225 mg, 1.83 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 pL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336mg, 1.95mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (315 mg, 71%). "H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.47 (s, 3H), 2.54 (s, 3H), 2.84-2.94 (m, 4H), 4.26 (q, 2H), 5.35 (s, 2H), 7.17-7.25 (m, 2H), 7.59 (s, 1H), 8.36 (dd, 1H). UPLC-MS (Method 1): Ry = 1.12 min; MS (ESIpos): m / z = 352 [M+H]". Step 2 8-methyl-2-[(2-methylpyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid hydrogen chloride (1 / 1) and 8-methyl-2-[(2-methylpyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid =\ = § 4 CIH So ‘CH, \ CHy A CH, CH, ¥ 1] OH XA_A OH J CH, XN ol \ 0 0 a CH, XN C IN oO Cc 0 According to GP D ethyl 8-methyl-2-[(2-methylpyridin-3-yl)methyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 313 mg, 891 umol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 6.7 mL, 13 mmol) in a 1:1 mixture of ethanol and THF (14 mL) at 70 °C overnight. Upon acidification with 6 N aqueous hydrochloric acid (pH 4) and dilution with EtOAc a precipitate was formed which was isolated by filtration and dried to give the hydrochloride salt of the desired carboxylic acid (Intermediate 14-1, 225 mg, 67%). The filtrate was separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSO, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (Intermediate 14-2, 47 mg, 15%). 14-1: 'H NMR (400 MHz, DMSO-d6) 5 [ppm]: 2.44 (s, 3H), 2.79 (s, 3H), 2.86-2.94 (m, 4H), 5.52 (s, 2H), 7.68 (s, 1H), 7.73-7.77 (m, 1H), 7.83-7.85 (m, 1H), 8.65 (dd, 1H), 12.84 (br. s., 1H). 14-1: UPLC-MS (Method 1): R; = 0.50 min; MS (ESlpos): m / z = 324 [M-CIT*. Intermediates 15-1 and 15-2* Step 1 ethyl 8-methyl-2-[(6-methylpyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate CH, 7 = $A N~N CH; ~~ CH, £2 oo Fr Oo’ 4s on $ {7 o- N oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (6- methylpyridin-3-yl)methanol (1.50 eq., 225 mg, 1.83 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 UL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336mg, 1.95mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (SiC, hexane / EtOAc) the title compound (299 mg, 66%). "H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.43 (s, 3H), 2.48 (s, 3H), 2.83-2.92 (m, 4H), 4.26 (q, 2H), 5.28 (s, 2H), 7.22 (d, 1H), 7.56 (dd, 1H), 7.63 (s, 1H), 8.40 (d, 1H). UPLC-MS (Method 1): Ry = 1.17 min; MS (ESIpos): m / z = 352 [M+H]*. Step 2 8-methyl-2-[(6-methylpyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid hydrogen chloride (1 / 1) and 8-methyl-2-[(6-methylpyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid CH, 7 CH, 7 3 = = A Wh CIH No N=N h IN—~ N—N ~u 7 N CHgy l CH, 1 OH / CHa WL ( OH N\ 0 0 ii N\ {ot 0 ‘o According to GP D ethyl 8-methyl-2-[(6-methylpyridin-3-yl)methyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxylate (1.00 eq., 291 mg, 828 umol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 6.2 mL, 12 mmol) in a 1:1 mixture of ethanol and THF (12 mL) at 70 °C overnight. Upon acidification with 6 N aqueous hydrochloric acid (pH 3) and dilution with EtOAc a precipitate was formed which was isolated by filtration and dried to give the hydrochloride salt of the desired carboxylic acid (Intermediate 15-1, 195 mg, 63%). The filtrate was separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOy, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (Intermediate 15-2, 44 mg, 15%). 15-1: 'H NMR (400 MHz, DMSO-d8) 5 [ppm]: 2.46 (s, 3H), 2.57 (s, 3H), 2.82-2.91 (m, 4H), 5.39 (s, 2H), 7.57 (d, 1H), 7.67 (s, 1H), 7.94 (d, 1H), 8.59 (d, 1H), 12.84 (br. s., 1H). 15-1: UPLC-MS (Method 1): R = 0.51 min; MS (ESIpos): m / z = 324 [M-CI. Intermediates 16-1 and 16-2* Step 1 ethyl 2-[(2,6-dimethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate CH, 7 = $4 CH, N~N CH; ~~ CH, £2 oo Fr Ci’ 4s on $ {7 o- N oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (2,6- dimethylpyridin-3-yl)methanol (1.50 eq., 251 mg, 1.83 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 UL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336mg, 1.95mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (SiC, hexane / EtOAc) the title compound (312 mg, 63%). "H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.39 (s, 3H), 2.47 (s, 3H), 2.83-2.93 (m, 4H), 4.26 (q, 2H), 5.29 (s, 2H), 7.04 (d, 1H), 7.20 (d, 1H), 7.55 (s, TH). UPLC-MS (Method 1): Rt = 1.23 min; MS (ESIpos): m / z = 366 [M+H]". Step 2 2-[(2,6-dimethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylic acid hydrogen chloride (1 / 1) and 2-[(2,6-dimethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylic acid CH, CH, F / = = CH, . CH, bi A \ 3 i ‘N=N N=N - ~u IN=—=N CHy Ln FH IN~IN po IN CH | CHa \ GH XN OH \ OH RB [> 0 0 0 0 According to GP D ethyl 2-[(2,6-dimethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxylate (1.00 eq., 305 mg, 835 uymol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 6.3 mL, 13 mmol) in a 1:1 mixture of ethanol and THF (12 mL) at 70 °C overnight. Upon acidification with 6 N aqueous hydrochloric acid (pH 3) and dilution with EtOAc a precipitate was formed which was isolated by filtration and dried to give the hydrochloride salt of the desired carboxylic acid (Intermediate 16-1, 86 mg, 27%). The filtrate was separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSO, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (Intermediate 16-2, 91 mg, 24%). 16-1: 'H NMR (400 MHz, DMSO-d8) & [ppm]: 2.44 (s, 3H), 2.62 (br. s., 3H), 2.74 (br. s., 3H), 2.84-2.93 (m, 4H), 5.45 (s, 2H), 7.57 (br. s., 2H), 7.65 (s, 1H), 7.81 (br. s., 1H), 12.83 (br. s., 1H). 16-1: UPLC-MS (Method 1): R; = 0.58 min; MS (ESIpos): m / z = 338 [M-CIT*. Intermediates 17-1 and 17-2: Step 1 ethyl 8-methyl-2-[(2-methylpyridin-4-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate \ NN CH; ~~ CHj J Co” YN Ap TN oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (2- methylpyridin-4-yl)methanol (1.10 eq., 165 mg, 1.34 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 UL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336mg, 1.95mmol) in toluene (12mL) at rt overnight to give upon column chromatography (SiOz, CHzCl2 / hexane) the title compound (524 mg, 44% purity, 54%). H NMR (400 MHz, DMSO-d6) 8 [ppm]: 1.29 (t, 3H), 2.43 (s, 3H), 2.47 (s, 3H), 2.85-2.95 (m, 4H), 4.26 (q, 2H), 5.31 (s, 2H), 6.94 (d, 1H), 7.05 (s, 1H), 7.66 (s, 1H), 8.38 (d, 1H). UPLC-MS (Method 1): Ri = 1.15 min; MS (ESIpos): m / z = 352 [M+H]*. Step 2 8-methyl-2-[(2-methylpyridin-4-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid hydrogen chloride (1 / 1) and 8-methyl-2-[(2-methylpyridin-4-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid and CIH Ne| Ne NN CH, MN CHg OH NA A OH / Wu oR WJ {7 of A o ‘o / uw LH3 WJ { ot \ oo According to GP D ethyl 8-methyl-2-[(2-methylpyridin-4-yl)methyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 522 mg, 1.22 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 17 eq., 10 mL, 21 mmol) in a 1:1 mixture of ethanol and THF (12 mL) at 70 °C overnight and at rt for two days . Upon acidification with 4 N aqueous hydrochloric acid (pH 3.5) and dilution with EtOAc a precipitate was formed which was isolated by filtration and dried to give the hydrochloride salt of the desired carboxylic acid (Intermediate 17-1, 168 mg, 61%). The filtrate was separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na.SOs, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (Intermediate 17-2, 285 mg, 50% purity, 36%). 17-1: 'H NMR (400 MHz, DMSO-d6) 5 [ppm]: 2.44 (s, 3H), 2.66 (s, 3H), 2.87-2.95 (m, 4H), 5.57 (s, 2H), 7.39 (d, 1H), 7.53 (s, 1H), 7.73 (s, 1H), 8.65 (d, TH), 12.84 (br. s., 1H). 17-1: UPLC-MS (Method 1): Rt = 0.51 min; MS (ESIpos): m / z = 324 [M-CI]*. Intermediates 18-1 and 18-2: Step 1 ethyl 2-[(2,6-dimethylpyridin-4-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (2,6- dimethylpyridin-4-yl)methanol (1.50 eq., 251 mg, 1.83 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 UL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336mg, 1.95mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (419 mg, 83%). "H NMR (400 MHz, DMSO-d8) & [ppm]: 1.29 (t, 3H), 2.22 (s, 3H), 2.41 (s, 3H), 2.47 (s, 3H), 2.85-2.95 (m, 4H), 4.26 (q, 2H), 5.28 (s, 2H), 6.71 (s, 1H), 7.00 (s, 1H), 7.62 (s, 1H). UPLC-MS (Method 1): Ry = 1.29 min; MS (ESIpos): m / z = 366 [M+H]". Step 2 2-[(2,6-dimethylpyridin-4-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylic acid hydrogen chloride (1 / 1) and 2-[(2,6-dimethylpyridin-4-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylic acid sC nat AN =N, CH, \ CHa 7 A \ 2 N Tp N—~N ~u N-N CH, 1 CHa ag np NA J OH fm Foray c | FH oH §) Cr OH DD 0 0 ° 0 0 According to GP D ethyl 2-[(2,6-dimethylpyridin-4-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 408 mg, 1.12 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 8.4 mL, 17 mmol) in a 1:1 mixture of ethanol and THF (16 mL) at 70 °C overnight. Upon acidification with 6 N aqueous hydrochloric acid (pH 3) and dilution with EtOAc a precipitate was formed which was isolated by filtration and dried to give the hydrochloride salt of the desired carboxylic acid (Intermediate 18-1, 94 mg, 22%). The filtrate was separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOy, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (Intermediate 18-2, 161 mg, 32%). 18-1: 'H NMR (400 MHz, DMSO-d8) & [ppm]: 2.35 (br. s., 3H), 2.45 (s, 3H), 2.55 (br. s., 3H), 2.85-2.94 (m, 4H), 5.46 (s, 2H), 8.97 (br. s., 1H), 7.33 (br. s., TH), 7.69 (s, 1H), 12.83 (br. s., 1H). 18-1: UPLC-MS (Method 1): R; = 0.58 min; MS (ESIpos): m / z = 338 [M-CI]*. Intermediate 19: Step 1 ethyl 8-methyl-2-[(pyrimidin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylate | h Ny) NN NN CH, CH, Fre oy Oo” / WW CH WJ [7 on \ 0" o According to GP C (conditions B) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 260 mg, 1.06 mmol) was reacted with 2- (chloromethyl)pyrimidine (1.50 eq., 204 mg, 1.58 mmol) and potassium carbonate (15eq., 2.2 g, 16 mmol) in MeCN (5 mL) at 60 °C overnight. DMAP (5 mol%, 6.5 mg, 53 pmol) was added and stirring at 60 °C continued for 4 days to give after filtration the crude title compound (332 mg, 79%) which was not further purified. H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.44 (s, 3H), 2.86-2.95 (m, 4H), 4.26 (q, 2H), 5.51 (s, 2H), 7.45 (t, 1H), 7.63 (s, 1H), 8.79-8.80 (m, 2H). UPLC-MS (Method 1): Rt = 1.03 min; MS (ESIpos): m / z = 339 [M+H]". Step 2 8-methyl-2-[(pyrimidin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid | A N / ) LN ‘Ne=N CH, 1 / nw Cha S$ { or IR oo According to GP D ethyl 8-methyl-2-[(pyrimidin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.00 eq., 332 mg, 834 umol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 6.3 mL, 13 mmol) in a 1:1 mixture of ethanol and THF (8 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and concentrated under reduced pressure to give the crude title compound along with salts (1.8 g) which was not further purified. UPLC-MS (Method 1): Rt = 0.44 min; MS (ESIpos): m / z = 311 [M+H]". Intermediate 20: Step 1 ethyl 8-methyl-2-[(pyrimidin-5-yl)methyl]-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylate \ NN CH; ~~ CH, o—’ YN Ap TN oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (pyrimidin-5-yl)methanol (1.50 eq., 201 mg, 1.83 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 UL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336mg, 1.95mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (Si-NH SiOz, hexane / CH:Cl. / MeOH) the title compound (483 mg, 52% purity, 61%). "H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 2.47 (s, 3H), 2.83-2.93 (m, 4H), 4.26 (q, 2H), 5.39 (s, 2H), 7.70 (s, 1H), 8.74 (s, 2H), 9.13 (s, 1H). UPLC-MS (Method 1): Ry = 1.02 min; MS (ESIpos): m / z = 339 [M+H]*. Step 2 8-methyl-2-[(pyrimidin-5-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]Jindazole-7- carboxylic acid \ Ne | Ne CH, / ww CH J) [7 or BR 0" To According to GP D ethyl ethyl 8-methyl-2-[(pyrimidin-5-yl)methyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 480 mg, 52% purity, 738 pmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 5.5mL, 11 mmol) in a 1:1 mixture of ethanol and THF (5.2 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 6 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na.SOs, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (439 mg, 37% purity, 71%). "H NMR (400 MHz, DMSO-d6) 5 [ppm]: 2.46 (s, 3H), 2.83-2.92 (m, 4H), 5.38 (s, 2H), 7.70 (s, 1H), 8.74 (s, 2H), 9.13 (s, 1H), 12.73 (br. s., 1H). UPLC-MS (Method 1): Rt = 0.44 min; MS (ESIpos): m / z = 311 [M+H]". Intermediate 21: Step 1 ethyl 2-{[(2R)-1,4-dioxan-2-ylJmethyl}-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylate According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 250 mg, 1.02 mmol) was reacted with [(2R)-1,4-dioxan-2-ylJmethanol (1.50 eq., 180 mg, 1.52 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 410 uL, 1.6 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 280mg, 1.62 mmol) in toluene (8 mL) at rt overnight. Another amount of tri-n- butylphosphine (0.30 eq., 76 pL, 300 ymol) and TMAD (0.30 eq., 52 mg, 0.31 mmol) was added and stirring at rt continued for four days to give upon two consecutive column chromatographies (SiOz, CH2Cl. / MeOH) the title compound (739 mg, 35-40% purity, 74%). UPLC-MS (Method 1): Rt = 1.12 min; MS (ESIpos): m / z = 347 [M+H]". Step 2 2-{[(2R)-1,4-dioxan-2-ylJmethyl}-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid O— I —) Ne | Ne CH, / ww CH J) [7 or BR 0" To According to GP D ethyl 2-{[(2R)-1,4-dioxan-2-yljmethyl}-8-methyl-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 739 mg, 40% purity, 850 pmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 6.4 mL, 13 mmol) in a 1:1 mixture of ethanol and THF (6 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 4 N HCI (pH 3) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na2SO;, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (712 mg, 41% purity, 100%). UPLC-MS (Method 1): Rt = 0.49 min; MS (ESIpos): m / z = 319 [M+H]". Intermediate 22: Step 1 ethyl 2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylate O— 7 4 —r \ NN CH; ~~ CH, o—’ YN Ap TN oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 347 mg, 1.41 mmol) was reacted with [(2S)-1,4-dioxan-2-ylimethanol (CAS No. [406913-93-7]; 1.50 eq., 250 mg, 2.12 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 560 pL, 2.3 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 389 mg, 2.26 mmol) in toluene (8 mL) at rt for 4 days to give upon column chromatography (Si-NH SiOz, hexane / CHzCl2) the title compound (483 mg, 65% purity, 64%). H NMR (400 MHz, DMSO-d6) 8 [ppm]: 1.30 (t, 3H), 2.82-2.93 (m, 4H), 3.26 (dd, 1H), 3.45 (dt, 1H), 3.54 (dt, 1H), 3.62-3.64 (m, 1H), 3.72-3.76 (m, 2H), 3.80-3.87 (m, 1H), 4.05- 4.14 (m, 2H), 4.27 (q, 2H), 7.48 (s, 1H). UPLC-MS (Method 1): Rt = 1.13 min; MS (ESIpos): m / z = 347 [M+H]*. Step 2 2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid Ce 7 ——Cy AY Ne | Ne CHy / ww hj ) { or BB oo According to GP D ethyl 2-{[(2S)-1,4-dioxan-2-yllmethyl}-8-methyl-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 480 mg, 65% purity, 900 pmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 23 eq., 10 mL, 21 mmol) in a 1:1 mixture of ethanol and THF (10 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOs, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (422 mg, 64% purity, 61%). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 2.47 (s, 3H), 2.81-2.91 (m, 4H), 3.26 (dd, 1H), 3.44 (dt, 1H), 3.54 (dt, 1H), 3.62-3.64 (m, 1H), 3.72-3.75 (m, 2H), 3.82-3.87 (m, 1H), 4.05- 4.14 (m, 2H), 7.47 (s, 1H), 12.73 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.48 min; MS (ESIpos): m / z = 319 [M+H]*. Intermediate 23: Step 1 ethyl 8-methyl-2-[(oxetan-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate “] a N—N CH; ~~ CHj J Ci yp r-1X CH § [7 o- N\ oo According to GP C (conditions B) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 270 mg, 1.10 mmol) was reacted with 3- (bromomethyl)oxetane (1.50 eq., 248 mg, 1.64 mmol) and potassium carbonate (15 eq., 2.3 g, 16 mmol) in MeCN (8 mL) at 60 °C overnight. DMAP (5 mol%, 6.7 mg, 55 pmol) was added and stirring at 60 °C continued for 4 days to give after filtration the crude title compound (509 mg, 68% purity, 100%) which was not further purified. H NMR (400 MHz, DMSO-d8) 5 [ppm]: 1.29 (t, 3H), 2.48 (s, 3H), 2.81-2.85 (m, 2H), 2.88- 2.92 (m, 2H), 3.36-3.40 (m, 1H), 4.26 (q, 2H), 4.35-4.43 (m, 3H), 4.49 (d, 1H), 4.64 (dd, 2H). 7.55 (s, 1H). UPLC-MS (Method 1): Ry = 1.07 min; MS (ESIpos): m / z = 317 [M+H]*. Step 2 8-methyl-2-[(oxetan-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxylic acid -< em N— [a CHy / nw CH §! [7 or N\ oo According to GP D ethyl 8-methyl-2-[(oxetan-3-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.00 eq., 510 mg, 68% purity, 1.1 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 8.2 mL, 16 mmol) in a 1:1 mixture of ethanol and THF (10 mL) at 70 °C overnight. The reaction mixture was neutralized with aqueous 4 N HCI (pH 8) and concentrated under reduced pressure to give the crude title compound along with salts (1.9 g) which was not further purified. UPLC-MS (Method 1): Ry = 0.44 min; MS (ESIpos): m / z = 289 [M+H]*. Intermediate 24: Step 1 ethyl 8-methyl-2-[(3-methyloxetan-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylate JON oi N—=N CH; CH; Vd EE J o0—" / CHa WJ { o- I oO 0 According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (3- methyloxetan-3-yl)methanol (1.5 eq., 190 pL, 1.8 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 pL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336mg, 1.95mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (Si-NH SiO, hexane / CH2Cl>) the title compound (529 mg, 52% purity, 68%). "H NMR (400 MHz, DMSO-d6) 6 [ppm]: 1.17 (s, 3H), 1.29 (, 3H), 2.48 (s, 3H), 2.83-2.93 (m, 4H), 4.21-4.29 (m, 6H), 4.60 (d, 2H), 7.55 (s, 1H). UPLC-MS (Method 1): Ry = 1.17 min; MS (ESIpos): m / z = 331 [M+H]*. Step 2 8-methyl-2-[(3-methyloxetan-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]Jindazole-7- carboxylic acid Jo Ken, N—=N CHy Il OH / Ww CHa WJ { of IN o 0 According to GP D ethyl 8-methyl-2-[(3-methyloxetan-3-yl)methyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 527 mg, 52% purity, 829 pmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 6.2 mL, 12 mmol) in a 1:1 mixture of ethanol and THF (6 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 4 N HCI (pH 3) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOs,, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (500 mg, 42% purity, 84%). TH NMR (400 MHz, DMSO-d6) & [ppm]: 1.16 (s, 3H), 2.45 (s, 3H), 2.81-2.89 (m, 4H), 4.22 (d, 2H), 4.26 (s, 2H), 4.60 (d, 2H), 7.52 (s, 1H), 12.75 (br. s., 1H). UPLC-MS (Method 1): Rt = 0.49 min; MS (ESIpos): m / z = 303 [M+H]". Intermediate 25: Step 1 ethyl 2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-glindazole- 7-carboxylate Jo SC N—=N CH; CH; Vd EE J o0—" / CHa WJ { o- I oO 0 According to GP C (conditions B) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 270 mg, 1.10 mmol) was reacted with 3- (bromomethyl)-3-fluorooxetane (1.50 eq., 278 mg, 1.64 mmol) and potassium carbonate (15 eq., 2.3g, 16 mmol) in MeCN (8 mL) at 60 °C overnight. DMAP (5 mol%, 6.7 mg, 55 umol) was added and stirring at 60 °C continued for 4 days to give after filtration the crude title compound (433 mg, 85% purity, 100%) which was not further purified. "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 2.83-2.94 (m, 4H), 4.27 (q, 2H), 4.59-4.68 (m, 4H), 4.75-4.85 (m, 2H), 7.55 (s, 1H). UPLC-MS (Method 1): Rt = 1.13 min; MS (ESIpos): m / z = 335 [M+H]". Step 2 2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylic acid Jo SC N—=N CHy Il OH / Ww CHa WJ { of IN o 0 According to GP D ethyl 2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 433 mg, 85% purity, 1.1 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 8.3 mL, 17 mmol) in a 1:1 mixture of ethanol and THF (10 mL) at 70 °C overnight. The reaction mixture was neutralized with aqueous 4 N HCI (pH 6) and concentrated under reduced pressure to give the crude title compound along with salts (1.8 g) which was not further purified. UPLC-MS (Method 1): Rt = 0.46 min; MS (ESIpos): m / z = 307 [M+H]". Intermediate 26: Step 1 ethyl 8-methyl-2-{[(2R)-oxetan-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate oo N—=N CHa, CH, J Cie 1 ow OM \ 7 NN O- Yr 0 0 According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 330 mg, 1.34 mmol) was reacted with [(2R)-oxetan-2-ylJmethanol (1.50 eq., 177 mg, 2.01 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 540 UL, 2.1 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 369mg, 2.14 mmol) in toluene (5mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (197 mg, 46%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 2.37-2.46 (m, 1H), 2.60-2.68 (m, 1H), 2.83-2.93 (Mm, 4H), 4.24-4.37 (m, 5H), 4.46-4.51 (m, 1H), 4.94-5.00 (m, 1H), 7.52 (s, 1H). UPLC-MS (Method 1): Ry = 1.00 min; MS (ESIpos): m / z = 317 [M+H]*. Step 2 8-methyl-2-{[(2R)-oxetan-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid oo N—| N=N CH, OH / or Sd Co I o 0 According to GP D ethyl 8-methyl-2-{[(2R)-oxetan-2-yl]methyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.00 eq., 190 mg, 601 umol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 4.5 mL, 9.0 mmol) in a 1:1 mixture of ethanol and THF (8 mL) at 70 °C for three days. The reaction mixture was acidified with aqueous 6 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOy, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (198 mg, 91%). UPLC-MS (Method 1): Ry = 0.50 min; MS (ESIpos): m / z = 289 [M+H]*. Intermediate 27: Step 1 ethyl 8-methyl-2-{[(2S)-oxetan-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate oo A N—~N CH, CH, 7 o—" sg IY CHa §! { o- N\ oO © According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 330 mg, 1.34 mmol) was reacted with [(2S)-oxetan-2-yllmethanol (1.50 eq., 177 mg, 2.01 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 540 UL, 2.1 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 369mg, 2.14 mmol) in toluene (5mL) at rt overnight to give upon column chromatography (SiC, hexane / EtOAc) the title compound (233 mg, 53%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 2.37-2.46 (m, 1H), 2.60-2.68 (m, 1H), 2.83-2.94 (m, 4H), 4.24-4.37 (m, 5H), 4.47-4.51 (m, 1H), 4.94-5.00 (m, 1H), 7.52 (s, 1H). UPLC-MS (Method 1): Rt = 1.11 min; MS (ESIpos): m / z = 317 [M+H]". Step 2 8-methyl-2-{[(2S)-oxetan-2-yl]methyl}-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylic acid oo = N—| N=N CH, OH / or Sd Co I o 0 According to GP D ethyl 8-methyl-2-{[(2S)-oxetan-2-yl]methyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.00 eq., 228 mg, 721 umol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 5.4 mL, 11 mmol) in a 1:1 mixture of ethanol and THF (10 mL) at 70 °C for three days. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na2SOs, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (198 mg, 86%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 2.38-2.45 (m, 1H), 2.47 (s, 3H), 2.60-2.68 (m, 1H), 2.82-2.91 (m, 4H), 4.24-4.36 (m, 3H), 4.46-4.51 (m, 1H), 4.94-5.00 (m, 1H), 7.50 (s, 1H), 12.80 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.50 min; MS (ESIpos): m / z = 289 [M+H]*. Intermediate 28: Step 1 ethyl 8-methyl-2-{[(2R)-4-methylmorpholin-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate HaC N— 7 —) N~N CH, CH, f° Co 7 Oi’ / on on WJ [7 o. ID o ‘o According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 313 mg, 1.27 mmol) was reacted with [(2R)-4-methylmorpholin-2-yljmethanol (CAS No. [1159598-35-2]; 1.50 eq., 250 mg, 1.91 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 510 pL, 2.0 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 350 mg, 2.03 mmol) in toluene (8 mL) at rt overnight. Another amount of tri-n-butylphosphine (0.30 eq., 95 pL, 0.38 mmol) and TMAD (0.30 eq., 66 mg, 0.38 mmol) was added and stirring at rt continued for three days to give upon column chromatography (Si-NH SiOz, CH2Clo / MeOH) the title compound (921 mg, 44% purity, 88%). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.30 (t, 3H), 1.72-1.78 (m, 1H), 1.96 (dt, 1H), 2.16 (s, 3H), 2.54-2.57 (m, 1H), 2.63-2.66 (m, 1H), 2.82-2.86 (m, 3H), 2.89-2.93 (m, 2H), 3.45 (dt, 1H), 3.74-3.80 (m, 2H), 4.10 (d, 2H), 4.27 (q, 2H), 7.48 (s, 1H). UPLC-MS (Method 1): Rt = 1.10 min; MS (ESIpos): m / z = 360 [M+H]*. Specific rotation: [a]p® = -7.2° + / - 0.49° (C = 10.0 mg / mL, methanol). Step 2 8-methyl-2-{[(2R)-4-methylmorpholin-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid H;C Nos 4 —C) ‘Ne / N CH, F OH / Ww oR WJ {ol BR o ‘o According to GP D ethyl 8-methyl-2-{[(2R)-4-methylmorpholin-2-yllmethyl}-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxylate (1.00 eq., 912 mg, 44% purity, 1.12 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 8.4 mL, 17 mmol) in a 1:1 mixture of ethanol and THF (12 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and concentrated under reduced pressure to give the crude title compound along with salts (1.15 g) which was not further purified. UPLC-MS (Method 1): Ry = 0.50 min; MS (ESIpos): m / z = 332 [M+H]". Intermediate 29: Step 1 ethyl 8-methyl-2-{[(2S)-4-methylmorpholin-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate H3C ‘N— 4 —ry NN CHz CH, rr = gq Oo” / on oR WJ ( IR o ‘o According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 313 mg, 1.27 mmol) was reacted with [(2S)-4-methylmorpholin-2-ylJmethanol (CAS No. [1159598-33-0]; 1.50 eq., 250 mg, 1.91 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 510 pL, 2.0 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 350 mg, 2.03 mmol) in toluene (8 mL) at rt overnight. Another amount of tri-n-butylphosphine (0.30 eq., 95 pL, 0.38 mmol) and TMAD (0.30 eq., 66 mg, 0.38 mmol) was added and stirring at rt continued for three days to give upon column chromatography (Si-NH SiOz, CH2Clo / MeOH) the title compound (192 mg, 85% purity, 36%). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.30 (t, 3H), 1.72-1.77 (m, 1H), 1.96 (dt, 1H), 2.16 (s, 3H), 2.54-2.57 (m, 1H), 2.63-2.67 (m, 1H), 2.82-2.86 (m, 3H), 2.89-2.93 (m, 2H), 3.45 (dt, 1H), 3.75-3.80 (m, 2H), 4.10 (d, 2H), 4.27 (q, 2H), 7.48 (s, TH). UPLC-MS (Method 1): Ry = 1.10 min; MS (ESIpos): m / z = 360 [M+H]". Step 2 8-methyl-2-{[(2S)-4-methylmorpholin-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid H;C N— dq —) N— Ny CH, l OH / Wn on WJ {ol BR o ‘o According to GP D ethyl 8-methyl-2-{[(2S)-4-methylmorpholin-2-yllmethyl}-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxylate (1.00 eq., 192 mg, 85% purity, 534 pmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 4.0 mL, 8.0 mmol) in a 1:1 mixture of ethanol and THF (6 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and concentrated under reduced pressure to give the crude title compound along with salts (691 mg) which was not further purified. UPLC-MS (Method 1): Ry = 0.50 min; MS (ESIpos): m / z = 332 [M+H]*. Intermediate 30: Step 1 ethyl 8-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate oS \— L a. NN CHgy CH, FI 7 o—" / CH3 Ng! { o- TN 0 © According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (2R)-tetrahydrofuran-2-ylmethanol (CAS No. [22415-59-4]; 1.1 eq., 130 pL, 1.3 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 pL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336 mg, 1.95 mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (Si-NH SiOz, CH2Cl2 / MeOH) the title compound (470 mg, 68% purity, 79%). H NMR (400 MHz, DMSO-d8) & [ppm]: 1.29 (t, 3H), 1.54-1.57 (m, 1H), 1.75-1.82 (m, 2H), 1.90-1.97 (m, 1H), 2.82-2.93 (m, 4H), 3.60-3.65 (m, 1H), 3.72-3.78 (m, 1H), 4.03- 4.17 (m, 3H), 4.27 (q, 2H), 7.49 (s, 1H). UPLC-MS (Method 1): Ry = 1.22 min; MS (ESIpos): m / z = 331 [M+H]*. Step 2 8-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylic acid o™S 3 _ N—N CH, I! / W CHa OW) { of \ o © According to GP D ethyl 8-methyl-2-[(2R)-tetrahydrofuran-2-yimethyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 470 mg, 68% purity, 967 pmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 18 eq., 8.5 mL, 17 mmol) in a 1:1 mixture of ethanol and THF (8 mL) at 70 °C for 24 h and subsequently at rt for two days. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na;SO,, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (380 mg, 69% purity, 76%). H NMR (400 MHz, DMSO-d8) & [ppm]: 1.54-1.57 (m, 1H), 1.75-1.82 (m, 2H), 1.88-1.97 (m, 1H), 2.47 (s, 3H), 2.81-2.90 (m, 4H), 3.60-3.65 (m, 1H), 3.72-3.78 (m, 1H), 4.02-4.17 (m, 3H), 7.47 (s. 1H), 12.73 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.52 min; MS (ESIpos): m / z = 303 [M+H]*. Intermediate 31: Step 1 ethyl 8-methyl-2-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate oS Ne NN CHgy CH, FI 7 o—" / CH3 Ng! { o- TN 0 © According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (2S)-tetrahydrofuran-2-ylmethanol (CAS No. [57203-01-7]; 1.1 eq., 130 pL, 1.3 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 uL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336 mg, 1.95 mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (Si-NH SiOz, CH2Cl. / MeOH) the title compound (437 mg, 72% purity, 78%). H NMR (400 MHz, DMSO-d8) & [ppm]: 1.29 (t, 3H), 1.54-1.57 (m, 1H), 1.75-1.82 (m, 2H), 1.90-1.97 (m, 1H), 2.82-2.93 (m, 4H), 3.60-3.65 (m, 1H), 3.72-3.78 (m, 1H), 4.03- 4.16 (m, 3H), 4.27 (q, 2H), 7.48 (s, 1H). UPLC-MS (Method 1): Ry = 1.22 min; MS (ESIpos): m / z = 331 [M+H]*. Step 2 8-methyl-2-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid o™S Ne NN CH, & / CHa SA or TN oo According to GP D ethyl 8-methyl-2-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 435 mg, 72% purity, 948 pumol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 21 eq., 9.9 mL, 20 mmol) in a 1:1 mixture of ethanol and THF (10 mL) at 70 °C for 24 h and subsequently at rt for two days. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOs, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (373 mg, 78% purity, 73%). H NMR (400 MHz, DMSO-d8) & [ppm]: 1.54-1.57 (m, 1H), 1.75-1.82 (m, 2H), 1.88-1.96 (m, 1H), 2.47 (s, 3H), 2.81-2.90 (m, 4H), 3.60-3.65 (m, 1H), 3.72-3.78 (m, 1H), 4.02-4.16 (m, 3H), 7.47 (s. 1H), 12.72 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.51 min; MS (ESIpos): m / z = 303 [M+H]*. Intermediate 32: Step 1 ethyl 2-{[1-(tert-butoxycarbonyl)azetidin-3-ylJmethyl}-8-methyl-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxylate CHj H3C CHj Y-CH, 0 Yo No lu em ‘Ne | N=N CHj CH, o—’ [Ww ChR3 J) { o- N oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 330 mg, 1.34 mmol) was reacted with tert- butyl 3-(hydroxymethyl)azetidine-1-carboxylate (CAS No. [142253-56-3]; 1.50 eq., 376 mg, 2.01 mmol), tri-n-butylphosphine (CAS No. [998-40-3], 1.6eq., 540 pL, 2.1 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 369 mg, 2.14 mmol) in toluene (9 mL) at rt overnight to give upon column chromatography (SiO, hexane / EtOAc) the title compound (420 mg, 69%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 1.29 (t, 3H), 1.35 (s, 9H), 2.81-2.98 (m, 5H), 3.66- 3.69 (Mm, 2H), 3.88 (br. s., 2H), 4.24-4.29 (m. 4H). 7.58 (s, 1H). UPLC-MS (Method 1): Rt = 1.34 min; MS (ESIpos): m / z = 416 [M+H]*. Step 2 2-{[1-(tert-butoxycarbonyl)azetidin-3-ylJmethyl}-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid CH, H3C CHj Y-CH, Nd N [eR em N— M-N CH, 7. x Ole § C7 or IR 0° To According to GP D ethyl 2-{[1-(fert-butoxycarbonyl)azetidin-3-yl]methyl}-8-methyl-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxylate (1.00 eq., 417 mg, 1.00 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 7.5 mL, 15 mmol) in a 1:1 mixture of ethanol and THF (8 mL) at 70 °C for 24 h and subsequently at rt for two days. The reaction mixture was acidified with aqueous 4 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSO,, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (327 mg, 76%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.35 (s, 9H), 2.47 (s, 3H), 2.80-2.96 (m, 5H), 3.66-3.69 (m, 2H), 3.85-3.94 (m, 2H), 4.26 (d, 2H), 7.56 (s, 1H), 12.85 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.65 min; MS (ESIpos): m / z = 388 [M+H]". Intermediate 33: Step 1 ethyl 8-methyl-2-[(3R)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate J ~~ — R N—N CH; ~~ CHj J Ci [Ww on WV [70 \ o 0 According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (3R)-tetrahydrofuran-3-ylmethanol (CAS No. [124506-31-6];, 1.5eq., 187mg, 1.83 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 pL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336 mg, 1.95 mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (465 mg, 100%). H NMR (400 MHz, DMSO-d8) & [ppm]: 1.29 (t, 3H), 1.56-1.65 (m, 1H), 1.88-1.96 (m, 1H), 2.65-2.74 (m, 1H), 2.81-2.94 (m, 4H), 3.49 (dd, 1H), 3.59-3.68 (m, 2H), 3.73-3.80 (m, 1H), 4.00-4.09 (m, 2H), 4.27 (q, 2H), 7.56 (s, 1H). UPLC-MS (Method 1): Ry = 1.17 min; MS (ESIpos): m / z = 331 [M+H]*. Step 2 8-methyl-2-[(3R)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylic acid J CN — Q Ne | NN CHy OH sg IY Cha $$ { © I oo According to GP D ethyl 8-methyl-2-[(3R)-tetrahydrofuran-3-yimethyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 458 mg, 1.39 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 10 mL, 21 mmol) in a 1:1 mixture of ethanol and THF (20 mL) at 70 °C overnight and for two days at rt. The reaction mixture was acidified with aqueous 6 N HCI (pH 3) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na.SOs, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (166 mg, 38%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 1.56-1.85 (m, 1H), 1.88-1.96 (m, 1H), 2.47 (s, 3H), 2.63-2.72 (m, 1H), 2.81-2.91 (m, 4H), 3.49 (dd, 1H), 3.59-3.68 (m, 2H), 3.74-3.78 (m, 1H), 3.99-4.08 (m, 2H), 7.54 (s, 1H), 12.78 (br. s. 1H). UPLC-MS (Method 1): Ry = 0.48 min; MS (ESIpos): m / z = 303 [M+H]*. Intermediate 34: Step 1 ethyl 8-methyl-2-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate J aN r— NN CH; ~~ CHjy J Oo” 0 ¥ CHa $! { "o N o © According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 402 mg, 1.63 mmol) was reacted with (3S)-tetrahydrofuran-3-ylmethanol (CAS No. [124391-75-9]; 1.5eq., 250mg, 2.45 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 650 WL, 2.6 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 450 mg, 2.61 mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (365 mg, 67%). H NMR (400 MHz, DMSO-d8) & [ppm]: 1.29 (t, 3H), 1.56-1.65 (m, 1H), 1.88-1.96 (m, 1H), 2.65-2.74 (m, 1H), 2.82-2.93 (m, 4H), 3.49 (dd, 1H), 3.59-3.68 (m, 2H), 3.73-3.79 (m, 1H), 4.00-4.09 (m, 2H), 4.26 (q, 2H), 7.56 (s, 1H). UPLC-MS (Method 1): Rt = 1.11 min; MS (ESIpos): m / z = 331 [M+H]*. Step 2 8-methyl-2-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid J CN ba Ne | NN CHy OH sg IY Cha $$ { © I oo According to GP D ethyl 8-methyl-2-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 357 mg, 1.08 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 8.1 mL, 16 mmol) in a 1:1 mixture of ethanol and THF (16 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 6 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na,SOs, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (311 mg, 86%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 1.56-1.85 (m, 1H), 1.88-1.96 (m, 1H), 2.48 (s, 3H), 2.63-2.72 (m, 1H), 2.81-2.92 (m, 4H), 3.49 (dd, 1H), 3.59-3.68 (m, 2H), 3.74-3.78 (m, 1H), 4.00-4.09 (m, 2H), 7.55 (s, 1H), 12.78 (br. s. 1H). UPLC-MS (Method 1): Rt = 0.47 min; MS (ESIpos): m / z = 303 [M+H]". Intermediate 35: Step 1 ethyl 2-chloro-4,4,4-trifluoro-3-oxobutanoate oOo Oo Toon F AA een, F CI To a solution of ethyl 4,4 4-trifluoro-3-oxobutanoate (1.00 eq., 500 mmol, 92.0 g) in dichloromethane (100 mL) was added a solution of sulfuryl chloride (CAS No. [7791-25- 5]; 1.10 eq., 550 mmol, 44 mL) in dichloromethane (50 mL) at -5 to 0 °C. The reaction mixture was warmed to room temperature and stirred at this temperature for 12 hours. The mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine and concentrated under reduced pressure. The obtained material was purified by column chromatography (100 - 200 mesh, petroleum ether: ethyl acetate = 50:1, then 5:1) to give ethyl 2-chloro-4,4,4-trifluoro-3-oxobutanoate (66.0 g, 60%) as yellow oil. "H NMR (400 MHz, CDCls) 8 [ppm]: 1.34 (t, 3H), 4.33 (q, 2H), 4.48 (s, 1H). Step 2 ethyl 4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1-benzofuran-2-carboxylate F CH, Va i O N\~F F o- AX OQ O To a solution of cyclohexane-1,3-dione (1.00 eq., 44.6 mmol, 5.00 g) in toluene (15 mL) was added ethyl 2-chloro-4,4,4-trifluoro-3-oxobutanoate (2.20 eq, 98.1 mmol, 21.4 g) from step 1 at 20 °C and the reaction mixture subsequently stirred at 100 °C for 36 hours. The mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine and concentrated under reduced pressure. The obtained material was purified by column chromatography (100 - 200 mesh, petroleum ether: ethyl acetate = 50:1, then 20:1) to give ethyl 4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1-benzofuran- 2-carboxylate (7.2 g, 57%) as a yellow ail. H NMR (400 MHz, CDCl3) 5 [ppm]: 1.40 (t, 3H), 2.23 (quint, 2H), 2.59-2.62 (m, 2H), 2.99 (t, 2H), 4.43 (q, 2H), 4.48 (s, 1H). LC-MS (Method B): Rt = 0.89 min; MS (ESIpos): m / z = 277 [M+H]". Step 3 (5E / Z)-ethyl 5-(hydroxymethylene)-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1- benzofuran-2-carboxylate F F 0 CH, FF NF J [oy nr Q 0 According to GP A (conditions B) a solution of ethyl formate (CAS No. [109-94-4]; 6.0 eq., 87 mmol, 7.0 mL) in toluene (40 mL) was treated with sodium hydride (CAS No. [7646- 69-7]; 3.00 eq., 43.4 mmol, 1.74 g, 60% purity) at 0 °C. After stirring for 0.5 hours, a solution of ethyl 4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1-benzofuran-2-carboxylate (1.00 eq., 14.5 mmol, 4.00 g) from step 2 in toluene (10 mL) was added to the mixture. The reaction mixture was stirred at room temperature for 2 hours and quenched with aqueous 2N HCI (pH~3). The phases were separated, and the aqueous phase extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtrated and concentrated to give crude (5E / Z)-ethyl 5- (hydroxymethylene)-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1-benzofuran-2- carboxylate (4.4 g, 100%) as brown oil which was not further purified. H NMR (400 MHz, CDCl) 8 [ppm]: 1.41 (t, 3H), 2.70 (t, 2H), 2.97 (t, 2H), 4.44 (q, 2H), 4.48 (s, 1H), 7.37-7.40 (m, 1H), 13.48-13.50 (m, 1H). LC-MS (Method B): Ry = 0.73 min; MS (ESIpos): m / z = 305 [M+H]". Step 4 ethyl 8-(trifluoromethyl)-4,5-dihydro-1H-furo[2,3-gJindazole-7-carboxylate H fF N—N CH, FF NF 7 (5 i © IN 0 0 According to GP B a solution of crude (5E / Z)-ethyl 5-(hydroxymethylene)-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1-benzofuran-2-carboxylate (1.0 eq., 15 mmol, 4.4 g) from step 3 in ethanol (60 mL) was treated with a solution of hydrazine dihydrochloride (CAS No. [5341-61-7]; 2.0 eq., 29 mmol, 3.0 g) in water (20 mL) at room temperature. The reaction mixture was stirred at 60 °C for 2 hours, quenched with saturated aqueous sodium carbonate solution (pH ~9) and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtrated and concentrated. The obtained material was purified by column chromatography (100 - 200 mesh, petroleum ether: ethyl acetate = 20:1 then 2:1) and dissolved in methanol. The mixture was concentrated again to give ethyl 8-(trifluoromethyl)-4,5-dihydro-1H-furo[2,3- glindazole-7-carboxylate (2.2 g, 51%) as a yellow solid. H NMR (400 MHz, DMSO-d6) & [ppm]: 1.31 (t, 3H), 2.86-2.90 (m, 2H), 2.97-3.01 (m, 2H). 4.34 (q, 2H), 7.58 (s, 1H), 12.64 (br s, 1H). LC-MS (Method B): Ry = 0.70 min; MS (ESIpos): m / z = 301 [M+H]". Step 5 ethyl 2-[(pyridin-2-yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate \ F F N~N CH NF 7 LY ie” A NC Oo Oo According to GP C (conditions A) ethyl 8-(trifluoromethyl)-4,5-dihydro-1H-furo[2,3- glindazole-7-carboxylate (1.00 eq., 500 mg, 1.67 mmol) from step 4 was reacted with (pyridin-2-yl)methanol (1.1 eq., 200 mg, 1.83 mmol), tri-n-butylphosphine (CAS No. [998- 40-3]; 1.6 eq., 660 pL, 2.7 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 459 mg, 2.66 mmol) in toluene (21 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (322 mg, 48%; along with another product fraction of 264 mg which contained ca 15% of the corresponding N1-regioisomer). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.30 (t, 3H), 2.87-2.91 (m, 2H), 2.98-3.02 (m, 2H), 4.34 (q, 2H), 5.40 (s, 2H), 7.09 (d, 1H), 7.31 (ddd, 1H), 7.71 (s, 1H), 7.78 (dt, 1H), 8.54 (ddd, 1H). UPLC-MS (Method 1): Rt = 1.34 min; MS (ESIpos): m / z = 392 [M+H]*. Step 6 2-[(pyridin-2-yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylic acid \ N FF -N §! ro IR 0" Yo According to GP D ethyl 2-[(pyridin-2-yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 320 mg, 818 umol) from step 5 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 6.1 mL, 12 mmol) in a 1:1 mixture of ethanol and THF (12 mL) at 70 °C for 2.5 hours. The reaction mixture was acidified with aqueous 2 N HCI (pH 4) and the formed precipitate filtered off. The solid was washed with water and EtOAc and dried to give the desired carboxylic acid (255 mg, 83%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 2.86-2.90 (m, 2H), 2.95-2.99 (m, 2H), 5.39 (s, 2H), 7.08 (d, 1H), 7.31 (dd, 1H), 7.69 (s, 1H), 7.78 (dt, 1H), 8.54 (ddd, 1H), 13.89 (br. s., 1H). ®F NMR (377 MHz, DMSO-d6) & [ppm]: -54.73 (s, 3F). UPLC-MS (Method 1): Ry = 0.52 min; MS (ESIpos): m / z = 364 [M+H]". Intermediate 36: Step 1 methyl 2-chloro-3-cyclopropyl-3-oxopropanoate oO O° AA CHa 0 V Al Cl To a solution of methyl 3-cyclopropyl-3-oxopropanoate (1.00 eq., 20.0 g, 141 mmol) in dichloromethane (150 mL) was added sulfuryl chloride (0.99 eq., 12 mL, 140 mmol) at 0 °C. The reaction mixture was stirred at 25 °C for 2 hours. Water (200 mL) was added to the mixture and the organic layer was seperated. The organic layer was washed with saturated sodium bicarbonate, brine and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 50: 1, then 20: 1) to give methyl 2-chloro-3-cyclopropyl-3-oxopropanoate (27.0 g, 98%) as yellow oil. H NMR (400 MHz, CDCl): 8 [ppm] = 1.07-1.11 (m, 2H), 1.17-1.21 (m, 2H), 2.27-2.33 (m, 1H), 3.86 (s, 3H), 4.95 (s, 1H). LC-MS (Method C): Ry = 0.55 min; MS (ESlpos): m / z = 177 [M+H]". Step 2 methyl 3-cyclopropyl-4-0x0-4,5,6,7-tetrahydro-1-benzofuran-2-carboxylate Oo P O-CH, I| I C I< QO C 0 To a mixture of methyl 2-chloro-3-cyclopropyl-3-oxopropancate (1.00 eq., 17.0 g, 96.3 mmol) from step 1 in 1,2-dichloroethane (100 mL) were added cyclohexane-1,3- dione (1.00 eq., 10.8 g, 96.3 mmol) and triethylamine (1.2 eq., 16 mL, 120 mmol) at room temperature. The mixture was stirred at 50 °C for 60 hours under nitrogen protection. The pH was adjusted to ~1 by aqueous hydrochloride (12 M) and the mixture was stirred for another 16 hours. Water was added to the mixture and the organic layer was seperated. The aqueous phase was extracted with ethyl acetate. The combined organic layers were washed with saturated sodium carbonate solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash column chromatography (petroleum ether: ethyl acetate = 1: 0 to 5: 1) to give methyl 3-cyclopropyl-4-oxo-4,5,6,7-tetrahydro-1-benzofuran-2-carboxylate (8.0 g, 35%) as a light yellow solid. H NMR (400 MHz, DMSO-d6): 5 [ppm] = 0.86-0.91 (m, 2H), 1.20-1.23 (m, 2H), 2.01- 2.07 (m, 2H), 2.41-2.44 (m, 2H), 2.65-2.72 (m, 1H), 2.90 (t, 2H), 3.81 (s, 3H). LC-MS (Method C): Ry = 0.80 min: MS (ESlpos): m / z = 235 [M+H]". Step 3 (5E / Z)-methyl 3-cyclopropyl-5-(hydroxymethylene)-4-ox0-4,5,6,7-tetrahydro-1- benzofuran-2-carboxylate oO Pv O—CH, 7 HO p- A o ‘o According to GP A (conditions B) a mixture of sodium hydride (2.00 eq., 1.02 g, 60% purity, 25.6 mmol) in toluene (60 mL) was treated with methyl formate (3.0 eq., 2.4 mL, 38 mmol) and methyl 3-cyclopropyl-4-oxo-4,5,6,7-tetrahydro-1-benzofuran-2- carboxylate (1.00 eq., 3.00 g, 12.8 mmol) from step 2 at 0 °C. The mixture was stirred at 40 °C for 12 hours and subsequently quenched with saturated aqueous ammonium chloride and diluted with water. The mixture was extracted with ethyl acetate, the organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to give (5E / Z)-methyl 3-cyclopropyl-5-(hydroxymethylene)-4-oxo-4,5,6,7- tetrahydro-1-benzofuran-2-carboxylate (3.50 g) which was used directly without further purification. LC-MS (Method C): Ry = 0.84 min; MS (ESIpos): m / z = 263 [M+H]". Step 4 methyl 8-cyclopropyl-4,5-dihydro-1H-furo[2,3-glindazole-7-carboxylate N=R Pp ( 0-CH - 3 BR oo yf ariide (REZ math] 2. Aveda According to GP B a solution of crude (5E / Z)-methy| 3-cyclopropyl-5-(hydroxymethylene)- 4-0x0-4,5,6,7-tetrahydro-1-benzofuran-2-carboxylate (3.50 g, 13.3 mmol) from step 3 in methanol (50 mL) and water (5.0 mL) was added hydrazine dihydrochloride (3.00 eq., 4.20 g, 40.0 mmol) at 25 °C. The mixture was stirred at 50 °C for 1 hour. The mixture was added slowly to saturated aqueous sodium carbonate at 0 °C. The precipitate was collected and purified by flash column chromatography (petroleum ether: ethyl acetate = 1: 0 to 1: 1) to give methyl 8-cyclopropyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (1.50 g, 42% over two steps) as a yellow solid. H NMR (400 MHz, DMSO-d6): & [ppm] = 0.88-0.93 (m, 2H), 1.52-1.54 (m, 2H), 2.74- 2.87 (m, 5H), 3.80 (s, 3H), 7.51 (s, TH), 12.46 (br s, 1H). LC-MS (Method D): Ry = 0.89 min; MS (ESIpos): m / z = 259 [M+H]". Step 5 methyl 8-cyclopropyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylate § NN P O-CH, WA NN Oo [e] According to GP C (conditions A) methyl 8-cyclopropyl-4,5-dihydro-1H-furo[2,3- glindazole-7-carboxylate (1.00 eq., 400 mg, 1.55 mmol) from step 4 was reacted with (pyridin-2-yl)methanol (1.1 eq., 186 mg, 1.70 mmol), tri-n-butylphosphine (CAS No. [998- 40-3]; 1.6 eq., 620 pL, 2.5 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 427 mg, 2.48 mmol) in toluene (20 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (391 mg, 69%). H NMR (400 MHz, DMSO-d6) 3 [ppm]: 0.83-0.88 (m, 2H), 1.43-1.47 (m, 2H), 2.68-2.75 (m, 1H), 2.78-2.89 (m, 4H), 3.79 (s, 3H), 5.36 (s, 2H), 7.04 (d, 1H), 7.31 (ddd, 1H), 7.64 (s, 1H), 7.78 (dt. 1H), 8.54 (ddd, 1H). UPLC-MS (Method 1): Ry = 1.18 min; MS (ESIpos): m / z = 350 [M+H]*. Step 6 8-cyclopropyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]Jindazole-7- carboxylic acid 7 NN P N\ OF ov 0 Oo According to GP D methyl 8-cyclopropyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.00 eq., 385 mg, 1.10 mmol) from step 5 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 8.3 mL, 17 mmol) in a 1:1 mixture of ethanol and THF (18 mL) at 70 °C for 4 hours. The reaction mixture was concentrated under reduced pressure, the concentrate acidified with aqueous 2 N HCI (pH 3) and the formed precipitate filtered off. The solid was washed with water and EtOAc and dried to give the desired carboxylic acid (360 mg, 93%). H NMR (400 MHz, DMSO-d6) & [ppm]: 0.79-0.84 (m, 2H), 1.41-1.45 (m, 2H), 2.73-2.87 (m, 5H), 5.37 (s, 2H), 7.06 (d, 1H), 7.33 (dd, 1H), 7.64 (s, 1H), 7.80 (dt, 1H), 8.54-8.56 (m, 1H), 12.83 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.55 min; MS (ESIpos): m / z = 336 [M+H]*. Intermediate 37: Step 1 3,6,6-trimethyl-6,7-dihydro-1-benzofuran-4(5H)-one oO CH, 11 al I Nes H,C In analogy to K. Kanematsu et al., Heterocycles 1990, 31, 6, 1003-1006 and J. Org. Chem. 1993, 58, 3960-3968: To a solution of 3-bromoprop-1-yne (CAS No. [106-96-7]; 2.00 eq., 25 mL, 290 mmol) in anhydrous acetonitrile (20 mL) was added dimethyl sulfide (CAS No. :[75-18-3]; 0.57 eq., 6.0 mL, 82 mmol) and the reaction mixture stirred in a light-protected flask at rt overnight. A solution of sodium ethoxide (1.1 eq., 37 mL of a 21% solution in ethanol, 160 mmol) and 5,5-dimethylcyclohexane-1,3-dione (CAS No. [126-81-8]; 1.00eq., 20.0g, 143 mmol) in ethanol (365 mL) was added and the mixture heated to reflux for 1.5 hours. The reaction mixture was diluted with water, concentrated under reduced pressure and the obtained residue extracted with dichloromethane. The combined organic layers were concentrated under reduced pressure, the residue taken up with toluene (150 mL) and treated with 4-methylbenzenesulfonic acid (CAS No. [104-15-4], 1.11eq., 27.3g, 159 mmol) at room temperature overnight. The reaction mixture was quenched with saturated aqueous NaHCO, the layers separated, and the aqueous layer extracted with dichloromethane. The combined organic layers were filtered with a hydrophobic filter, concentrated under reduced pressure and the obtained crude product subjected to column chromatography (SiOz, hexane / EtOAc) to give the title compound (9.4 g, 34%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.04 (s, 6H), 2.09 (d, 3H), 2.30 (s, 2H), 2.74 (s, 2H), 7.43-7.44 (m, 1H). UPLC-MS (Method 1): Rt = 1.11 min; MS (ESIpos): m / z = 179 [M+H]*. Step 2 2-bromo-3,6,6-trimethyl-6,7-dihydro-1-benzofuran-4(5H)-one 0 CHj © Fs ID Br Hc” IN""0 CH, In analogy to US6,048,880; example 2, step 2 (page 20): A solution of 3,6,6-trimethyl-6,7-dihydro-1-benzofuran-4(5H)-one (1.00 eq., 7.64 g, 42.9 mmol) from step 1 in pyridine (60 mL) was treated with 1-bromopyrrolidine-2,5-dione (NBS, CAS No. [128-08-5]; 1.01 eq., 7.71 g, 43.3 mmol) and stirred at rt for two days. Another amount of 1-bromopyrrolidine-2,5-dione (1.00 eq., 7.63 g, 42.9 mmol) was added and stirring at rt continued overnight. The reaction mixture acidified with aqueous 2 N HCI (pH 4) and extracted with dichloromethane. The combined organic layers were dried with Na.SOs, filtered, concentrated under reduced pressure and the crude product subjected to column chromatography (SiOz, hexane / EtOAc) to give the title compound (5.7 g, 52%). H NMR (400 MHz, DMSO-d8) 8 [ppm]: 1.05 (s, 6H), 2.05 (s, 3H), 2.32 (s, 2H), 2.76 (s, 2H). UPLC-MS (Method 1): Ry = 1.32 min; MS (ESlpos): m / z = 257 / 259 [M+H]* (Br isotope pattern). Step 3 (5E / Z)-2-bromo-5-[(dimethylamino)methylidene]-3,6,6-trimethyl-6,7-dihydro-1- benzofuran-4(5H)-one oO H4C 7 CHs HsC 3 N IN 1 | Br H4C og HC op CHj According to GP A (conditions A) 2-bromo-3,6,6-trimethyl-8,7-dihydro-1-benzofuran- 4(5H)-one (1.00 eq., 3.50 g, 13.6 mmol) from step 2 was reacted with 1-tert-butoxy- N,N,N',N-tetramethylmethanediamine (Bredereck’s reagent, CAS No. [5815-08-7]; 1.20 eq., 3.37 mL, 16.3 mmol) in toluene (35 mL) at 100 °C for 3 h. Another amount of 1- tert-butoxy-N,N,N',N-tetramethylmethanediamine (1.20 eq., 3.37 mL, 16.3 mmol) was added and stirring at 100 °C continued for another 24 h. Another amount of 1-tert-butoxy- N,N,N',Ntetramethylmethanediamine (1.20 eq., 3.37 mL, 16.3 mmol) was added and stirring at 100 °C continued for 10 h and subsequently at rt for three days. The reaction mixture was concentrated under reduced pressure and the obtained crude title compound used in the subsequent reaction without further purification steps. UPLC-MS (Method 1): Ri= 1.33 / 1.37 min; MS (ESIpos): m / z = 312 / 314 [M+H]* (Br isotope pattern). Step 4 7-bromo-4,4,8-trimethyl-4,5-dihydro-1H-furo[2,3-g]indazole H N—~N N-N CH, no CH y 3 2 7 TN Br HC 0 drs H;C According to GP B crude (5E / Z)-2-bromo-5-[(dimethylamino)methylidene]-3,6,6- trimethyl-6, 7-dihydro-1-benzofuran-4(5H)-one (1.0 eq., 4.3 g, 14 mmol) from step 3 was reacted with hydrazine hydrate 1:1 (5.0 eq., 3.3 mL, 68 mmol) in ethanol (50 mL) at 70 °C overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (1.38 g, 35% over two steps). H NMR (400 MHz, DMSO-d8) 3 [ppm]: 1.22 (s, 6H), 2.13 (s, 3H), 2.66 (s, 2H), 7.53 (s, 1H), 12.39 (s, 1H). UPLC-MS (Method 1): Ry = 1.25 min; MS (ESlpos): m / z = 281 / 283 [M+H]* (Br isotope pattern). Step 5 7-bromo-4,4,8-trimethyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-glindazole \ Ne | NN CH, [Ww CH, SAA IR Br HaC z CMH CH, According to GP C (conditions B) 7-bromo-4,4,8-trimethyl-4,5-dihydro-1H-furo[2,3- glindazole (1.0eq., 56g, 35mmol) from step4 was reacted with 2- (bromomethyl)pyridine (1.5 eq., 1.2 g, 6.9 mmol), potassium carbonate (15 eq., 9.6 g, 69 mmol) and DMAP (14 mg, 120 umol, 2.5 mol%) in EtOAc (75 mL) at 75 °C overnight. Another amount of 2-(bromomethyl)pyridine (0.75 eq., 600 mg, 3.5 mmol) was added and stirring at 75 °C continued for another 3 days to give upon column chromatography (SiOz, hexane / EtOAC) the title compound (200 mg, 7%). "H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.26 (s, 6H), 2.08 (s, 3H), 2.69 (s, 2H), 5.36 (s, 2H), 7.04 (d, 1H), 7.31 (ddd, 1H), 7.69 (s, 1H), 7.78 (dt, 1H), 8.53-8.55 (m, 1H). UPLC-MS (Method 1): Ry = 1.32 min; MS (ESlpos): m / z = 371 / 373 [M+H]* (Br isotope pattern). Intermediate 38: Step 1 3-methyl-5H-spiro[[1]benzofuran-6,1'-cyclopropan]-4(7H)-one 0 CHj Oo Fos I Oo In analogy to K. Kanematsu et al., Heterocycles 1990, 31, 6, 1003-1006 and J. Org. Chem. 1993, 58, 3960-3968: To a solution of 3-bromoprop-1-yne (CAS No. [106-96-7]; 2.00 eq., 12 mL, 145 mmol) in anhydrous acetonitrile (10 mL) was added dimethyl sulfide (CAS No. :[75-18-3]; 0.57 eq., 3.0 mL, 41 mmol) and the reaction mixture stirred in a light-protected flask at rt overnight. A solution of sodium ethoxide (1.1 eq., 19 mL of a 21% solution in ethanol, 81 mmol) and spiro[2.5]octane-5,7-dione (CAS No. [893411-52-4]; 1.00 eq., 10.0g, 72.4 mmol) in ethanol (190 mL) was added and the mixture heated to reflux for 1.5 hours. The reaction mixture was diluted with water, concentrated under reduced pressure and the obtained residue extracted with dichloromethane. The combined organic layers were concentrated under reduced pressure, the residue taken up with toluene (75 mL) and treated with 4- methylbenzenesulfonic acid (CAS No. [104-15-4]; 4 mol%, 0.50 g, 2.9 mmol) at room temperature overnight. The reaction mixture was quenched with saturated aqueous NaHCOs, the layers separated, and the aqueous layer extracted with dichloromethane. The combined organic layers were filtered with a hydrophobic filter, concentrated under reduced pressure and the obtained crude product subjected to column chromatography (SiOz, hexane / EtOAC) to give the title compound (3.8 g, 29%). H NMR (400 MHz, DMSO-d6) 8 [ppm]: 0.42-0.44 (m, 2H), 0.47-0.50 (m, 2H), 2.11 (d, 3H), 2.28 (s, 2H), 2.75 (s, 2H). 7.44 (m. 1H). UPLC-MS (Method 1): Ry = 1.07 min; MS (ESIpos): m / z = 177 [M+H]*. Step 2 2-bromo-3-methyl-5H-spiro[[1]benzofuran-6,1'-cyclopropan]-4(7H)-one CHa oO Ha | N—pr 0 A solution of 3-methyl-5H-spiro[[1]benzofuran-6,1'-cyclopropan]-4(7H)-one (1.00 eq., 3.80 g, 21.6 mmol) from step 1 in pyridine (30 mL) was treated with 1-bromopyrrolidine- 2,5-dione (NBS, CAS No. [128-08-5]; 1.01 eq., 3.88 g, 21.8 mmol) and stirred at rt overnight. Another amount of 1-bromopyrrolidine-2,5-dione (1.00 eq., 3.84 g, 21.6 mmol) was added and stirring at rt continued overnight. The reaction mixture acidified with aqueous 2 N HCI (pH 4) and extracted with dichloromethane. The combined organic layers were dried with Na,SQq, filtered, concentrated under reduced pressure and the crude product subjected to column chromatography (SiOz, hexane / EtOAc) to give the title compound (2.68 g, 46%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 0.42-0.46 (m, 2H), 0.48-0.52 (m, 2H), 2.07 (s, 3H), 2.31 (s, 2H), 2.78 (s, 2H). UPLC-MS (Method 1): Ry = 1.28 min; MS (ESlpos): m / z = 255 / 257 [M+H]* (Br isotope pattern). Step 3 (5E / Z)-2-bromo-5-[(dimethylamino)methylidene]-3-methyl-5H-spiro[[1]benzofuran- 6,1'-cyclopropan]-4(7H)-one 0 ] H.C H Cy | o Br | HsC According to GP A (conditions A) 2-bromo-3-methyl-5H-spiro[[1]benzofuran-6,1'- cyclopropan]-4(7H)-one (1.00 eq., 2.00 g, 7.84 mmol) from step 2 was reacted with 1- tert-butoxy-N,N,N' N'-tetramethylmethanediamine (Bredereck’s reagent, CAS No. [5815- 08-7]; 1.2 eq., 1.9 mL, 9.4 mmol) in toluene (20 mL) at 100 °C overnight. The reaction mixture was concentrated under reduced pressure and the obtained crude title compound used in the subsequent reaction without further purification steps. UPLC-MS (Method 1): Ri = 1.33 min; MS (ESlpos): m / z = 310 / 312 [M+H]* (Br isotope pattern). Step 4 7'-bromo-8'-methyl-1',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole] H N—N Nei CH, AY CH; { / I Br oO According to GP B crude (5E / Z)-2-bromo-5-[(dimethylamino)methylidene]-3-methyl-5H- spiro[[1]benzofuran-6,1'-cyclopropan]-4(7H)-one (1.0 eq., 2.5 g, 8.1 mmol) from step 3 was reacted with hydrazine hydrate 1:1 (5.0 eq., 2.0 mL, 40 mmol) in ethanol (35 mL) at 70 °C for 5 hours to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (1.3 g, 59% over two steps). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 0.78-0.80 (m, 2H), 0.82-0.85 (m, 2H), 2.14 (s, 3H), 2.78 (s, 2H), 7.29 (s, 1H), 12.33 (s, 1H). UPLC-MS (Method 1): Ry = 1.20 min; MS (ESlpos): m / z = 279 / 281 [M+H]* (Br isotope pattern). Step 5 7'-bromo-8'-methyl-2'-[(pyridin-2-yl)methyl]-2',5'-dihydrospiro[cyclopropane-1,4'- furo[2,3-glindazole] \ 2 N—=N CH, 1 SP I Br 0 According to GP C (conditions A) 7'-bromo-8'-methyl-1',5-dihydrospiro[cyclopropane- 1,4'-furo[2,3-glindazole] (1.00 eq., 300 mg, 1.22 mmol) from step 4 was reacted with (pyridin-2-yl)methanol (1.1 eq., 376 mg, 3.45 mmol), tri-n-butylphosphine (CAS No. [998- 40-3); 1.6 eq., 1.2 mL, 5.0 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 864 mg, 5.02 mmol) in toluene (40 mL) at rt for two days to give upon column chromatography (SiO, hexane / EtOACc) the title compound (933 mg, 72%). "H NMR (400 MHz, DMSO-d8) & [ppm]: 0.78-0.82 (m, 2H), 0.84-0.88 (m, 2H), 2.09 (s, 3H), 2.80 (s, 2H), 5.34 (s, 2H), 7.03 (d, 1H), 7.33 (ddd, 1H), 7.44 (s, 1H), 7.80 (dt, 1H), 8.54 (ddd, 1H). UPLC-MS (Method 1): Ry = 1.33 min; MS (ESlpos): m / z = 370 / 372 [M+H]* (Br isotope pattern). Step 6 8'-methyl-2'-[(pyridin-2-yl)methyl]-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3- glindazole]-7'-carboxylic acid \ N—=N CH, ¥ OH SQ! Co) I oo According to GP E 7'-bromo-8'-methyl-2'-[(pyridin-2-yl)methyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole] (1.00 eq., 500 mg, 1.35 mmol) from step 5 was carbonylated in a steel autoclave (50 mL) in the presence of bis(diphenylphosphino)ferrocene (CAS No. [12150-46-8]; 0.200 eq., 155 mg, 271 pmol), palladium(ll) acetate (5.0 mol%, 15mg, 68 umol) and potassium acetate (4.0 eq., 530 mg, 5.40 mmol) in DMSO (20 mL) under a carbon monoxide pressure of ca. 15 bar at 100 °C for 23 hours to give upon work-up the crude title compound (0.9 g, 32% purity, 65%) which was used in the subsequent reactions without further purification steps. UPLC-MS (Method 1): R; = 0.64 min; MS (ESIpos): m / z = 336 [M+H]*. Intermediate 39: 7'-bromo-8'-methyl-2'-[(pyridin-3-yl)methyl]-2',5'-dihydrospiro[cyclopropane-1,4'- furo[2,3-glindazole] =\ \ N—=N CH, 1 SP I Br 0 According to GP C (conditions A) 7'-bromo-8'-methyl-1',5-dihydrospiro[cyclopropane- 1,4'-furo[2,3-glindazole] (1.00 eq., 200 mg, 716 umol) from Intermediate 38, step 4 was reacted with (pyridin-3-yl)methanol (1.10 eq., 86.0 mg, 788 pmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.60 eq., 286 uL, 1.15 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 197 mg, 1.15 mmol) in toluene (10 mL) at rt overnight to give upon column chromatography (SiOz, CH2Cl. / MeOH) the title compound (430 mg, 38% purity, 62%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 0.77-0.81 (m, 2H), 0.83-0.87 (m, 2H), 2.11 (s, 3H), 2.79 (s, 2H), 5.28 (s, 2H), 7.38 (dd, 1H), 7.44 (s, 1H), 7.60-7.62 (m, 1H), 8.48-8.50 (m, 2H). UPLC-MS (Method 1): Ry = 1.31 min; MS (ESlpos): m / z = 370 / 372 [M+H]* (Br isotope pattern). Intermediate 40-1: Step 1 7'-bromo-2'-{[(2S)-1,4-dioxan-2-ylJmethyl}-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole] Co 7 I —l) AY NN CH, / un “Ha | BR Br 0 According to GP C (conditions A) 7'-bromo-8'-methyl-1',5-dihydrospiro[cyclopropane- 1,4'-furo[2,3-glindazole] (1.00 eq., 700 mg, 2.51 mmol) from Intermediate 38, step 4 was reacted with [(2S)-1,4-dioxan-2-yllmethanol (CAS No. [406913-93-7]; 1.10 eq., 326 mg, 2.76 mol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 1.0 mL, 4.0 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 691 mg, 4.01 mmol) in toluene (32 mL) at rt for two days to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (595 mg, 65% purity, 41%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 0.76-0.80 (m, 2H), 0.82-0.85 (m, 2H), 2.12 (s, 3H), 2.77-2.78 (m, 2H), 3.24 (dd, 1H), 3.43 (dt, 1H), 3.53 (dt, 1H), 3.61-3.64 (m, 1H), 3.69-3.73 (m, 2H), 3.78-3.84 (m. 1H), 3.97-4.07 (m, 2H), 7.25 (s, 1H). UPLC-MS (Method 1): Ry = 1.31 min; MS (ESlpos): m / z = 379 / 381 [M+H]* (Br isotope pattern). Step 2 2'-{[(2S)-1,4-dioxan-2-ylJmethyl}-8'-methyl-2',5'-dihydrospiro[cyclopropane-1,4'- furo[2,3-glindazole]-7'-carboxylic acid O— 7 I — AY NN CH, OH / on “Ha Sg { "ol TN 0" “Yo According to GP E 7-bromo-2'-{[(2S)-1,4-dioxan-2-yljmethyl}-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole] (1.00 eq., 989 mg, 2.61 mmol) from step 1 was carbonylated in a steel autoclave (90mL) in the presence of bis(diphenylphosphino)ferrocene (CAS No. [12150-46-8]; 0.201 eq., 300 mg, 524 pmol), palladium(ll) acetate (5.0 mol%, 29 mg, 130 pmol) and potassium acetate (4.00 eq., 1.02 g, 10.4 mmol) in DMSO (40 mL) under a carbon monoxide pressure of ca. 16 bar at 100 °C for 23 hours to give upon work-up the crude title compound (0.67 g, 60% purity, 45%) which was used in the subsequent reactions without further purification steps. "H NMR (400 MHz, DMSO-d6) 5 [ppm]: 0.78-0.87 (m, 4H), 2.85-2.86 (m, 2H), 3.25 (dd, 1H), 3.44 (dt, 1H), 3.54 (dt, 1H), 3.61-3.64 (m, 1H), 3.70-3.74 (m, 2H), 3.80-3.86 (m, 1H), 4.00-4.06 (m, 2H), 7.29 (s, 1H), 12.86 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.51 min; MS (ESIpos): m / z = 345 [M+H]*. Intermediate 40-2: 7'-bromo-N,N,8'-trimethylspiro[cyclopropane-1,4'-furo[2,3-g]indazole]-2'(5'H)- carboxamide H3C >. oO WW; HC N=N CH, SAC TN Br oO Isolated from the reaction mixture of Intermediate 40-1, step 1 (166 mg, 18%). Intermediate 41: Step 1 ethyl 3-methyl-4-oxo0-4,7-dihydro-5H-spiro[[1]benzofuran-6,1'-cyclopropane]-2- carboxylate CH CHj FY a o—" 0 0 BR 0 0 To a mixture of spiro[2.5]octane-5,7-dione (CAS No. [893411-52-4]; 1.00 eq., 5.00 g, 36.2 mmol) in 1,2-dichloroethane (80 mL) were added ethyl 2-chloro-3-oxobutanoate (CAS No. [609-15-4]; 1.0 eq., 5.0 mL, 36 mmol) and triethylamine (1.2 eq, 6.1 mL, 43 mmol) at room temperature and the mixture was stirred at 50 °C for 15 hours. The pH was adjusted to ~2 by aqueous 2 N HCI and then stirring at room temperature continued for another 7 hours. Water was added to the mixture and the organic layer was seperated. The organic layer was washed with water, filtered with a hydrophobic filter, concentrated under reduced pressure and the obtained crude product subjected to column chromatography (SiOz, hexane / EtOAc) to give the title compound (3.5 g, 36%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 0.44-0.48 (m, 2H), 0.50-0.54 (m, 2H), 1.29 (t, 3H), 2.35 (s, 2H), 2.47 (s, 3H), 2.86 (s, 2H), 4.29 (q, 2H). UPLC-MS (Method 1): Rt = 1.14 min; MS (ESIpos): m / z = 249 [M+H]". Step 2 ethyl (5E / Z)-5-[(dimethylamino)methylidene]-3-methyl-4-ox0-4,7-dihydro-5H- spiro[[1]benzofuran-6,1'-cyclopropane]-2-carboxylate 0 CH, CH, ! v 7 o0—" 0 Q CH, HCl 0 N | | N\ TO According to GP A (conditions A) ethyl 3-methyl-4-oxo-4,7-dihydro-5H- spiro[[1]benzofuran-6,1'-cyclopropane]-2-carboxylate (1.00 eq., 3.40 g, 13.7 mmol) from step1 was reacted with 1-fert-butoxy-N,N,N'N-tetramethylmethanediamine (Bredereck’s reagent, CAS No. [5815-08-7]; 1.2 eq., 3.4 mL, 16 mmol) in toluene (35 mL) at 100 °C for 5 days. The reaction mixture was concentrated under reduced pressure and the obtained crude title compound used in the subsequent reaction without further purification steps. UPLC-MS (Method 1): Ry = 1.16 / 1.23 min; MS (ESIpos): m / z = 304 [M+H]*. Step 3 ethyl 8'-methyl-1',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]-7'- carboxylate H N—~N CH; CHj Fe Co 7 CY 0 / 7 “Ha ( { © A oo According to GP B crude ethyl (5E / Z)-5-[(dimethylamino)methylidene]-3-methyl-4-oxo- 4,7-dihydro-5H-spiro[[1]benzofuran-6,1'-cyclopropane]-2-carboxylate (1.0eq., 4.2g, 14 mmol) from step 2 was reacted with hydrazine hydrate 1:1 (5.0 eq., 3.3 mL, 68 mmol) in ethanol (35 mL) at 70 °C for 5 hours to give upon column chromatography (SiOz, hexane / EtOACc) the title compound (1.49 g, 84% purity, 34% over two steps). "H NMR (400 MHz, DMSO-d6) & [ppm]: 0.80-0.82 (m, 2H), 0.85-0.88 (m, 2H), 1.30 (t, 3H), 2.53 (s, 3H), 2.87 (s, 2H), 4.27 (q, 2H), 7.34 (s, 1H), 12.44 (s, 1H). UPLC-MS (Method 1): Ri = 1.03 min; MS (ESIpos): m / z = 273 [M+H]*. Step 4 ethyl 2'-(cyclopropylmethyl)-8'-methyl-2',5'-dihydrospiro[cyclopropane-1,4'- furo[2,3-glindazole]-7'-carboxylate P N=N CH CH, 7 So / WW on Ng) [0 RN o 0 According to GP C (conditions A) ethyl 8'-methyl-1',5"-dihydrospiro[cyclopropane-1,4'- furo[2,3-glindazole]-7'-carboxylate (1.00 eq., 400 mg, 1.47 mmol) from step 3 was reacted with cyclopropylmethanol (1.5 eq., 180 pL, 2.2 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 590 pL, 2.4 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 405mg, 2.35mmol) in toluene (7 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (263 mg, 49%). H NMR (400 MHz, DMSO-d6) & [ppm]: 0.31-0.35 (m, 2H), 0.48-0.53 (m, 2H), 0.79-0.83 (m, 2H), 0.85-0.89 (m, 2H), 1.16-1.24 (m, 1H), 1.29 (t, 3H), 2.52 (s, 3H), 2.87 (s, 2H), 3.88 (d, 2H), 4.27 (q, 2H), 7.37 (s, 1H). UPLC-MS (Method 1): Rt = 1.40 min; MS (ESIpos): m / z = 327 [M+H]". Step 5 2'-(cyclopropylmethyl)-8'-methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3- glindazole]-7'-carboxylic acid P N—N CH, OH N / 0 0 According to GP D ethyl 2'-(cyclopropylmethyl)-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-gJindazole]-7'-carboxylate (1.00 eq., 260 mg, 797 umol) from step 4 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 6.0 mL, 12 mmol) in a 1:1 mixture of ethanol and THF (12 mL) at 70 °C for 4 hours and at room temperature for 4 days. The reaction mixture was concentrated under reduced pressure, the concentrate acidified with aqueous 2 N HCI (pH 3) and the formed precipitate filtered off. The solid was washed with water and EtOAc and dried to give the desired carboxylic acid (146 mg, 55%). "H NMR (400 MHz, DMSO-d6) 3 [ppm]: 0.33-0.34 (m, 2H), 0.50-0.52 (m, 2H), 0.80-0.86 (m, 4H), 1.17-1.23 (m, 1H), 2.83 (s, 2H), 3.87 (d, 2H), 7.34 (s, 1H). UPLC-MS (Method 1): Ry = 0.59 min; MS (ESIpos): m / z = 299 [M+H]*. Intermediate 42: Step 1 ethyl 3-methyl-4-oxo-4,7-dihydro-5H-spiro[[1]benzofuran-6,1'-cyclobutane]-2- carboxylate oO CHj CHg J Di’ Oo CHs 0- BR Oo oO To a mixture of spiro[3.5]nonane-6,8-dione (CAS No. [221342-48-9]; 1.00 eq., 2.00 g, 13.1 mmol) in 1,2-dichloroethane (30 mL) were added ethyl 2-chloro-3-oxobutanoate (CAS No. [609-154]; 1.0eq., 1.8 mL, 13 mmol) and triethylamine (1.2 eq, 2.2 mL, 16 mmol) at room temperature and the mixture was stirred at 50 °C for three days and then left standing at room temperature for another three days. The pH was adjusted to ~2 by aqueous 2 N HCI and then stirring at room temperature continued for another two hours. Water was added to the mixture and the organic layer was seperated. The organic layer was washed with water, filtered with a hydrophobic filter, concentrated under reduced pressure and the obtained crude product subjected to column chromatography (SiOz, hexane / EtOAC) to give the title compound (955 mg, 26%). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 1.77-1.94 (m, 6H), 2.44 (s, 3H), 2.62 (s, 2H), 3.09 (s, 2H), 4.28 (q, 2H). UPLC-MS (Method 1): Ry = 1.23 min; MS (ESIpos): m / z = 263 [M+H]*. Step 2 ethyl (5E / Z)-5-[(dimethylamino)methylidene]-3-methyl-4-ox0-4,7-dihydro-5H- spiro[[1]benzofuran-6,1'-cyclobutane]-2-carboxylate CH, J [oy Q CH, H3C { O- ! HsC o According to GP A (conditions A) ethyl 3-methyl-4-oxo-4,7-dihydro-5H- spiro[[1]benzofuran-6,1'-cyclobutane]-2-carboxylate (1.00 eq., 500 mg, 1.91 mmol) from step 1 was reacted with 1-tert-butoxy-N, N,N’ N'tetramethylmethanediamine (Bredereck’s reagent, CAS No. [5815-08-7]; 1.2 eq., 470 WL, 2.3 mmol) in toluene (5 mL) at 100 °C for three days. The reaction mixture was concentrated under reduced pressure and the obtained crude title compound used in the subsequent reaction without further purification steps. UPLC-MS (Method 1): Ry = 1.23 / 1.25 min; MS (ESIpos): m / z = 318 [M+H]". Step 3 ethyl 8'-methyl-1',5'-dihydrospiro[cyclobutane-1,4'-furo[2,3-glindazole]-7'- carboxylate H N~N CHj CH, o—’ 7a CHa = o- TN © oO According to GP B crude ethyl (5E / Z)-5-[(dimethylamino)methylidene]-3-methyl-4-oxo- 4,7-dihydro-5H-spiro[[ 1]benzofuran-6,1'-cyclobutane]-2-carboxylate (1.0 eq., 600 mg, 1.9 mmol) from step 2 was reacted with hydrazine hydrate 1:1 (5.0 eq., 460 pL, 9.5 mmol) in ethanol (5 mL) at 70 °C for 13 hours to give upon column chromatography (SiOz, hexane / EtOAC) the title compound (134 mg, 25% over two steps). H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.30 (t, 3H), 1.93-2.13 (m, 6H), 3.05 (s, 2H), 4.27 (a, 2H), 7.79 (s, 1H), 12.54 (s, 1H). UPLC-MS (Method 1): Rt = 1.12 min; MS (ESIpos): m / z = 287 [M+H]*. Step 4 ethyl 8'-methyl-2'-[(pyridin-2-yl)methyl]-2',5'-dihydrospiro[cyclobutane-1,4'- furo[2,3-glindazole]-7'-carboxylate 7 NN CHjy CH, J 8 SA Ce BR oo According to GP C (conditions A) ethyl 8-methyl-1',5'-dihydrospiro[cyclobutane-1,4'- furo[2,3-glindazole]-7'-carboxylate (1.00 eq., 130 mg, 454 umol) from step 3 was reacted with (pyridin-2-yl)methanol (1.1 eq., 55 mg, 500 uml), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 180 uL, 730 pmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 125mg, 726 umol) in toluene (7.5mL) at rt for two days to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (111 mg, 58%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 1.89-2.13 (m, 6H), 2.45 (s, 3H), 3.08 (s, 2H), 4.26 (q, 2H), 5.41 (s, 2H), 7.06 (d, 1H), 7.31 (ddd, 1H), 7.78 (dt, 1H), 7.94 (s, 1H), 8.55 (ddd, 1H). UPLC-MS (Method 1): Ry = 1.27 min; MS (ESIpos): m / z = 378 [M+H]". Step 5 8'-methyl-2'-[(pyridin-2-yl)methyl]-2',5'-dihydrospiro[cyclobutane-1,4'-furo[2,3- glindazole]-7'-carboxylic acid 7 NN CH, OH [i or J) [7 ol BR oo According to GP D ethyl 8'-methyl-2'-[(pyridin-2-yl)methyl]-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-glindazole]-7'-carboxylate (1.00 eq., 100 mg, 265 umol) from step 4 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 2.0 mL, 4.0 mmol) in a 1:1 mixture of ethanol and THF (4 mL) at 70 °C for 4 hours and at room temperature overnight. The reaction mixture was concentrated under reduced pressure, the concentrate acidified with aqueous 2 N HCI (pH 3) and the formed precipitate filtered off. The solid was washed with water and EtOAc and dried to give the desired carboxylic acid (70 mg, 64%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 1.91-2.05 (m, 2H), 2.06-2.13 (m, 4H), 2.42 (s, 3H), 3.03 (s, 2H), 5.40 (s, 2H), 7.05 (d, 1H), 7.31 (ddd, 1H), 7.78 (dt, 1H), 7.92 (s, 1H), 8.54 (ddd. 1H). UPLC-MS (Method 1): Ry = 0.63 min; MS (ESIpos): m / z = 350 [M+H]*. Intermediate 43: 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-1H-furo[2,3-glindazole- 7-carboxamide H o™S N—~N Ne CHj N— 7, IY CHa py ( { N- N\ 0 0 To an ice-cooled solution of 1-[(28)-tetrahydrofuran-2-ylJmethanamine (CAS No. [7175- 81-7]; 3.0 eq., 1.3 mL, 12 mmol) in dichloromethane (20 mL) under argon atmosphere was dropwise added trimethylaluminum (CAS No. [75-24-1]; 3.0 eq., 2.0 M solution in toluene, 6.1 mL, 12 mmol) and stirring continued for 5 minutes. To this mixture was added dropwise a suspension of ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 1.00 g, 4.06 mmol) in dichloromethane (10 mL). The reaction mixture was warmed to rt and stirred for one hour upon which it was warmed to 40 °C and stirring at 40 °C continued for four days. The reaction mixture was quenched with a saturated aqueous solution of potassium sodium tartrate, the phases separated, and the aqueous phase extracted with dichloromethane twice. The combined organic phases were washed with brine, dried with MgSO, filtered and concentrated under reduced pressure. The obtained crude material was subjected to column chromatography (Si-NH SiOz, EtOAc / MeOH) and subsequent trituration with acetonitrile to give the title compound (453 mg, 35%). H NMR (400 MHz, DMSO-d6) 3 [ppm]: 1.54-1.62 (m, 1H), 1.73-1.92 (m, 3H), 2.83-2.92 (m, 4H), 3.18-3.28 (m, 2H), 3.58-3.64 (m, 1H), 3.74-3.79 (m, 1H), 3.91-3.98 (m, 1H), 7.50 (s, 1H), 7.97 (t, 1H), 12.41 (s, 1H). UPLC-MS (Method 1): Ry = 0.82 min; MS (ESIpos): m / z = 302 [M+H]". Intermediate 44: Step 1 ethyl 8-methyl-2-[phenyl(*H,)methyl]-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylate ‘N~N CH; CH, FE oy o—" / Wn CR WJ [7 oo N oo According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 304 mg, 1.23 mmol) was reacted with phenyl(Hz)methanol (CAS No. [21175-64-4]; 1.5eq., 190 uL, 1.9 mmol), tri-n- butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 pL, 2.0 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 340 mg, 1.98 mmol) in toluene (8 mL) at rt for three days to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (364 mg, 83%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 2.48 (s, 3H), 2.83-2.93 (m, 4H), 4.26 (q, 2H), 7.22-7.36 (m, 5H), 7.61 (s, 1H). UPLC-MS (Method 1): Ry = 1.33 min; MS (ESIpos): m / z = 339 [M+H]". Step 2 8-methyl-2-[phenyl(?Hz)methyl]-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxylic acid Ne | N=N CH 1 / ww CHa QO) { of IR oo According to GP D ethyl 8-methyl-2-[phenyl(3Hz)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.00 eq., 355 mg, 1.05 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 7.9 mL, 16 mmol) in a 1:1 mixture of ethanol and THF (14 mL) at 70 °C overnight and for two days at rt. The reaction mixture was acidified with aqueous 6 N HCI (pH 3-4) upon which a precipitate was formed. The precipitate was isolated by filtration, washed with water and dried under reduced pressure to give the desired carboxylic acid (214 mg, 64%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 2.46 (s, 3H), 2.82-2.91 (m, 4H), 7.23-7.30 (m, 3H), 7.33-7.37 (m, 2H), 7.59 (s, 1H), 12.80 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.58 min; MS (ESIpos): m / z = 311 [M+H]*. Intermediate 45: Step 1 ethyl 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxylate a Ww Oo 7 N—=N CH CH, FE 7 [o LY on WJ [oo N 0 © According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 300 mg, 1.22 mmol) was reacted with (5- cyclopropyl-1,2,4-oxadiazol-3-yl)methanol (CAS No. [915920-06-8]; 1.5 eq., 256 mg, 1.83 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 490 pL, 1.9 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 336 mg, 1.95 mmol) in toluene (8 mL) at rt for three days to give upon column chromatography (SiOz hexane / EtOAc) the title compound (363 mg, 73%). H NMR (400 MHz, DMSO-d6) & [ppm]: 1.06-1.10 (m, 2H), 1.21-1.25 (m, 2H), 1.29 (t, 3H), 2.29-2.36 (m, 1H), 2.46 (s, 3H), 2.84-2.94 (m, 4H), 4.26 (q, 2H), 5.41 (s, 2H), 7.62 (s, 1H). UPLC-MS (Method 1): Rt = 1.19 min; MS (ESIpos): m / z = 369 [M+H]". Step 2 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid a w Oo NT N~N CH, 1 / ww “Asa 3 { or \ oo According to GP D ethyl 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-methyl-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxylate (1.00 eq., 354 mg, 961 pumol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15eq., 7.2 mL, 14 mmol) in a 1:1 mixture of ethanol and THF (14 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 6 N HCI (pH 3-4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na2SO;, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (275 mg, 76%). H NMR (400 MHz, DMSO-d6) 3 [ppm]: 1.06-1.10 (m, 2H), 1.20-1.25 (m, 2H), 2.29-2.36 (m, 1H), 2.44 (s, 3H), 2.82-2.92 (m, 4H), 5.41 (s, 2H), 7.61 (s, 1H), 12.81 (br. s., 1H). UPLC-MS (Method 1): Rt = 0.51 min; MS (ESIpos): m / z = 341 [M+H]". Intermediate 46: Step 1 ethyl 2-{2-[(tert-butoxycarbonyl)amino]ethyl}-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate H3C CHs Y-CH, 0 NN ‘=0 HN "IN NN CHj CHy / Oi’ / Ww CHa WJ { o- N\ 0 © According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 350 mg, 1.42 mmol) was reacted with tert- butyl (2-hydroxyethyl)carbamate (CAS No. [26690-80-2]; 1.50 eq., 344 mg, 2.13 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 570 pL, 2.3 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 392 mg, 2.27 mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) and subsequent trituration with acetonitrile the title compound (285 mg, 46%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 1.29 (t, 3H), 1.36 (s, 9H), 2.81-2.92 (m, 4H), 3.25- 3.30 (m, 2H), 4.08 (t, 2H), 4.27 (q, 2H), 6.95 (t, 1H), 7.47 (s, 1H). UPLC-MS (Method 1): Rt = 1.21 min; MS (ESIpos): m / z = 390 [M+H]". Step 2 2-{2-[(tert-butoxycarbonyl)amino]ethyl}-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid HaC CHg Y-CH, oO NN ‘=0 HN "% N—| N=N CH, IY CHa WJ { or N\ oo According to GP D ethyl 2-{2-[(tert-butoxycarbonyl)amino]ethyl}-8-methyl-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxylate (1.00 eq., 280 mg, 719 umol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 5.4 mL, 11 mmol) in a 1:1 mixture of ethanol and THF (9 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 6 N HCI (pH 4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with Na,SQs, filtrated and concentrated under reduced pressure to give the desired carboxylic acid (301 mg, 100%). H NMR (400 MHz, DMSO-d) 8 [ppm]: 1.36 (s, 9H), 2.47 (s, 3H), 2.80-2.89 (m, 4H), 3.25-3.30 (m, 2H), 4.08 (t, 2H), 6.94 (1, 1H), 7.45 (s, 1H), 12.68 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.54 min; MS (ESIpos): m / z = 362 [M+H]". Intermediate 47: Step 1 ethyl 2-{2-[4-(tert-butoxycarbonyl)piperazin-1-yl]ethyl}-8-methyl-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxylate CHjy HaC, C HsC—X 0 7] O=" N— J —N "N NN CH; ~~ CH, J OO’ / Ww CH J) {7 o- BR 0 0 According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 1.00 eq., 350 mg, 1.42 mmol) was reacted with tert- butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate (CAS No. [77279-24-4]; 1.50 eq., 491mg, 2.13 mmol), tri-n-butylphosphine (CAS No. [998-40-3], 1.6eq., 570 uL, 2.3 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 392 mg, 2.27 mmol) in toluene (8 mL) at rt overnight to give upon column chromatography (SiOz, hexane / EtOAc) and subsequent trituration with acetonitrile the title compound (567 mg, 83%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 1.39 (s, 9H), 2.37-2.39 (m, 4H), 2.49 (s, 3H), 2.70 (t, 2H), 2.82-2.92 (mM, 4H), 3.27-3.30 (m, 4H), 4.18 (t, 2H), 4.26 (q, 2H), 7.54 (s, 1H). UPLC-MS (Method 1): Ry = 1.32 min; MS (ESIpos): m / z = 459 [M+H]". Step 2 2-{2-[4-(tert-butoxycarbonyl)piperazin-1-yl]ethyl}-8-methyl-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxylic acid hydrogen chloride (1 / 1) CHjy HaG, C FRAY 0 / o=" N— / —N 'N CIH Ne NN CH, sg IY CHa WJ { ~ or A 0 0 According to GP D ethyl 2-{2-[4-(fert-butoxycarbonyl)piperazin-1-yljethyl}-8-methyl-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxylate (1.00 eq., 560 mg, 1.22 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 9.2 mL, 18 mmol) in a 1:1 mixture of ethanol and THF (18 mL) at 70 °C overnight. The reaction mixture was acidified with aqueous 6 N HCI (pH 3-4) and diluted with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc. The combined organic phases were washed with brine, dried with NazSOs;, filtrated and concentrated under reduced pressure to give the desired carboxylic acid as HCI salt (518 mg, 86%). "H NMR (400 MHz, DMSO-d8) & [ppm]: 1.41 (s, 9H), 2.84-2.93 (m, 4H), 3.05-3.20 (m, 4H), 3.50-3.57 (m, 4H), 4.01 (br. s., 2H), 4.53 (br. s., 2H), 7.61 (s, 1H), 10.35 (br. s., 1H), 12.85 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.62 min; MS (ESIpos): m / z = 431 [M-CI']*. Intermediate 48: Step 1 ethyl 2'-{[(2S)-1,4-dioxan-2-ylImethyl}-8'-methyl-2',5'-dihydrospiro[cyclobutane- 1,4'-furo[2,3-glindazole]-7'-carboxylate Yi / rl N~N CH; CH; J OO’ sg IY CH §! [7 o- \ 0 0 According to GP C (conditions A) ethyl 8'-methyl-1',5-dihydrospiro[cyclobutane-1,4'- furo[2,3-gJindazole]-7'-carboxylate (prepared according to Intermediate 42, step 3; 1.00 eq., 500 mg, 1.75 mmol) was reacted with [(2S)-1,4-dioxan-2-ylJmethanol (CAS No. [406913-93-7]; 1.10 eq., 227 mg, 1.92 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6eq, 700 UL, 2.8 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 481mg, 2.79 mmol) in toluene (30 mL) at rt for 2 days to give upon column chromatography (SiOz, hexane / ethyl acetate) the title compound (291 mg, 86% purity, 34%). H NMR (400 MHz, DMSO-d8) 5 [ppm]: 1.30 (t, 3H), 2.06-2.13 (m, 6H), 2.49 (s, 3H), 3.05- 3.06 (m, 2H), 3.28 (dd, 1H), 3.46 (dt, 1H), 3.56 (dt, 1H), 3.62-3.65 (m, 1H), 3.73-3.76 (m, 2H), 3.85-3.91 (Mm, 1H), 4.10-4.12 (m. 2H). 4.27 (q, 2H). 7.76 (s, 1H). UPLC-MS (Method 1): Ry = 1.26 min; MS (ESIpos): m / z = 387 [M+H]*. Step 2 2'-{[(2S)-1,4-dioxan-2-ylJmethyl}-8'-methyl-2',5'-dihydrospiro[cyclobutane-1,4'- furo[2,3-glindazole]-7'-carboxylic acid O— 7] m—F NN CH, / CH J C7 or BR 0 0 According to GP D ethyl 2-{[(2S)-1,4-dioxan-2-ylmethyl}-8'-methyl-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-glindazole]-7'-carboxylate (1.00 eq., 240 mg, 621 pumol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 4.7 mL, 9.3 mmol) in a 1:1 mixture of ethanol and THF (10 mL) at 70 °C for 4 hours and at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, the concentrate acidified with aqueous 2 N HCI (pH 3) and the formed precipitate filtered off. The solid was washed with water and EtOAc and dried to give the desired carboxylic acid (209 mg, 60% purity, 56%). UPLC-MS (Method 1): Ry = 0.56 min; MS (ESIpos): m / z = 359 [M+H]". Intermediate 49: Step 1 ethyl 2-[(6-cyanopyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-glindazole- 7-carboxylate =% \ Ne=N CH, CHy rc Ei Ol’ sg ¥ CHa OW) { ~ o- N oO © According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7- carboxylate (commercially available; 1.00 eq., 245 mg, 994 pmol) was reacted with 5- (hydroxymethyl)pyridine-2-carbonitrile (CAS No. [58553-48-3]; 1.50 eq. 200 mg, 1.49 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 400 pL, 1.6 mmol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 274 mg, 1.59 mmol) in toluene (8 mL) at rt overnight and at 40 °C for one day. Another amount of tri-n-butylphosphine (1.0 eq., 250 pL, 1.0 mmol) and TMAD (1.0 eq., 170 mg, 1.0 mmol) were added and stirring at 40 °C continued for 10 days to give upon column chromatography (SiOz, hexane / EtOAc) the title compound (72 mg, 18%). "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 2.47 (s, 3H), 2.86-2.94 (m, 4H), 4.26 (q, 2H), 5.48 (s, 2H), 7.71 (s, 1H), 7.82 (dd, 1H), 8.03 (dd, 1H), 8.86-8.87 (m, 1H). UPLC-MS (Method 1): Ry = 1.20 min; MS (ESIpos): m / z = 363 [M+H]". Step 2 2-[(6-carboxypyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylic acid 0 oH mt Wi N—=N CH, 7 ny re XN OF BD 0 © According to GP D ethyl 2-[(6-cyanopyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.00 eq., 72.0 mg, 199 pymol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 1.5 mL, 3.0 mmol) in a 1:1 mixture of ethanol and THF (2 mL) at 70 °C overnight and at room temperature for 2 days. The reaction mixture was acidified with aqueous 6 N HCI (pH 3) and concentrated under reduced pressure and the obtained crude dicarboxylic acid (268 mg) used without further purification. UPLC-MS (Method 1): Ry = 0.18 min; MS (ESIpos): m / z = 354 [M+H]". Intermediate 50: Step 1 ethyl 4-oxo-3-(trifluoromethyl)-4,7-dihydro-5H-spiro[[1]benzofuran-6,1'- cyclopropane]-2-carboxylate F F QO CH, FF NF J oO—" J yr NC 0 O To a solution of spiro[2.5]octane-5,7-dione (CAS No. [893411-52-4]; 1.00 eq., 67.5 mmol, 9.33 g) in toluene (30 mL) was added ethyl 2-chloro-4,4,4-trifluoro-3-oxobutanoate (see Intermediate 35, step 1;2.2 eq, 150 mmol, 23 mL) and the reaction mixture subsequently stirred at 100 °C for 43 hours. The mixture was poured into water and extracted twice with ethyl acetate. The combined organic layer was washed with brine, dried with NazSOs, filtrated and concentrated under reduced pressure. The obtained material was purified by column chromatography (Si-NH SiOz, hexane / EtOAc) to give the title compound (3.2 g, 15%). H NMR (400 MHz, DMSO-d8) & [ppm]: 0.48-0.51 (m, 2H), 0.54-0.57 (m, 2H), 1.30 (t, 3H), 2.45 (s, 2H), 2.96 (s, 2H), 4.36 (q, 2H). UPLC-MS (Method 1): Ry = 1.22 min; MS (ESIpos): m / z = 303 [M+H]". Step 2 ethyl (5E / Z)-5-[(dimethylamino)methylidene]-4-oxo-3-(trifluoromethyl)-4,7-dihydro- S5H-spiro[[1]benzofuran-6,1'-cyclopropane]-2-carboxylate F 0 CH, Fr NF / O— A Yr HaC. O- N | | \ TYR According to GP A (conditions A) ethyl 4-oxo-3-(trifluoromethyl)-4,7-dihydro-5H- spiro[[1]benzofuran-6,1'-cyclopropane]-2-carboxylate (1.00 eq., 1.53 g, 5.06 mmol) from step1 was reacted with 1-fert-butoxy-N,N,N'N-tetramethylmethanediamine (Bredereck’s reagent, CAS No. [5815-08-7]; 1.2 eq., 1.1 mL, 6.1 mmol) in toluene (30mL) at 100°C for 29h. Another amount of 1-tert-butoxy-N,N,N'N- tetramethylmethanediamine (1.5 eq., 1.4 mL, 7.6 mmol) was added and stirring at 100 °C continued for another 19 h. The reaction mixture was concentrated under reduced pressure and the obtained crude title compound used in the subsequent reaction without further purification steps. UPLC-MS (Method 1): Ry = 1.23 / 1.29 min: MS (ESIpos): m / z = 358 [M+H]". Step 3 ethyl 8'-(trifluoromethyl)-1',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-g]indazole]- 7'-carboxylate H CHjy J FF VF CO” yn NF = O- TN o © According to GP B crude ethyl (5E / Z)-5-[(dimethylamino)methylidene]-4-oxo-3- (trifluoromethyl)-4,7-dihydro-5H-spiro[[1]benzofuran-6,1'-cyclopropane]-2-carboxylate (1.00 eq., 1.81 g, 5.06 mmol) from step 2 was reacted with hydrazine dihydrochloride (CAS No. [5341-61-7]; 2.0 eq., 1.1 g, 10 mmol) in a mixture of ethanol (13 mL) and water (2 mL) at 70 °C for 1 hour to give upon column chromatography (SiO, hexane / EtOAc) the title compound (192 mg, 11% over two steps). H NMR (500 MHz, DMSO-d6) 3 [ppm]: 0.83-0.86 (m, 2H), 0.88-0.91 (m, 2H), 1.31 (t, 3H), 2.97 (s, 2H), 4.35 (q, 2H), 7.42 (s, 1H), 12.62 (s, 1H). ®F NMR (470 MHz, DMSO-d6) & [ppm]: -55.0 (s). UPLC-MS (Method 1): Rt = 1.15 min; MS (ESIpos): m / z = 327 [M+H]". Step 4 ethyl 2'-{[(2S)-1,4-dioxan-2-yl]Jmethyl}-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxylate Cie J / ——Cy nC F CHg NN NF | a) ro TN oo According to GP C (conditions ~~ A) ethyl 8'-(trifluoromethyl)-1',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxylate (1.00 eq., 142 mg, 435 pmol) from step 3 was reacted with [(2S)-1,4-dioxan-2-yljmethanol (CAS No. [406913-93-7]; 1.1 eq., 77 mg, 650 pmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6eq., 170 uL, 700 ymol) and TMAD (CAS No. [10465-78-8]; 1.60 eq., 120 mg, 696 pmol) in toluene (5 mL) at rt for 5 days to give upon column chromatography (SiOz, hexane! ethyl acetate) the title compound (97 mg, 52%). H NMR (400 MHz, DMSO-d6) [ppm]: 0.79-0.91 (m, 4H), 1.31 (t, 3H), 2.92-3.02 (m, 2H), 3.25 (dd, 1H), 3.43 (dt, 1H), 3.53 (dt, 1H), 3.61-3.64 (m, 1H), 3.71-3.75 (m, 2H), 3.79-3.85 (m, 1H), 4.10-4.11 (m, 2H), 4.35 (q, 2H), 7.38 (s, 1H). UPLC-MS (Method 1): Rt = 1.29 min; MS (ESIpos): m / z = 427 [M+H]". Step 5 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxylic acid Cm 7 I — S F . I~. op g! "on TN o 0 According to GP D ethyl 2-{[(2S)-1,4-dioxan-2-yllmethyl}-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxylate (1.0eq., 97 mg, 230 pmol) from step 4 was reacted with aqueous lithium hydroxide (2 M; 15 eq., 1.7 mL, 3.4 mmol) in a 1:1 mixture of ethanol and THF (4 mL) at 70 °C for 4 hours. The reaction mixture was acidified with aqueous 2 N HCI (pH 2) and the formed precipitate filtered off. The solid was washed with water and EtOAc and dried to give a first crop of the desired carboxylic acid (57 mg, 60%). The combined filtrates and washing solutions were re- extracted with ethyl acetate (twice), the combined organic phases dried with Na2SOs, filtrated and concentrated under reduced pressure to give a second crop of the desired carboxylic acid (34 mg, 87% purity, 33%). H NMR (400 MHz, DMS0-d8) 8 [ppm]: 0.79-0.92 (m, 4H), 2.90-2.99 (m, 2H), 3.25 (dd, 1H), 3.43 (dt, 1H), 3.53 (dt, 1H), 3.61-3.64 (m, 1H), 3.70-3.75 (m, 2H), 3.80-3.85 (m, 1H), 4.00-4.11 (m, 2H), 7.37 (s, 1H), 13.94 (br. s., 1H). UPLC-MS (Method 1): Ry = 0.55 min; MS (ESIpos): m / z = 399 [M+H]". Intermediate 51: Step 1 ethyl 2-[(4-fluoropyridin-2-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-gJindazole- 7-carboxylate Ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7-carboxylate (commercially available; 1.0 eq, 100 mg, 406 umol), 2-(chloromethyl)-4-fluoropyridine (1.5 eq, 88.7 mg, 609 pmol) and caesium carbonate (CAS No [534-17-8], 3.0 eq, 397 mg, 1.22 mmol) were added to DMF (3.0 ml) and stirred 24h at rt overnight under nitrogen. 2, 2-(chloromethyl)- 4-fluoropyridine (1.5 eq, 88.7 mg, 609 pmol) and caesium carbonate (CAS No [534-17- 8], 3.0 eq, 397 mg, 1.22 mmol) were added again and stirred at rt overnight under nitrogen. The reaction mixture was filtered and washed with ethyl acetate. The filtrate was evaporated and purified by column chromatography (SiOz, hexane / ethyl acetate) to give the product (563.1 mg, 37 % yield). H NMR (400 MHz, DMSO-d6) 8 [ppm]: 1.27 — 1.31 (m, 3 H) 2.46 (s, 3 H) 2.85 - 2.94 (m, 4H) 423-429 (m, 2H) 5.40 (s, 2H) 7.19— 7.22 (m, 1H) 7.65 (s, 1 H) 7.71 (td, 1 H) 8.55 (d, 1 H) LC-MS (Method 1): Rt = 1.22 min; MS (ESIpos): m / z = 356 [M+H]* Step 2 2-[(4-fluoropyridin-2-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-gJindazole-7- carboxylic acid F \ N “N cH, NA on I 0 © According to GP D ethyl 2-[(4-fluoropyridin-2-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.0 eq, 563.0 mg, 149 umol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 5 eq, 370 pL, 750 pmol) in a 1:1 mixture of ethanol and THF (2.0 mL) at 70 °C overnight. Upon acidification (pH 2) with 6 N aqueous hydrochloric acid and evaporated. To the residue were added DCM (20m) and i-PrOH (1ml) and stirred at rt. The DCM phase was decanted and evaporated. And then THF (20 ml) was added and co-evaporated. The crude (75 mg) was used in the subsequent reaction without further purification steps. LC-MS (Method 1): Rt = 0.52 min; MS (ESIpos): m / z = 328 [M+H]* Intermediate 52: Step 1 ethyl 8-methyl-2-[(pyridazin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate =\ N § CHs RB CHgs Non en §! { o— BR o © A solution of ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7-carboxylate (commercially available; 1.0 eq, 180 mg, 731 umol) and 3-(chloromethyl)pyridazine chloride (CAS No [27349-66-2], 1.5 eq, 180 mg, 1096 pmol) in DMF (24.0 ml) under nitrogen is treated with caesium carbonate (CAS No [534-17-8], 20.0 eq., 4.76 g, 14.6 mmol) and stirred at 80°C overnight. The solid was filtered and washed with ethyl acetate and was evaporated. The residue was purified by column chromatography (SiO, hexane / ethyl acetate) to give the product (87 mg, 35 % yield). H NMR (400 MHz, DMSO-d6) 8 [ppm]: 1.27 — 1.31 (m, 3 H) 2.46 (s, 3 H) 2.85 - 2.95 (m, 4H) 4.21430 (m, 2 H) 5.63 (5, 2 H) 7.38 - 7.43 (m, 1H), 7.67 = 7.71 (m, 1 H) 7.72 (s, 1H) 9.13-9.22 (m, 1 H) LC-MS (Method 1): Ry = 1.02 min; MS (ESIpos): m / z = 339 [M+H]" Step 2 8-methyl-2-[(pyridazin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid =\ N yy 8 CHa \ N=N cH, GF YY TN oo According to GP D ethyl 8-methyl-2-[(pyridazin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.0 eq, 87.0 mg, 257 umol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 5 eq, 640 pL, 1.3 mmol) in a 1:1 mixture of ethanol and THF (5.0 mL) at 70 °C overnight. Upon acidification (pH 2) with 6 N aqueous hydrochloric acid, the resulting mixture was evaporated. To the residue were added DCM (50 ml) and i-PrOH (4 x 5 ml) and stirred 30 min at rt. Hexane was added until precipitation, filtered, washed with hexane / DCM (1:1) and evaporated. To the residue, was added DCM and brine (2 ml) and stirred. The phases were separated, and the DCM phase was evaporated to give the product (35.0 mg, 44 % yield). LC-MS (Method 2): Rt = 0.72 min; MS (ESIpos): m / z = 311 [M+H]* Intermediate 53: Step 1 ethyl 2-[(6-chloropyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-gJindazole- 7-carboxylate J y $A \ CHs N=~N CH Sp od BR 0" o According to GP C (conditions A) Ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available;1.00 eq., 250 mg, 1.05 mmol) was reacted with (6- chloropyridin-3-yl)methanol (1.5 eq., 218 mg, 1.52 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 0.4 mL, 1.6 mmol) and TMAD (CAS No. [10465-81-3]; 1.6 eq., 279 mg, 1.6 mmol) in toluene (5.8 ml) at rt overnight. The reaction mixture was filtered and extracted with water. The water phase was extracted twice with DCM. The combined organic layers (DCM and toluene phases) were dried over a hydrophobic filter paper and evaporated to give a crude material. It was then purified by column chromatography (SiOz, hexane! EtOAc) to give the title compound (140 mg, 36% yield). LC-MS (Method 1): Rt = 1.28 min; MS (ESIpos): m / z = 372 [M+H]* Step 2 ethyl 2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylate —CHs = \ 4 CHa R CHa NeN i §! "oo I oO © Ethyl 2-[(6-chloropyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxylate (1.0 eq, 350 mg, 941 umol) from step 1 was dissolved in dioxane (22 ml) and flushed with nitrogen. 1,1’-Bis(diphenylphosphino)ferrocenedichloropalladium(ll) (76.8 mg, 94.1 umol; CAS-RN:[72287-26-4]) was firstly added and diethylzinc in hexane (CAS No [557-20-0], 4.5 eq, 4.2 ml, 1.0 M, 4.2 mmol) was then added dropwise. The resulting reaction mixture was stirred for 4h at 100°C. To the reaction mixture were added water and DCM. The layers were separated, and the water layer was extracted with DCM and with ethyl acetate. The organic layers were dried by hydrophobic filtration and evaporated. The crude material was purified by silica gel column chromatography (hexane / DCM) to give the title compound (187 mg, 55 % yield). LC-MS (Method 1): Ry = 1.26 min; MS (ESIpos): m / z = 366 [M+H]" Step 3 2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid —CH, = $A NN ep, Ng! { oH N\ oo According to GP D ethyl 2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.0 eq, 94.0 mg, 257 umol) from step 2 was reacted with aqueous lithium hydroxide (2 M; 5 eq, 640 pL, 1.3 mmol) in a 1:1 mixture of ethanol and THF (3.0 mL) at 70 °C overnight. Upon acidification (pH 2) with 6 N aqueous hydrochloric acid, the resulting mixture was evaporated. To the residue was added DCM (30 ml), water (20 ml) and i-PrOH (2 ml). The water phase was extracted with DCM / i-PrOH (9:1). The combined organic phase was dried over a hydrophobic filter paper and evaporated to give the product (55 mg, 63 % yield) as a crude material, which was used in the next step without further purification. LC-MS (Method 1): Rt = 0.56 min; MS (ESIpos): m / z = 338 [M+H]* Intermediate 54: Step 1 ethyl 8-methyl-2-[(1,3-oxazol-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate CHa o o-' A 1 ~~ CH, Xe. AY N-N I Ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-g]indazole-7-carboxylate (commercially available; 1.00 eq., 100 mg, 406 umol) was reacted with (1,3-oxazol-2-yl) methanol (CAS No [14774-37-9], 1.5 eq., 60.4 mg, 609 pmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 160 WL, 650 umol) and 1,1'-(azedicarbonyl)dipiperidine (CAS No. [10465-81-3]; 1.6 eq., 112 mg, 650 umol) in toluene (3.0 ml) at rt overnight. The same amounts of reagents were added and stirred again at rt overnight. The reaction mixture was filtered and extracted with water. The water phase was re-extracted with DCM. The organic layers were combined and dried over a hydrophobic filter paper and evaporated to give a crude material. It was then purified by column chromatography (NH, SiOz, hexane / DCM) to give the title compound (60 mg), which was used in the next step without further purification. LC-MS (Method 1): Rt = 1.10 min; MS (ESIpos): m / z = 328 [M+H]* Step 2 8-methyl-2-[(1,3-oxazol-2-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid \ OH -) Hs XN oO TN oof According to GP D ethyl 8-methyl-2-[(1,3-oxazol-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.0 eq, 60 mg, 183 pmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq, 1.4 mL, 2.7 mmol) in a 1:1 mixture of ethanol and THF (1.3 mL) at 70 °C overnight. Upon acidification (pH 2) with 6 N aqueous hydrochloric acid, the resulting mixture was evaporated. The resulting crude material was used in the subsequent reaction without further purification steps (90 mg). LC-MS (Method 1): Ry = 0.47 min; MS (ESIpos): m / z = 300 [M+H]" Intermediate 55: Step 1 ethyl 8-methyl-2-[(oxan-4-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate —Q \ CHa N=N H | A on IY oo Ethyl 8-methyl-4,5-dihydro-1H-furo[2, 3-glindazole-7-carboxylate (commercially available; 1.00 eq., 100 mg, 406 pmol) was reacted with (oxan-4-yl)methanol (CAS No [14774-37-9], 1.5 eq., 70.8 mg, 609 umoal), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 160 pL, 650 pmol) and 1,1’-(azodicarbonyl)dipiperidine (CAS No. [10465-81-3]; 1.6 eq., 112 mg, 650 umol) in toluene (3.0 ml) at rt overnight. The same amounts of reagents were added and stirred again at rt overnight. The reaction mixture was filtered and extracted with water. The water phase was extracted with DCM. The combined organic layers were dried over a hydrophobic filter paper and evaporated to give a crude material. It was then purified by column chromatography (NH, SiOz, hexane / DCM) to give the title compound (314 mg), which was used in the next step without further purification. LC-MS (Method 1): Rt = 1.21 min; MS (ESIpos): m / z = 345 [M+H]* Step 2 8-methyl-2-[(oxan-4-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxylic acid —Q \ N-N GH, J) { OH A o 0 According to GP D ethyl 8-methyl-2-[(oxan-4-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (1.0 eq, 210 mg, 610 umol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 15 eq, 4.6 mL, 9.1 mmol) in a 1:1 mixture of ethanol and THF (4.3 mL) at 70 °C overnight. Upon acidification (pH 2) with 8 N aqueous hydrochloric acid, the resulting mixture was evaporated, and the crude material was used in the subsequent reaction without further purification steps (350 mg). LC-MS (Method 1): Ry = 0.53 min; MS (ESIpos): m / z = 317 [M+H]" Intermediate 56: Step 1 ethyl 8-methyl-2-{[(2R and 2S)-oxan-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (Racemate) pois CH, CHa, g: re o_’ N-n CHy \ 0- i o “o According to GP C (conditions A) ethyl 8-methyl-4,5-dihydro-1H-furo[2,3-glindazole-7- carboxylate (commercially available; 100 mg, 406 pmol) and [(2R and 2S)-oxan-2- yllmethanol (racemate, 70.8 mg, 609 pmol, CAS-RN:[100-72-1]) were suspended in toluene (3 mL) together with TMAD (112 mg, 650 pmol, CAS No. [10465-78-8]). Carefully tri-n-butylphosphine (160 ul, 650 umol, CAS No. [998-40-3]) was added and the reaction mixture stirred for 18 h at rt. Further TMAD (112 mg, 650 pmol) and tri-n-butylphosphine (160 ul, 650 pmol) were then added and stirring continued for 18 h at rt and 4 h at 45°C. After additional tri-n-butylphosphine (160 pl, 650 pmol), stirring was prolonged for 3 days at rt. After filtration, water was added to the filtrate, and the aqueous phase was extracted with dichloromethane. After evaporation of the organic layer, the crude material was purified by Biotage Isolera™ chromatography (SNAP KP-NH — 28 g), eluting with hexane- dichloromethane, 1:0 to 3:2) to afford the title compound (100 mg, 72% yield). LC-MS (Method 1); Rt = 1.33 min; MS (ESIpos): m / z = 345 [M+H]* Step 2 8-methyl-2-{[(2R and 2S)-oxan-2-ylJmethyl}-4,5-dihydro-2H-furc[2,3-g]indazole-7- carboxylic acid (Racemate) / poll) A EE \ OH I o Yo According to GP D ethyl 8-methyl-2-{[(2R and 2S)-oxan-2-ylJmethyl}-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (racemate, 100 mg, 290 umol) from step 1 was reacted with aqueous lithium hydroxide (15 eq, 2.2 ml, 2.0 M, 4.4 mmol) in a 1:1 mixture of ethanol and THF (4.1 mL) at 70°C overnight. The reaction mixture was acidified with aqueous 6 N HCI (pH 4) and concentrated in vacuo. The resulting crude product (140 mg) was used in the next step without further purification. LC-MS (Method 1): Rt = 0.59 min; MS (ESIpos): m / z = 317 [M+H]* Intermediate 57: Step 1 ethyl 2-[(6-methylpyridin-3-yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate F CHs nF [} * IN 0 oO According to GP C (conditions A) ethyl 8-(trifluoromethyl)-4,5-dihydro-1H-furo[2,3- glindazole-7-carboxylate (1.0 eq., 325 mg, 1.08 mmol) from Intermediate 35 step 4 was reacted with (6-methylpyridin-3-yl)methanol (CAS No [34107-46-5], 1.7 eq., 227 mg, 1.84 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 430 pL, 1.7 mmol) and TMAD (CAS No. [10465-78-8]; 1.6 eq., 298 mg, 1.73 mmol) in toluene (10 ml) at rt overnight. The reaction mixture was filtered and extracted with water. The water phase was re-extracted with DCM. The organic phases were dried over Na;SOq, filtered and evaporated under reduced pressure to give a crude material. The crude was then purified by column chromatography (NH, SiOz, hexane / DCM) to give the title product (460.5 mg), which was used in the next step without further purification. LC-MS (Method 1): Ry = 1.24 min; MS (ESIpos): m / z = 406 [M+H]" Step 2 2-[(6-methylpyridin-3-yl)methyl]-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylic acid F mod HS NaN F Fr S * A OH 0 © According to GP D ethyl 2-[(6-methylpyridin-3-yl)methyl]-8-(trifluoromethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxylate (1.0 eq, 460 mg, 1.13 mmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 5 eq, 2.8 mL, 5.7 mmol) in a 1:1 mixture of ethanol and THF (9.2 mL) at 70 °C overnight. Upon acidification (pH 2) with 6 N aqueous hydrochloric acid and the resulting mixture was evaporated. To the crude was added DCM (75 ml) and i-PrOH (2 x 0.5 ml) and stirred at rt. The DCM phase was decanted and the remaining solid was dissolved in DCM (75 ml) and i-PrOH (5 ml) and stirred at rt and the resulting DCM phase was decanted and the solution was evaporated to yield the product as a solid (226 mg, 53 % yield). LC-MS (Method 1): Rt = 0.56 min; MS (ESIpos): m / z = 378 [M+H]* Intermediate 58: Step 1 methyl 8-cyclopropyl-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate QO— / ~~) N=N V S$ O-CHs I 0 0 According to GP C (conditions A) methyl 8-cyclopropyl-4,5-dihydro-1H-furo[2,3- glindazole-7-carboxylate (1.0 eq., 250 mg, 968 pmol) from Intermediate 36 step 4 was reacted with [(2S)-1,4-dioxan-2-ylJmethanol (CAS No [406913-93-7], 1.5 eq., 172 mg, 1.45 mmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 380 pL, 1.5 mmol) and TMAD (CAS No. [10465-78-8]; 1.6 eq., 267 mg, 1.55 mmol) in toluene (5.5 ml) at rt overnight. The reaction mixture was filtered and extracted with water. The combined water phase was re-extracted with DCM. The combined organic layers were dried with Na;SOs, filtered and evaporated. The crude material was purified by column chromatography (SiOz, hexane / DCM) to give the title compound (350 mg). LC-MS (Method 1): Rt = 1.19 min; MS (ESIpos): m / z = 359 [M+H]* Step 2 8-cyclopropyl-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4,5-dihydro-2H-furo[2,3-g]indazole- 7-carboxylic acid O— / (3 “NeN Vv 9 OH Yr 0 0 According to GP D methyl 8-cyclopropyl-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (1.0 eq, 350 mg, 977 pmol) from step 1 was reacted with aqueous lithium hydroxide (2 M; 5 eq, 2.4 mL, 4.9 mmol) in a 1:1 mixture of ethanol and THF (5.0 mL) at 70 °C overnight. Upon acidification (pH 2) with 6 N aqueous hydrochloric acid and the resulting mixture was evaporated under reduced pressure. To the residue was added DCM (40 ml) and i-PrOH (1 ml) and stirred 30 min at rt. The organic phase was separated and evaporated under reduced pressure to give the title compound (400 mg), which was used in the following step without further purification. LC-MS (Method 1): Rt = 0.51 min; MS (ESIpos): m / z = 345 [M+H]* Intermediate 59: Step 1 ethyl 8'-methyl-2'-[(pyridin-4-yl)methyl]-2',5'-dihydrospiro[cyclobutane-1,4'- furo[2,3-glindazole]-7'-carboxylate CHs CHs CY! bh. 3 N-N CH, MMA To N oo According to GP C (conditions A) ethyl 8-methyl-2',5'-dihydrospiro[cyclobutane-1,4'- furo[2,3-glindazole]-7'-carboxylate (190 mg, 664 pmol, intermediate 42 (step 3)) and pyridin-4-yl)methanol (109 mg, 995 pmol, CAS-RN:[586-95-8]) were suspended in toluene with (3.8 mL) together TMAD (183 mg, 1.06 mmol; CAS No. [10465-78-8]). Carefully tri-n-butylphosphine (260 pl, 1.1 mmol, CAS No. [998-40-3]) was added and the reaction mixture stirred for 18 h at rt. Water was added to the reaction mixture and then concentrated in vacuo. The residue was diluted with 3 ml acetonitrile and purified by preparative HPLC (Method A, gradient D). The product fractions were pooled and concentrated in vacuo to afford 18.0 mg (6% yield, 79% purity) of the title compound. H NMR (400 MHz, DMSO-d6) [ppm]: 1.29 (t, 3H), 2.01-2.15 (m, 6H), 2.46 (s, 3H), 3.01- 3.15 (m, 2H), 4.26 (q, 2H), 5.39 (s, 2H), 7.13-7.16 (m, 2H), 7.97 (s, 1H), 8.52-8.55 (m, 2H) LC-MS (Method 1): Rt = 1.27 min; MS (ESIpos): m / z = 378 [M+H]* Step 2 8'-methyl-2'-[(pyridin-4-yl)methyl]-2',5'-dihydrospiro[cyclobutane-1,4'-furo[2,3- glindazole]-7'-carboxylic acid CHa OH N-N CHs SA of TN oo According to GP D ethyl 8'-methyl-2'-[(pyridin-4-yl)methyl]-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-glindazole]-7'-carboxylate (18.0 mg, 79 % purity, 37.7 umol) from step 1 was reacted with aqueous lithium hydroxide (2190 ul, 2.0 M, 380 pmol) in THF (430 pl) at rt overnight. After stirring for further 2 h at 30°C, the reaction mixture was acidified with aqueous 2 N HCI (pH 2) and concentrated in vacuo and used in the next step without further purification (12 mg, 91% yield). LC-MS (Method 2): Ry= 0.77 min; MS (ESIpos): m / z = 350 [M+H]*. Intermediate 60: Step 1 ethyl 8'-methyl-2'-[(5-methylpyridin-2-yl)methyl]-2',5'-dihydrospiro[cyclobutane- 1,4'-furo[2,3-glindazole]-7'-carboxylate CHa 0 7 CHs RB CHa \ SEE \ O— BB 0 o According to GP C (conditions A) ethyl 8-methyl-2',5'-dihydrospiro[cyclobutane-1,4'- furo[2,3-glindazole]-7'-carboxylate (190 mg, 664 umol, intermediate 42 (step 3)) and (5- methylpyridin-2-yl) methanol (123 mg, 995 umol, CAS-RN:[22940-71-2]) were suspended in toluene with (3.8 mL) together TMAD (183 mg, 1.06 mmol; CAS No. [10465-78-8]). Carefully tri-n-butylphosphine (260 pl, 1.1 mmol, CAS No. [998-40-3]) was added and the reaction mixture stirred for 18 h at rt. Water was added to the reaction mixture and then concentrated in vacuo. The residue was diluted with 3 ml acetonitrile and purified by preparative HPLC (Method A, gradient E). The product fractions were pooled and concentrated in vacuo to afford 49.5 mg (16% yield, 85% purity) of the title compound. H NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.29 (t, 3H), 1.99-2.14 (m, 6H), 2.27 (s, 3H), 2.45 (s, 3H), 3.07 (s, 2H), 4.26 (q, 2H), 5.36 (s, 2H), 7.01 (d, 1H), 7.56-7.62 (m, 1H), 7.91 (s, 1H), 8.36-8.40 (m, 1H). LC-MS (Method 1): Rt = 1.37 min; MS (ESIpos): m / z = 392 [M+H]* Step 2 8'-methyl-2'-[(5-methylpyridin-2-yl)methyl]-2',5'-dihydrospiro[cyclobutane-1,4'- furo[2,3-glindazole]-7'-carboxylic acid CHgs = . \ Nn CH, SA on TN oo According to GP D ethyl 8-methyl-2"-[(5-methylpyridin-2-yl)methyl]-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-glindazole]-7'-carboxylate (49.5 mg, 85 % purity, 107 pmol) from step 1 was reacted with aqueous lithium hydroxide (540 pl, 2.0 M, 1.1 mmol) in THF (1.2 ml) at rt overnight. After stirring for further 2 h at 30°C, the reaction mixture was acidified with aqueous 2 N HCI (pH 2) and concentrated in vacuo and used in the next step without further purification (35 mg, 90% yield). LC-MS (Method 2): Ry = 1.03 min; MS (ESIpos): m / z = 364 [M+H]" Intermediate 61: Step 1 ethyl 8-methyl-2-[2-(pyridin-2-yl)ethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate Die \ NN cn Vy 7 XN Oo ly 0 o- CHs According to GP C (conditions B), to a mixture of cesium carbonate (1.59 g, 4.87 mmol; CAS-RN:[534-17-8]) in N,N-dimethylformamide (6.0 mL) were added ethyl 8-methyl-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxylate (commercially available; 400 mg, 1.62 mmol) and 2-(pyridin-2-yl)ethyl methanesulfonate (981 mg, 4.87 mmol) at 25°C. The mixture was stirred at 60°C for 12 h. Further 2-(pyridin-2-yl)ethyl methanesulfonate (981 mg, 4.87 mmol) was added to the mixture and then stirred at 60°C for another 8 h. Water was added to the mixture and then extracted with ethyl acetate. The combined organic layer was concentrated under reduced pressure to give a residue. The residue was purified by pre-HPLC [Instrument ACSWH-GX-C; Column: Phenomenex Gemini-NX C18 75*30mm*3um; eluent A: water (0.225% formic acid in water), eluent B: acetonitrile; gradient: 0-10 min 10-40% B; flow 25 ml / min; temperature: RT; Detector: UV 220 / 254 nm.] followed by lyophilization to afford 250 mg (41% yield, 94% purity) of the title compound as a light yellow solid. "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.30 (t, 3H), 2.78-2.84 (m, 2H), 2.86-2.91 (m, 2H), 3.25 (t, 2H), 4.26 (q, 2H), 4.45 (t, 2H), 7.21-7.28 (m, 2H), 7.45 (s, 1H), 7.69 (td, 1H), 8.52 (d, 1H)(methyl signal below DMSO). LC-MS (Method B): Rt = 0.68 min; MS (ESlpos): m / z = 352 [M+H]* Step 2 8-methyl-2-[2-(pyridin-2-yl)ethyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxylic acid NN cn, SA on \ Oo 0 According to GP D ethyl 8-methyl-2-[2-(pyridin-2-yl)ethyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate (150 mg, 427 pmol) from step 1 was reacted with aqueous lithium hydroxide (4.3 ml, 1.0 M, 4.3 mmol) in THF (750 uL) at rt overnight. After stirring for further 2 h at 30°C, the reaction mixture was acidified with aqueous 2 N HCI (pH 2) and concentrated in vacuo and resulting precipitate was filtered off to afford 123 mg (88% yield, 99% purity) of the title compound. "H NMR (400 MHz, DMSO-d6) & [ppm]: 2.33 (s, 3H), 2.75-2.93 (m, 4H), 3.50 (br t, 2H), 4.57 (t, 2H), 7.51 (s, 1H), 7.81 (br d, 2H), 8.36 (br t, 1H), 8.78 (dd, 1H), 12.76 (br s, 1H). LC-MS (Method 1): Ry = 0.55 min; MS (ESIpos): m / z = 324 [M+H]* Intermediate 62: Step 1 2,2-difluoro-2-(pyridin-2-yl)ethyl trifluoromethanesulfonate [7] # oT FF To a solution of 2,2-difluoro-2-(pyridin-2-yl)ethan-1-ol (300 mg, 1.89 mmol; CAS- RN:[267875-65-0]) in acetonitrile (5.0 mL) were added trifluoromethanesulfonic anhydride (380 pl, 2.3 mmol; CAS-RN:[358-23-6]) and pyridine (240 pl, 3.0 mmol) at 0°C. The mixture was stirred at 25°C for 1 h. Water was added to the mixture and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 540 mg (crude) of the title compound. LC-MS (Method C): Rt = 0.85 min; MS (ESIpos): m / z = 292 [M+H]* Step 2 ethyl 2-[2,2-difluoro-2-(pyridin-2-yl)ethyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxylate eA F Oi: \ My CHa NX Oo TN 0 o- CHs According to GP C (conditions B), to a stirred solution of ethyl 8-methyl-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (commercially available; 300 mg, 1.22 mmol) and 2,2- difluoro-2-(pyridin-2-yl)ethyl trifluoromethanesulfonate (532 mg, 1.83 mmol, intermediate 62 (step 1)) in acetonitrile (5.0 mL) was added potassium carbonate (337 mg, 2.44 mmol) at 25 °C. The mixture was stirred at 50°C for 12 h. Water was added to the mixture and then aqueous layer was extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash chromatography (silica gel, eluting with petroleum ether- ethyl acetate, 1: 0 to 2: 1) to afford 255 mg (50% yield, 93% purity) of the title compound as a yellow ail. "H NMR (400 MHz, DMSO-d6) & [ppm]: 1.29 (t, 3H), 2.39 (s, 3H), 2.80-2.94 (m, 4H), 4.26 (q, 2H), 5.02 (t, 2H), 7.52 (s, 1H), 7.59 (dd, 1H), 7.66 (d, 1H), 7.98 (td, 1H), 8.74 (d, 1H). LC-MS (Method B): Rt = 0.85 min; MS (ESlpos): m / z = 388 [M+H]*. Step 3 2-[2,2-difluoro-2-(pyridin-2-yl)ethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylic acid NF Xo \ N-N CHa J) { oH A o o According to GP D ethyl 2-[2,2-difluoro-2-(pyridin-2-yl)ethyl]-8-methyl-4,5-dihydro-2H- furo[2,3-gJindazole-7-carboxylate (150 mg, 387 pmol) from step 2 was reacted with aqueous lithium hydroxide (3.9 ml, 1.0 M, 3.9 mmol) in THF (680 pL) at rt overnight. After stirring for further 4 h at 50°C, the reaction mixture was acidified with aqueous 2 N HCI (pH 2) and resulting precipitate was filtered off to afford 116 mg (80% yield, 96% purity) of the title compound. H NMR (400 MHz, DMSO-d6) 8 [ppm]: 2.37 (s, 3H), 2.79-2.92 (m, 4H), 5.01 (t, 2H), 7.51 (s, 1H), 7.59 (dd, 1H), 7.63-7.71 (m, 1H), 7.98 (td, 1H), 8.74 (d, 1H), 12.21-13.27 (m, 1H). LC-MS (Method 1): Ry = 0.59 min; MS (ESIpos): m / z = 360 [M+H]* Intermediate 63: Step 1 ethyl 8'-methyl-2'-[(6-methylpyridin-3-yl)methyl]-2',5'-dihydrospiro[cyclopropane- 1,4'-furo[2,3-glindazole]-7'-carboxylate word CHa N=N CH i SAL 0 IY oO © According to GP C (conditions A) ethyl 8-methyl-1',5'-dihydrospiro[cyclopropane-1,4'- furo[2,3-glindazole]-7'-carboxylate (1.00 eq., 150 mg, 551 umol) from Intermediate 41 step 3 was reacted with (6-methylpyridin-3-yl)methanol (CAS No [34107-46-5], 1.5 eq., 102 mg, 826 pmol), tri-n-butylphosphine (CAS No. [998-40-3]; 1.6 eq., 220 pL, 880 pmol) and TMAD (CAS No. [10465-78-8]; 1.6 eq., 152 mg, 530 pmol) in toluene (3.1 ml) at rt overnight. The reaction mixture was filtered and extracted with water. The water phase was extracted with DCM. The combined organic layers were dried with NazSOy, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography (SiOz, hexane / EtOAc) to give the title compound (309 mg). LC-MS (Method 1): Rt = 1.24 min; MS (ESIpos): m / z = 378 [M+H]* Step 2 8'-methyl-2'-[(6-methylpyridin-3-yl)methyl]-2',5'-dihydrospiro[cyclopropane-1,4'- furo[2,3-glindazole]-7'-carboxylic acid nod YH N-N CHj §! { oH I oo According to GP D ethyl 8-methyl-2'-[(6-methylpyridin-3-yl)methyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxylate (1.0 eq, 308 mg, 816 pmol) from step 1 was reacted with aqueous lithium hydroxide (2M; 5eq, 2.0 mL, 4.1 mmol) in a 1:1 mixture of ethanol and THF (11.0 mL) at 70 °C overnight. Upon acidification (pH 2) with 6 N aqueous hydrochloric acid and the resulting mixture was evaporated under reduced pressure. To the residue was added DCM (50 ml) and i-PrOH (5x 1 ml) and stirred at rt. The DCM phase was decanted and evaporated to give the title compound (306 mg), which was directly used in the next step without further purification. LC-MS (Method 1); Rt = 0.56 min; MS (ESIpos): m / z = 350 [M+H]* Intermediate 64: ethyl 2-[(azetidin-3-yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxylate hydrogen chloride (1 / 1) cl HH N N ) \ CHs CY bt. \ CH, \ N-N cH, OW) { © \ 0" o- A solution of ethyl 2-{[1-(tert-butoxycarbonyl)azetidin-3-yllmethyl}-8-methyl-4,5-dihydro- 2H-furo[2,3-gindazole-7-carboxylate (4.00 g, 9.63 mmol, intermediate 32 (step 1) in4 M HCl in dioxane (20 mL) was stirred at 25°C for 2 h. The mixture was filtered to collect the solid. The solid was dried under reduced pressure to afford 3.40 g (100% yield) of the title compound as a light brown solid. H NMR (400 MHz, DMSO-d8) 5 [ppm]: 1.17 (t, 3H), 1.98 (s, 3H), 2.81-2.95 (m, 4H), 3.13- 3.23 (m, 1H), 3.76-3.87 (m, 2H), 3.88-3.99 (m, 2H), 4.26 (q, 2H), 4.35 (d, 2H), 7.55 (s, 1H) Intermediate 65: Step 1 ethyl 2'-[(6-methylpyridin-3-yl)methyl]-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxylate CHa = § F CHs N-N NLF 3) a IY oo According to GP C (conditions ~~ A) ethyl 8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxylate (150 mg, 68 % purity, 313 pmol, intermediate 50 (step 3)) and (6-methylpyridin-3-yl)methano...

Claims

CLAIMS 1. A compound of general formula (1): R72 R" 4 R Rk N—N rR? l 4 N—R rR N N 4 \ ¥ \ 0 1 I R 0 N- R R? nh in which: R! represents hydrogen, Ci-Cs-alkyl or C4-Cq-haloalkyl: R? represents hydrogen, C1-C4-alkyl or C1-Cs-haloalkyl: or R' and R? together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl ring; R? represents Ci-Ce-cycloalkyl, 3- to 6-membered heterocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R8, or R? represents phenyl, which is optionally substituted, one or more times, independently of each other, with R8, and additionally R? and R™ represent deuterium; R* represents hydrogen, C+-Cs-alkyl, C4-Cs-haloalkyl or Cs-Ce-cycloalkyl; RS, R® represent, independently of each other, hydrogen, C-Cs-alkyl, C2-Ce- hydroxyalkyl, (C1-Ca-alkoxy)-(C2-Ca-alkyl)-, Cas-Ce-cycloalkyl, Cs-Cs-haloalkyl, Ca- Ce-halocycloalkyl, 3- to 8-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, heterocycloalkyl fused with phenyl or heteroaryl, 3- to 6- membered heterocycloalkyl-(C1-Cs-alkyl)-, heterospirocycloalkyl-(C-Ca-alkyl)-, (heterocycloalkyl fused with phenyl or heteroaryl)-(C+-Cs-alkyl)-, phenyl-(C1-Ca- alkyl)- or heteroaryl-(C-Ca-alkyl)-, wherein said 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, heterocycloalkyl fused with phenyl or heteroaryl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R®, or RS and R® together with the nitrogen atom to which they are attached form a 3- to B-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom or heteroatom containing group selected from O, NH and S, and which may be optionally substituted, one or more times, independently of each other, with R®: R™ represents hydrogen, deuterium, or Cs-Ce-alkyl: R™ represents hydrogen, deuterium, or Ci-Cs-alkyl; R® represents halogen, cyano, Ci-Cs-alkyl, C1-Cs-haloalkyl, C+-Ca-alkoxy, C1-Cs-haloalkoxy, Cs-Ce-cycloalkyl, Ca-Cs-cycloalkyl-(Ci-Cs-alkyl)-, R'3-(C=0)-, R'"-0-(C=0)-, R"-NH-(C=0)-, or R'2-(SO5)-; R® represents halogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, HoN-C1-Cs-alkyl, C1-Cs-alkoxy, Ci-Ca-haloalkoxy, Ca-Cs-cycloalkyl, R'°-O-(C=0)-, oxo, 5- to 6- membered heterocycloalkyl-, 5- to 6-membered heterocycloalkyl-(C4-Ca-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, C+- Cs-alkyl, C4-Cq-haloalkyl, C1-Cs-alkoxy, or C+-Cs-haloalkoxy: R'™ represents hydrogen, C1-Cs-alkyl, or phenyl-CHa-; RM represents hydrogen, C1-Cqs-alkyl, or 5- to 6-membered heterocycloalkyl-(C-Ca- alkyl)-: R'2 represents Ci-Cs-alkyl or phenyl: R™ represents Ci-Cq-alkyl, C1-Cy-haloalkyl, (C1-Cs-alkoxy)-(Ci-Ca-alkyl)-, C1-Cs- alkyl-(C=0)-, Cs-Ce-cycloalkyl, or phenyl, wherein said Ci-Ce-cycloalkyl group is optionally substituted with C1-C4-alkyl or hydroxy and said phenyl group is optionally substituted, one or more times, independently of each other, with halogen, C+-Cs-alkyl, C+-Cs-haloalkyl, Ci-Ca-alkoxy, or C1-Ca-haloalkoxy; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

2. The compound according to claim 1, wherein R! represents hydrogen, Ci-Cs-alkyl or C4-Cq-haloalkyl: R2 represents hydrogen or C-Cs-alkyl; or R' and R? together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl or heterocycloalkyl ring; R? represents Ci-Ce-cycloalkyl, 4- to 6-membered heterocycloalkyl, heterocycloalkyl fused with heteroaryl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R®, or R? represents phenyl, which is optionally substituted, one or more times, independently of each other, with R®, and additionally R? and R represent deuterium; R* represents hydrogen, C+-Cs-alkyl, C4-Cs-haloalkyl or Cs-Ce-cycloalkyl; RS, R® represent, independently of each other, hydrogen, C,-Cs-hydroxyalkyl, (C+-C4-alkoxy)-(C2-Ca-alkyl)-, 3- to 6-membered heterocycloalkyl, heterospirocycloalkyl, phenyl, heteroaryl, 4- to 6-membered heterocycloalkyl- (C4-Ca-alkyl)-, heterospirocycloalkyl-(C1-Ca-alkyl)-, (heterocycloalkyl fused with heteroaryl)-(C-Ca-alkyl)-, or heteroaryl-(C1-Cs-alkyl)-, wherein said 3- to 6- membered heterocycloalkyl, phenyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with R®, or RS and R® together with the nitrogen atom to which they are attached form a 5-membered nitrogen containing heterocyclic ring, which may be optionally substituted, once with R®: R7 represents hydrogen, deuterium, or methyl: R™ represents hydrogen, deuterium, or methyl: R® represents halogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, C4-Ca-alkoxy, Ca-Ce- cycloalkyl, Ca-Cs-cycloalkyl-(C-Cs-alkyl)-, R'3-(C=0)-, R'%-0-(C=0)-, R''-NH- (C=0)-, or R'2(S0y)-; R® represents halogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, HaN-C4-Cs-alkyl, Ca-Cs- cycloalkyl, R'°-O-(C=0)-, oxo, 6-membered heterocycloalkyl-(C-Ca-alkyl)-, phenyl, or heteroaryl, wherein said phenyl or heteroaryl group is optionally substituted, one or more times, independently of each other, with halogen, C+- Cs-haloalkyl, or Ci-Ca-alkoxy; R'® represents hydrogen, C+-Cs-alkyl, or phenyl-CHa-; R' represents 5- to 6-membered heterocycloalkyl-(C-Ca-alkyl)-; R'2 represents Ci-Cs-alkyl; R™® represents Ci-Cs-alkyl, (C1-Cs-alkoxy)-(C1-Cs-alkyl)-, C4-Cs-alkyl-(C=0)-, Cs-Ces- cycloalkyl, or phenyl, wherein said Ca-Cs-cycloalkyl group is optionally substituted with methyl or hydroxy; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

3. The compound according to claim 1 or 2, wherein: R! represents hydrogen, methyl or trifluoromethyl; R2 represents hydrogen or methyl; or R' and R? together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; R? represents cyclopropyl, 4- to 6-membered heterocycloalkyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, or heteroaryl, wherein said groups are optionally substituted, one or more times, independently of each other, with R®, or R? represents phenyl, which is optionally substituted, one or more times, independently of each other, with R®, and additionally R? and R represent deuterium; R* represents hydrogen, methyl, Ci-haloalkyl or cyclopropyl; R® represents hydrogen; R® represents methoxy-ethyl, 5-membered heteroaryl, 4- to 6-membered heterocycloalkyl-(C-Cz-alkyl)-, heterospirocycloalkyl-methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl, or 5- to 6-membered heteroaryl-(C+- Cz-alkyl)-, wherein said 4- to 6-membered heterocycloalkyl or heteroaryl groups are optionally substituted, one or more times, independently of each other, with RS: R™ represents hydrogen, deuterium, or methyl: R™ represents hydrogen, deuterium, or methyl: Re represents fluoro, chloro, Ci-Cz-alkyl, trifluoromethyl, C1-Cs-alkoxy, cyclopropyl, cyclopropylmethyl, R'*-(C=0)-, R'*-0-(C=0)-, R""-NH-(C=0)-, or R'-(SO)-; R® represents fluoro, chloro, C-Cs-alkyl, trifluoromethyl, cyclopropyl, or oxo; R'® represents Ci-Cs-alkyl, or phenyl-CHz-; R" represents 5- to 6-membered heterocycloalkyl-methyl; R'2 represents methyl; R™ represents methyl, methoxymethyl, ethyl-(C=0)-, cyclopropyl, or phenyl, wherein said cyclopropyl group is optionally substituted with methyl or hydroxy; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

4. The compound according to claim 1, 2 or 3, wherein: R! represents hydrogen or methyl; R? represents hydrogen or methyl: or R' and R? together with the carbon atom to which they are attached form a 3- to 4-membered cycloalkyl ring; R? represents cyclopropyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yl, oxetan-3-yl, oxolan-3-yl, oxolan-2-yl, 3-methyloxetan-3-yl, 3-fluorooxetan-3-yl, pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, oxan-4-yl, 1,4-dioxan-2-yl, 6-methylpyridin-3-yl, 5- methylpyridin-2-yl, 3-methylpyridin-2-yl, 2-methylpyridin-4-yl, 6-methylpyridin-2- yl, 3-chloropyridin-2-yl, 6-ethylpyridin-3-yl, 1-acetylpiperidin-4-yl, 3-chloro-5- ethoxypyridin-2-yl, 1-benzoylpiperidin-4-yl, or a group selected from: Pe 0 boi \,.7 N of x ¥ C) 0 N HN: CH 4 i A CHa 1 A CHj AN + AN 7 [oo 1 F Ox A NA F SN | | rf = JF © i A a ~ CH; H H ofc “So 7 ) ls o LO ~~ © © 1 A Sy N AN ba < hd “XK or 4 So ” HC. N PEN CL A SN O° A ~~ ~~ oC. © NT oA OH ZN x o HN $ x i Me AN Ay hg , or ~~ , or represents phenyl, and additionally R7 and R™ represent deuterium; represents methyl, difluoromethyl, trifluoromethyl, or cyclopropyl; represents hydrogen; R® represents (oxolan-2-yl)methyl, (1,3-oxazol-4-yl)methyl, (1,2-oxazol-3-yl)methyl, (4-methyloxolan-2-yl)methyl, (pyrimidin-2-yl)methyl, (pyrazin-2-yl)methyl, (5- methyloxolan-2-yl)methyl, (5-methyloxolan-2-yl)methyl, (1,4-dioxan-2-yl)methyl, (4-methylphenyl)methyl, (5-methylpyrimidin-2-yl)methyl, (5-methylpyrazin-2- yl)methyl, (5-chloropyrazin-2-yl)methyl, (5-cyclopropyl-pyrazin-2-yl)methyl, 2,3- dihydro[1,4]dioxino[2,3-b]pyridin-2-yimethyl, 1,3-oxazol-2-ylmethyl, 1,3-thiazol-2- yimethyl, (1-methyl-1H-pyrazol-3-yl)methyl, (1-methyl-1H-imidazol-4-yl)methyl, (5-isopropyl-1,2-oxazol-3-yl)methyl, (5-cyclopropyl-1,2-oxazol-3-yl)methyl, (5,5- dimethyltetrahydrofuran-2-yl)methyl, (4,4-diflucrotetrahydrofuran-2-yl)methyl, (6,6-dimethyl-1,4-dioxan-2-yl)methyl, 5-oxaspiro[2.4]heptan-6-ylmethyl, or 2,6- dioxaspiro[3.4]octan-7-yimethyl; R™ represents hydrogen; R™ represents hydrogen; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

5. The compound according to claim 1, 2, 3, or 4 which is selected from the group consisting of: 2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-yimethyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-[(4-methylphenyl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-2-(pyridin-2-yImethyl)-N-[(2R / S)-tetrahydrofuran-2-yimethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-(pyridin-2-yImethyl)-N-[(2R)-tetrahydrofuran-2-yImethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-(pyridin-2-yImethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-N-[2-(4-methylpiperazin-1-yl)ethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(1,2,4-oxadiazol-3-yl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-N-(1,2-oxazol-3-yImethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2- (pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(5-methyl-1,2-oxazol-3-yl)methyl]-2-(pyridin-2-yImethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R / S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yimethyl]-8-methyl-2-(pyridin-2- yimethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7-carboxamide N-[(2R)-2,3-dihydro[1,4]dioxino[2, 3-b]pyridin-2-yImethyl]-8-methyl-2- (pyridin-2-ylmethyl)- 4 5-dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(28)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-(pyridin-2-yimethyl)- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide N-(2-hydroxy-2-methylpropyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-{[5-(morpholin-4-ylmethyl)-1,2-oxazol-3-ylJmethyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-(pyridin-2-yImethyl)-N-(2-{4-[5- (trifluoromethyl) pyridin-2-yl]piperazin-1- yl}ethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-(pyridin-2-yImethyl)-N-(2-{4-[3-(trifluoromethyl)phenyllpiperazin-1-yl}ethyl)- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide N-{[5-(3-methoxyphenyl)-1,2-oxazol-3-ylJmethyl}-8-methyl-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-4-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide N-{[5-(2-chlorophenyl)-1,2-oxazol-3-yl]methyl}-8-methyl-2-(pyridin-2-yImethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(5-isopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2- (pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide N-{[(2S)-1,4-dioxan-2-y]Jmethyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-(pyridin-2-yImethyl)-N-(4H-1,2,4-triazol-3-yImethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N,2-bis(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 8-methyl-N-(1H-pyrazol-3-yImethyl)-2-(pyridin-2-yImethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-2-(pyridin-2-yImethyl)-N-(1,3-thiazol-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-(1,2-oxazol-4-yImethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-2-(pyridin-2-yImethyl)-N-{[5-(trifluoromethyl)-1,2-oxazol-3-yl]methyl}-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(4-methyl-1,2-oxazol-3-yl)methyl]-2-(pyridin-2-yImethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[2-(3,3-dimethyl-2-oxoazetidin-1-yl)ethyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide N-(2-methoxyethyl)-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2, 3-g]indazole- 7-carboxamide [(2R / S)-2-(aminomethyl)pyrrolidin-1-yl][8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-glindazol-7-ylJmethanone [(2R)-2-(aminomethyl)pyrrolidin-1-yl][8-methyl-2-(pyridin-2-yImethyl)-4,5-dihydro-2H- furo[2,3-glindazol-7-ylJmethanone [(2S)-2-(aminomethyl)pyrrolidin-1-yl][8-methyl-2-(pyridin-2-yimethyl)-4,5-dihydro-2H- furo[2,3-glindazol-7-ylJmethanone 3-[({[8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-g]indazol-7- yl]carbonyl}amino)methyl]-1,2-oxazole-4-carboxylic acid 8-methyl-N-(1,3-oxazol-2-yImethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-2-(pyridin-2-yImethyl)-N-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-(pyridin-2-ylmethyl)-N-[(3R)-tetrahydrofuran-3-yImethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-(pyridin-2-yImethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(2R / S)-oxetan-2-yimethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-[(2R)-oxetan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-[(2S)-oxetan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-(oxetan-3-yImethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide N-[(3-fluorooxetan-3-yl)methyl]-8-methyl-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-{[(2R / S)-4-methylmorpholin-2-ylJmethyl}-2- (pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-{[(2R)-4-methylmorpholin-2-yl|methyl}-2-(pyridin-2-yimethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-N-{[(2S)-4-methylmorpholin-2-yljmethyl}-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-N-{[(2R / S)-5-oxotetrahydrofuran-2-ylJmethyl}-2-(pyridin-2-ylmethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-{[(2R)-5-oxotetrahydrofuran-2-ylJmethyl}-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-{[(2S)-5-oxotetrahydrofuran-2-yl|methyl}-2-(pyridin-2-ylmethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-(1-methyl-1H-pyrazol-3-yl)-2-(pyridin-2-yImethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-(pyridin-3-yl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2, 3-g]indazole-7- carboxamide 8-methyl-N-(2-phenylethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2,3-gJindazole-7- carboxamide N-(4-cyanophenyl)-8-methyl-2-(pyridin-2-yImethyl)-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide 8-methyl-2-(pyridin-3-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4, 5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylImethyl]-8-methyl-2-(pyridin-3-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-2-(pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4, 5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylImethyl]-8-methyl-2-(pyridin-4-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 2-(cyclopropylmethyl)-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 2-(cyclopropylmethyl)-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-2-[(2R / S)-2,3-dihydro[1,4]dioxino[2, 3- b]pyridin-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2, 3-glindazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-2-[(2R)-2,3-dihydro[ 1,4]dioxino[2,3-b]pyridin-2- yimethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2- yimethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-g]indazole-7-carboxamide 2-[(2R / S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2R / S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2, 3-gJindazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yImethyl]-8-methyl-N-[(2R / S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxamide 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yImethyl]-8-methyl-N-[(2R / S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2, 3-gJindazole-7-carboxamide 2-[(2R / 8)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yimethyl]-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2, 3-glindazole-7-carboxamide 2-[(28)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[(2S)- tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxamide 2-[(2R / S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(4-methylbenzyl)- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2, 3-b]pyridin-2-yImethyl]-8-methyl-N-(4-methylbenzyl)- 4 5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(28)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(4-methylbenzyl)- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(2R / S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-[2-(4- methylpiperazin-1-yl)ethyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2, 3-b]pyridin-2-yImethyl]-8-methyl-N-[2-(4- methylpiperazin-1-yl)ethyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxamide 2-[(2S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yImethyl]-8-methyl-N-[2-(4- methylpiperazin-1-yl)ethyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxamide 2-[(2R / 8)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yimethyl]-8-methyl-N-(1,2-oxazol-3- yimethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7-carboxamide 2-[(2R)-2,3-dihydro[1,4]dioxino[2, 3-b]pyridin-2-ylmethyl]-8-methyl-N-(1,2-oxazol-3- yimethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7-carboxamide 2-[(28)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-N-(1,2-oxazol-3- yimethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7-carboxamide 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-{[6-(trifluoromethyl)pyridin-2-ylJmethyl}- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-{[5-(trifluoromethyl)pyridin-2-ylJmethyl}- 4 5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(3-chloro-5-fluoropyridin-2-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-yimethyl]- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(3-chloro-5-ethoxypyridin-2-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4 5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(3-chloropyridin-2-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-yimethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(3-chloropyridin-2-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(3-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-yimethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3-methylpyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(5-methylpyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[(2R / S)-tetrahydrofuran-2-yimethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[2-(azetidin-1-yl)ethyl]-8-methyl-2-[(B-methylpyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-8-methyl-2-[(6-methylpyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-[2-(pyrrolidin-1-yl)ethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R / S)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-yimethyl]-8-methyl-2-[(6-methylpyridin- 2-yl)methyl]-4,5-dihydro-2H-furo[2, 3-glindazole-7-carboxamide N-[(2R)-2,3-dihydro[1,4]dioxino[2, 3-b]pyridin-2-yImethyl]-8-methyl-2-[(6-methylpyridin-2- yl)methyl]-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(28)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin-2-ylmethyl]-8-methyl-2-[(6-methylpyridin-2- yl)methyl]-4,5-dihydro-2H-furo[2,3-gJindazole-7-carboxamide 8-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-[(6-methylpyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-2-yl)methyl]-N-(1,3-oxazol-2-yImethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(2-methylpyridin-3-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2-methylpyridin-3-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(6-methylpyridin-3-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(6-methylpyridin-3-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 2-[(2,6-dimethylpyridin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(2,6-dimethylpyridin-3-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(2-methylpyridin-4-yl)methyl]-N-[(2S)-tetrahydrofuran-2-yimethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2-methylpyridin-4-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 2-[(2,6-dimethylpyridin-4-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(2,6-dimethylpyridin-4-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-(pyrimidin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-yimethyl]-8-methyl-2-(pyrimidin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-(pyrimidin-5-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4, 5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-yimethyl]-8-methyl-2-(pyrimidin-5-ylmethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 2-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-yimethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N,2-bis[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxamide 2-[(2S)-1,4-dioxan-2-ylmethyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2-[(2S)-1,4-dioxan-2-ylmethyl]-8-methyl-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-(oxetan-3-ylmethyl)-N-[(2S)-tetrahydrofuran-2-yimethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-(oxetan-3-ylmethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-2-[(3-methyloxetan-3-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3-methyloxetan-3-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 2-[(3-fluorooxetan-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2-[(3-fluorooxetan-3-yl) methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(2R)-oxetan-2-yImethyl]-N-[(2S)-tetrahydrofuran-2-yImethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(2R)-oxetan-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(2S)-oxetan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-yimethyl]-8-methyl-2-[(2S)-oxetan-2-yimethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-{[(2R)-4-methylmorpholin-2-ylJmethyl}-N-[(2S)-tetrahydrofuran-2-ylimethyl}- 4 5-dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylimethyl]-8-methyl-2-{[(2R)-4-methylmorpholin-2-yljmethyl}-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-{[(2S)-4-methylmorpholin-2-ylJmethyl}-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-yimethyl]-8-methyl-2-{[(2S)-4-methylmorpholin-2-yl]methyl}-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-yimethyl]-8-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N,2-bis[(28S)-tetrahydrofuran-2-yimethyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide N-[(2R)-1,4-dioxan-2-yImethyl]-8-methyl-2-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide tert-butyl 3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-yImethyl]carbamoyl}-4,5-dihydro-2H- furo[2,3-glindazol-2-yl)methyllazetidine-1-carboxylate tert-butyl 3-[(7-{[(2R)-1,4-dioxan-2-yImethyl]carbamoyl}-8-methyl-4,5-dihydro-2H- furo[2,3-glindazol-2-yl)methyllazetidine-1-carboxylate 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-[(3R)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2-[(3R)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-yImethyl]-8-methyl-2-[(3S)-tetrahydrofuran-3-ylmethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-8- (trifluoromethyl)-4, 5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-cyclopropyl-2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-cyclopropyl-N-[(2R)-1,4-dioxan-2-ylmethyl]-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-cyclopropyl-N-[(1-methyl-1H-pyrazol-3-ylmethyl]-2-(pyridin-2-yImethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-cyclopropyl-N-(1,3-oxazol-2-ylmethyl)-2-(pyridin-2-ylmethyl)-4,5-dihydro-2H-furo[2, 3- glindazole-7-carboxamide 8'-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2'-(pyridin-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 8'-methyl-N-(1,3-oxazol-2-yImethyl)-2'-(pyridin-2-yImethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-yimethyl]-2'-[(2S)-1,4-dioxan-2-yImethyl]-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-(1,3-oxazol-2-ylmethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-(cyclopropylmethyl)-8'-methyl-N-[(2S)-tetrahydrofuran-2-yimethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-(cyclopropylmethyl)-N-[(2S)-1,4-dioxan-2-yImethyl]-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-(cyclopropylmethyl)-N-[(2R)-1,4-dioxan-2-yImethyl]-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 8'-methyl-2'-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-[(2S)-1,4-dioxan-2-yImethyl]-8'-methyl-2'-(pyridin-2-yImethyl)-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-2-yImethyl)-2' 5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-glindazole]-7'-carboxamide 8-methyl-2-[phenyl(2H2)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4, 5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl-2- [phenyl (2H2)methyl]-4, 5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2- yimethyl]-4,5-dihydro-2H-furo[2, 3-g)indazole-7-carboxamide 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-N-[(2R)-1,4-dioxan-2-ylmethyl]-8-methyl- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide tert-butyl [2-(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyljcarbamoyl}-4, 5-dihydro-2H- furo[2,3-glindazol-2-yl)ethyl]carbamate tert-butyl [2-(7-{[(2R)-1,4-dioxan-2-yImethyl]carbamoyl}-8-methyl-4,5-dihydro-2H- furo[2,3-glindazol-2-yl)ethyl]carbamate tert-butyl 4-[2-(8-methyl-7-{[(2S)-tetrahydrofuran-2-yimethyl]carbamoyl}-4,5-dihydro-2H- furo[2,3-glindazol-2-yl)ethyl]piperazine-1-carboxylate tert-butyl 4-[2-(7-{[(2R)-1,4-dioxan-2-ylmethyl]carbamoyl}-8-methyl-4,5-dihydro-2H- furo[2,3-glindazol-2-yl)ethyl]piperazine-1-carboxylate 2'-[(2S)-1,4-dioxan-2-ylmethyl]-8'-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-glindazole]-7'-carboxamide N,2'-bis[(2S)-1,4-dioxan-2-yImethyl]-8'-methyl-2',5-dihydrospiro[cyclobutane-1,4'- furo[2,3-glindazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2'-[(2S)-1,4-dioxan-2-yimethyl]-8'-methyl-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-gJindazole]-7'-carboxamide 8-methyl-N-[(2S)-tetrahydrofuran-2-yimethyl]-2-[(6-{{(2S)-tetrahydrofuran-2- ylmethyl]carbamoyl}pyridin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3-g]indazole-7- carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2-[(6-{[(2R)-1,4-dioxan-2-ylmethyl]carbamoyl}pyridin-3- yl)methyl]-8-methyl-4,5-dihydro-2H-furo[2, 3-glindazole-7-carboxamide 4,4,8-trimethyl-2-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-yimethyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8'-methyl-2'-(pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-yimethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-2-yImethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 8'-methyl-2'-(pyridin-3-ylmethyl)-N-[(2S)-tetrahydrofuran-2-yimethyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-8'-methyl-2'-(pyridin-3-yImethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide NZ? ,N? 8'-trimethyl-N"-[(2S)-tetrahydrofuran-2-ylmethyl]spiro[cyclopropane-1,4'-furo[2, 3- glindazole]-2',7'(5'H)-dicarboxamide N7-[(2R)-1,4-dioxan-2-ylmethyl]-N? N? 8'-trimethylspiro[cyclopropane-1,4'-furo[2,3- glindazole]-2',7'(5'H)-dicarboxamide benzyl 3-fluoro-3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyljcarbamoyl}-4,5-dihydro- 2H-furo[2,3-gJindazol-2-yl)methyllazetidine-1-carboxylate benzyl 3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]jcarbamoyl}-4,5-dihydro-2H- furo[2,3-glindazol-2-yl)methyllazetidine-1-carboxylate 2-[(3-fluoroazetidin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-yimethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-(azetidin-3-ylmethyl)-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 2-(azetidin-3-ylmethyl)-N-[(2R)-1,4-dioxan-2-yImethyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 2-(2-aminoethyl)-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 2-(2-aminoethyl)-N-[(2R)-1,4-dioxan-2-yImethyl]-8-methyl-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-2-[2-(piperazin-1-yl)ethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-yimethyl]-8-methyl-2-[2-(piperazin-1-yl)ethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 2-[(1-acetylazetidin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-yimethyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(1-acetyl-3-fluoroazetidin-3-yl)methyl]-8-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[3-fluoro-1-(methylsulfonyl)azetidin-3-ylJmethyl}-8-methyl-N-[(2S)-tetrahydrofuran-2- yimethyl]-4,5-dihydro-2H-furo[2, 3-g)indazole-7-carboxamide methyl 3-fluoro-3-[(8-methyl-7-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}-4,5-dihydro- 2H-furo[2,3-glindazol-2-yl)methyl]azetidine-1-carboxylate 2'-[(2S)-1,4-dioxan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'- (trifluoromethyl) 2' 5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-{[(2R)-1,4-dioxan-2-yl|]methyl}-2'-{[(2S)- 1,4-dioxan-2-yljmethyl}-8'-(trifluoromethyl)- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-{[(21)-5,5-dimethyloxolan-2-ylJmethyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(oxan-4-yl)methyl]-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-{[(21)-oxan-2-yl]methyl}-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-N-{[(21)-2-methyloxolan-2-yl|methyl}-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-{[(21)-4,4-difluorooxolan-2-ylJmethyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-[(4-methyltetrahydrofuran-2-yl)methyl]-2-(2-pyridylmethyl)-4,5- dihydrofuro[2,3-gJindazole-7-carboxamide 8-methyl-N-{[(21,51)-5-methyloxolan-2-yllmethyl}-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 2,5-anhydro-1,3,4-trideoxy-3-methyl-1-({8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carbonyl}amino)-D-threo-pentitol (Racemate) 8-methyl-N-{[(61)-5-oxaspiro[2.4]heptan-6-ylJmethyl}-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-{[(21)-3,3-dimethyloxolan-2-ylJmethyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide N-{[(61)-2,5-dioxaspiro[3.4]octan-6-ylJmethyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-{[(24)-6,6-dimethyl-1,4-dioxan-2-ylJmethyl}-8-methyl-2-[(pyridin-2-yl)methyl]-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(4-fluoropyridin-2-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl|methyl}-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 2-[(5-fluoropyridin-3-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-ylJmethyl}-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-N-{[(2S)-oxolan-2-ylJmethyl}-2-[(pyridazin-3-yl)methyl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-8-methyl-2-[(pyridazin-3-yl)methyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-ylJmethyl}-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(6-ethylpyridin-3-yl)methyl]-8-methyl-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(1,3-oxazol-2-yl)methyl]-N-{[(2S)-oxolan-2-ylJmethyl}-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-ylmethyl}-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 8-methyl-2-{[(2t)-oxan-2-ylJmethyl}-N-{[(2S)-oxolan-2-yllmethyl}-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(6-methylpyridin-3-yl)methyl]-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-ylJmethy[}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-cyclopropyl-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-yl|methyl}-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-cyclopropyl-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-N-{[(2S)-oxolan-2-ylJmethyl}-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide N-{[(21)-5,5-dimethyloxolan-2-yl]methyl}-2'-{[(2S)-1,4-dioxan-2-yl|methyl}-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-{[(21)-6,6-dimethyl-1,4-dioxan-2-ylJmethyl}-2'-{[(2S)-1,4-dioxan-2-yl|methyl}-8'-methyl- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-{[(24)-4,4-difluorooxolan-2-ylJmethyl}-2'-{[(2S)-1,4-dioxan-2-yljmethyl}-8'-methyl-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-{[(2S)-1,4-dioxan-2-ylJmethyl}-8"-methyl-N-{[(2t,5t)-5-methyloxolan-2-ylJmethyl}-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2-[[(2S)-1,4-dioxan-2-yllmethyl]-8-methyl-N-[(4-methyltetrahydrofuran-2- yl)methyl]spiro[5H-furo[2,3-glindazole-4,1'-cyclopropane]-7-carboxamide 2'-{[(2S)-1,4-dioxan-2-ylJmethyl}-8'-methyl-N-{[(6)-5-oxaspiro[2.4]heptan-6-ylimethyl}- 2' 5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-{[(2S)-1,4-dioxan-2-yl]methyl}-N-{[(64)-2,5-dioxaspiro[3.4]octan-6-yllmethyl}-8'- methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2, 3-glindazole]-7'-carboxamide 2'-{[(2S)-1,4-dioxan-2-ylJmethyl}-N-{[(6R)-2,5-dioxaspiro[3.4]octan-6-ylJmethyl}-8'- methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2, 3-glindazole]-7'-carboxamide 2'-{[(2S)-1,4-dioxan-2-ylJmethyl}-N-{[(6S)-2,5-dioxaspiro[3.4]octan-6-yljmethyl}-8'- methyl-2',5'-dihydrospiro[cyclopropane-1,4'-furo[2, 3-glindazole]-7'-carboxamide 8'-Methyl-2'-(pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-yimethyl]-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2, 3-glindazol]-7'-carboxamide 8'-Methyl-2'-[(5-methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-glindazol]-7'-carboxamide N-{{(2R)-1,4-dioxan-2-yl]methyl}-8'-methyl-2'-[(6-methylpyridin-3-yl)methyl]-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 8'-methyl-2'-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yljmethyl}-2',5"- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2'-[(6-methylpyridin-3-yl)methyl]-8'- (trifluoromethyl)- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxclan-2-ylJmethyl}-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide 2'-[(5-methylpyridin-2-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2'-[(5-methylpyridin-2-yl)methyl]-8'- (trifluoromethyl)- 2',5'-dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-4-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclopropan-1,4'-furo[2,3-glindazol]-7'-carboxamide 2'-(Pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylimethyl]-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclopropan-1,4'-furo[2, 3-glindazol]-7'-carboxamide N-{[(2S)-oxolan-2-ylJmethyl}-2'-[(pyridin-2-yl)methyl]-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclopropane-1,4'-furo[2,3-glindazole]-7'-carboxamide N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-2-yimethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclopropan-1,4'-furo[2, 3-glindazol]-7'-carboxamide N,2-bis{[(2R)-1,4-dioxan-2-yl]methyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 2-{[(28)-1,4-dioxan-2-ylJmethyl}-N-{[(2S)-oxolan-2-yljmethyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-{[(21)-4,4-difluorooxolan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-ylJmethy}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide N-{[(2R)-4,4-difluorooxolan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide N-{[(2S)-4,4-difluorooxolan-2-yljmethyl}-2-{[(2S)-1,4-dioxan-2-yl]methy}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide N-{[(21)-5,5-dimethyloxolan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide N-{{(2R)-5,5-dimethyloxolan-2-ylJmethyl}-2-{{(2S)-1,4-dioxan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide N-{[(2S)-5,5-dimethyloxolan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-ylJmethyl}-N-{[(2+, 51)-5-methyloxolan-2-yllmethyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-ylmethyl}-N-{{(2R, 5R)-5-methyloxolan-2-yljmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-ylJmethyl}-N-{[(2S, 5R)-5-methyloxolan-2-yljmethyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-ylmethyl}-N-{{(2R, 5S)-5-methyloxolan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-ylmethyl}-N-{{(2S, 5S)-5-methyloxolan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(28)-1,4-Dioxan-2-yimethyl]-N-(1,3-thiazol-2-ylmethyl)-8-(trifluormethyl)-4,5-dihydro- 2H-furo[2,3-gJindazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[(5-methylpyrazin-2-yl)methyl]-8-(trifluormethyl)-4, 5- dihydro-2H-furo[2,3-glindazol-7-carboxamide 2-[(28)-1,4-Dioxan-2-yimethyl]-N-(pyrazin-2-ylmethyl)-8-(trifluormethyl)-4,5-dihydro-2H- furo[2,3-glindazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[(1-methyl-1H-imidazol-4-yl)methyl]-8-(trifluormethyl)- 4 5-dihydro-2H-furo[2,3-glindazol-7-carboxamide 2-[(28)-1,4-Dioxan-2-yimethyl]-N-(1,3-thiazol-5-ylmethyl)-8-(trifluormethyl)-4,5-dihydro- 2H-furo[2,3-glindazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(4-methylpyridin-2-yl)ethyl]-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-glindazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(pyridin-2-yl)ethyl]-8-(trifluormethyl)-4,5-dihydro-2H- furo[2,3-glindazol-7-carboxamide 2-[(28)-1,4-Dioxan-2-yimethyl]-N-[2-(3-methyl-1H-pyrazol-1-yl)ethyl]-8-(trifluormethyl)- 4,5-dihydro-2H-furo[2,3-glindazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(1H-imidazol-4-yl)ethyl]-8- (trifluormethyl)-4,5- dihydro-2H-furo[2,3-glindazol-7-carboxamide 2-[(28)-1,4-Dioxan-2-yimethyl]-N-[2-(pyridin-3-yl)ethyl]-8-(trifluormethyl)-4,5-dihydro-2H- furo[2,3-glindazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-ylmethyl]-N-[2-(1,3-thiazol-2-yl)ethyl]-8-(trifluormethyl)-4,5-dihydro- 2H-furo[2,3-gJindazol-7-carboxamide 2-[(28)-1,4-Dioxan-2-yimethyl]-N-[(B-methylpyridin-2-yl)methyl]-8-(trifluormethyl)-4,5- dihydro-2H-furo[2,3-glindazol-7-carboxamide 2-[(2S)-1,4-Dioxan-2-yimethyl]-N-(1,3-oxazol-4-ylmethyl)-8-(trifluormethyl)-4,5-dihydro- 2H-furo[2,3-gJindazol-7-carboxamide 2-{[(28)-1,4-dioxan-2-ylJmethyl}-N-[2-(pyrazin-2-yl)ethyl]-8-(trifluoromethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(oxan-4-yl)methyl]-8-(trifluoromethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide 2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-ylJmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-(difluoromethyl)-N-{[(2R)-1,4-dioxan-2-yl|methyl}-2-{{(2S)-1,4-dioxan-2-y]Jmethyl}-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-(difluoromethyl)-2-{[(2S)-1,4-dioxan-2-yllmethyl}-N-{[(2S)-oxclan-2-ylJmethyl}-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide (41)-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-4,8-dimethyl-2-[(pyridin-2-yl)methyl]-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide (4t)-4,8-dimethyl-N-{[(2S)-oxolan-2-yljmethyl}-2-[(pyridin-2-yl)methyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide (41)-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4,8-dimethyl-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide (41)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4,8-dimethyl-N-{[(2S)-oxolan-2-yljmethyl}-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide (44)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(pyridin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (41)-4-methyl-2-[(5-methyl-2-pyridyl)methyl]-N-[[(2S)-tetrahydrofuran-2-ylJmethyl]-8- (trifluoromethyl)-4,5-dihydrofuro[2, 3-g]indazole-7-carboxamide (44)-N-{[(2R)-1,4-dioxan-2-ylmethyl}-4-methyl-2-[(6-methylpyridin-3-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (41)-4-methyl-2-[(6-methylpyridin-3-yl)methyl]-N-{[(2S)-oxolan-2-yllmethyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (41)-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-yl[Jmethyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yllmethyl}-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (41)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-{[(2S)-oxolan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylImethyl}-4-methyl-N-{{(2S)-oxolan-2-yljmethyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl|methyl}-4-methyl-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(1,3-oxazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-2-{[(2S)-1,4-dioxan-2-yllmethy}-4-methyl-N-[(1,3-oxazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-2-{[(2S)-1,4-dioxan-2-yl|methyl}-4-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-gJindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(5-methylpyrazin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-2-{[(2S)-1,4-dioxan-2-yl|methyl}-4-methyl-N-[(5-methylpyrazin-2-yl) methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(1,3-thiazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-2-{[(28S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(1,3-thiazol-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylImethyl}-4-methyl-N-[(pyrazin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(pyrazin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(1,3-0xazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-2-{[(28S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(1,3-oxazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-8-(trifluoromethyl)-N-{[2- (trifluoromethyl)pyrimidin-5-yl]methyl}-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-yl|methyl}-4-methyl-8-(trifluoromethyl)-N-{[2- (trifluoromethyl)pyrimidin-5-yl]methyl}-4,5-dihydro-2H-furo[2,3-glindazole-7- carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-[(oxan-4-yl)methyl]-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yl|methyl}-4-methyl-2-[(oxan-4-yl)methyl]-8-(trifluioromethyl)- 4 5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-4-methyl-2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-yl|methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-4-methyl-2-[(oxan-4-yl)methyl]-N-{[(2S)-oxolan-2-ylJmethyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide (44)-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8-methyl-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-yl[Jmethyl}-8-methyl-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yllmethyl}-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8-methyl-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4t)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8-methyl-N-{[(2S)-oxolan-2-ylJmethyl}-4- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8-methyl-N-{[(2S)-oxolan-2-yllmethyl}-(4R)-4- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl]methyl}-8-methyl-N-{[(2S)-oxolan-2-yl|methyl}-(4S)-4- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide N-{{(2R)-1,4-dioxan-2-yl]methyl}-2-{{(2S)-1,4-dioxan-2-yl]methyl}-4,4-dimethyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[(2S)-1,4-dioxan-2-yl|methyl}-4,4-dimethyl-N-{[(2S)-oxolan-2-yl|methyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide N-[(2R)-1,4-dioxan-2-ylmethyl]-2'-[(2S)-1,4-dioxan-2-yimethyl]-8'- (trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2, 3-glindazol]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-8'-(trifluormethyl)- 2' 5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-glindazol]-7'-carboxamide 2'-[(2S)-1,4-dioxan-2-ylmethyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'- (trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2, 3-glindazol]-7'-carboxamide 2'-{[(2S)-1,4-dioxan-2-ylJmethyl}-N-[(1,3-oxazol-2-yl)methyl]-8'-(trifluoromethyl)-2',5'- dihydrospiro[cyclobutane-1,4'-furo[2,3-gJindazole]-7'-carboxamide N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-glindazol]-7'-carboxamide 2'-(Pyridin-2-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylimethyl]-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2, 3-glindazol]-7'-carboxamide N-(1,3-Oxazol-2-ylmethyl)-2'-(pyridin-2-ylmethyl)-8'- (trifluormethyl)-2', 5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-glindazol]-7'-carboxamide N-[(1-Methyl-1H-pyrazol-3-yl)methyl]-2'-(pyridin-2-ylmethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2, 3-glindazol]-7'-carboxamide 2'-[(5-Methylpyridin-2-yl)methyl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)- 2' 5'-dihydrospiro[cyclobutan-1,4'-furo[2,3-glindazol]-7'-carboxamide N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-[(5-methylpyridin-2-yl)methyl]-8'-(trifluormethyl)-2' 5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-glindazol]-7'-carboxamide N-[(1-Methyl-1H-pyrazol-3-yl)methyl]-2'-[(6-methylpyridin-2-yl)methyl]-8'- (trifluormethyl)- 2',5'-dihydrospiro[cyclobutan-1,4'-furo[2, 3-glindazol]-7'-carboxamide 2'-(Pyridin-4-ylmethyl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-glindazol]-7'-carboxamide N-[(2R)-1,4-Dioxan-2-ylmethyl]-2'-(pyridin-4-yimethyl)-8'-(trifluormethyl)-2',5'- dihydrospiro[cyclobutan-1,4'-furo[2,3-glindazol]-7'-carboxamide 2-(cyclopropylmethyl)-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-8-(trifluoromethyl)-4,5-dihydro- 2H-furo[2,3-glindazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[1-(methoxyacetyl)piperidin-4-yl]methy}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[1-(methoxyacetyl)piperidin-4-yllmethyl}-N-{[(2S)-oxolan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[1-(cyclopropanecarbonyl)piperidin-4-ylJmethyl}-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[1-(cyclopropanecarbonyl)piperidin-4-ylJmethyl}-N-{{(2S)-oxolan-2-yljmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(1-benzoylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-yl|methyl}-8-(trifluoromethyl)- 4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(1-benzoylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-ylJmethyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-{[(2S)-oxolan-2-ylJmethyl}-2-[2-(pyridin-3-yl)propan-2-yl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide (4R)-2-{[1-(cyclopropanecarbonyl)piperidin-4-ylJmethyl}-4-methyl-N-{[(2S)-oxolan-2- yllmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-2-{[1-(cyclopropanecarbonyl)piperidin-4-yljmethyl}-4-methyl-N-{[(2S)-oxolan-2- yllmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[1-(cyclopropanecarbonyl)piperidin-4-ylJmethyl}-N-{[(2R)-1,4-dioxan-2- yllmethyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7- carboxamide (4S)-2-{[1-(cyclopropanecarbonyl)piperidin-4-ylJmethyl}-N-{[(2R)-1,4-dioxan-2- yllmethyl}-4-methyl-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7- carboxamide (4R)-2-[(1-acetylpiperidin-4-yl)methyl]-4-methyl-N-{[(2S)-oxolan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-2-[(1-acetylpiperidin-4-yl)methyl]-4-methyl-N-{[(2S)-oxolan-2-yljmethy[}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[1-(1-hydroxycyclopropane-1-carbonyl)piperidin-4-ylJmethyl}-4-methyl-N-{[(2S)- oxolan-2-ylJmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7- carboxamide (48)-2-{[1-(1-hydroxycyclopropane- 1-carbonyl)piperidin-4-yljmethyl}-4-methyl-N-{[(2S)- oxolan-2-ylJmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7- carboxamide (4R)-2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-4-methyl-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2R)- 1,4-dioxan-2-ylJmethy[}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-{[1-(1-hydroxycyclopropane-1- carbonyl)piperidin-4-yllmethyl}-4-methyl-8-(trifluoromethyl)-4, 5-dihydro-2H-furo[2, 3- glindazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-2-{[1-(1-hydroxycyclopropane-1- carbonyl)piperidin-4-ylJmethyl}-4-methyl-8-(trifluoromethyl)-4, 5-dihydro-2H-furo[2, 3- glindazole-7-carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4- yllmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yllmethyl}-4-methyl-2-{{ 1-(2-oxobutanoyl)piperidin-4- yllmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4-yljmethyl}-N-{[(2S)-oxolan-2-ylJmethyl}- 8-(trifluoromethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7-carboxamide (4S)-4-methyl-2-{[1-(2-oxobutanoyl)piperidin-4-yljmethyl}-N-{{(2S)-oxolan-2-yljmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2, 3-glindazole-7-carboxamide (4R)-4-methyl-2-{[1-(1-methylcyclopropane-1-carbonyl)piperidin-4-ylmethyl}-N-{[(2S)- oxolan-2-ylJmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7- carboxamide (4S)-4-methyl-2-{{1-(1-methylcyclopropane- 1-carbonyl)piperidin-4-ylJmethyl}-N-{[(2S)- oxolan-2-ylJmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2, 3-glindazole-7- carboxamide (4R)-N-{[(2R)-1,4-dioxan-2-yl]methyl}-4-methyl-2-{[1-(1-methylcyclopropane-1- carbonyl)piperidin-4-ylJmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-gJindazole-7- carboxamide (4S)-N-{[(2R)-1,4-dioxan-2-yllmethyl}-4-methyl-2-{{1-(1-methylcyclopropane-1- carbonyl)piperidin-4-ylJmethyl}-8-(trifluoromethyl)-4,5-dihydro-2H-furo[2,3-gJindazole-7- carboxamide N,2-bis{[(2S)-1,4-dioxan-2-ylJmethyl}-8-(triflucromethyl)-4, 5-dihydro-2H-furo[2, 3- glindazole-7-carboxamide 2-{[(2R)-1,4-dioxan-2-yl]methyl}-N-{[(2S)-1,4-dioxan-2-ylJmethyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylImethyl}-4-methyl-N-[(2-methylpyrimidin-5-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-2-{[(28)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(2-methylpyrimidin-5-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-g]Jindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(5-methylpyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-2-{[(2S)-1,4-dioxan-2-yllmethyl}-4-methyl-N-[(5-methylpyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-N-[(pyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-2-{[(2S)-1,4-dioxan-2-yllmethy}-4-methyl-N-[(pyrimidin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl|methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(1-acetylpiperidin-4-yl)methyl]-N-{[(2R)- 1,4-dioxan-2-ylJmethyl}-8-(trifluoromethyl)- 4 5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[1-(cyclopropylmethyl)piperidin-4-yl]methyl}-N-{[(2S)-oxolan-2-yl]methyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(1-methylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(1-methylpiperidin-4-yl)methyl]-8-(trifluoromethyl)- 4 5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-{[1-(cyclopropylmethyl)piperidin-4-ylJmethyl}-N-{[(2R)-1,4-dioxan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide 2-[(1-ethylpiperidin-4-yl)methyl]-N-{[(2S)-oxolan-2-yl]methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-yl]methyl}-2-[(1-ethylpiperidin-4-yl)methyl]-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide 2,5-anhydro-1,3,4-trideoxy-1-{{(4R)-2-{[(2S)-1,4-dioxan-2-yl|methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carbonyl]amino}-4-methylpentitol 2,5-anhydro-1,3,4-trideoxy-1-{[(4S)-2-{[(2S)-1,4-dioxan-2-yl|methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carbonyl]amino}-4-methylpentitol (4R)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(1-methyl-1H-imidazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4S)-2-{[(2S)-1,4-dioxan-2-ylmethyl}-4-methyl-N-[(1-methyl-1H-imidazol-4-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(6-methylpyridin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-2-{[(2S)-1,4-dioxan-2-yl|methy}-4-methyl-N-[(6-methylpyridin-2-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-N-[(1,3-thiazol-5-yl) methyl]-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-2-{[(2S)-1,4-dioxan-2-yllmethyl}-4-methyl-N-[(1,3-thiazol-5-yl)methyl]-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide 8-methyl-N-{[(2S)-oxolan-2-ylJmethyl}-2-[(1+)-1-(pyridin-2-yl)ethyl]-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide 8-methyl-2-[(5-methylpyridin-2-yl)methyl]-N-[(3R)-oxolan-3-yl]-4,5-dihydro-2H-furo[2,3- glindazole-7-carboxamide 2-[(5-cyanopyridin-2-yl)methyl]-8-methyl-N-{[(2S)-oxolan-2-yl|methyl}-4,5-dihydro-2H- furo[2,3-glindazole-7-carboxamide N-{[(2R)-1,4-dioxan-2-ylJmethyl}-2-{[(2S)-1,4-dioxan-2-yl|methyl}-8-(trifluoromethyl)-4,5- dihydro-2H-furo[2,3-glindazole-7-carboxamide N-[(5-cyclopropylpyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-N-[(5-cyclopropylpyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl]methyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-N-[(5-cyclopropylpyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-yl|methyl}-4-methyl-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide (4R)-N-[(5-chloropyrazin-2-yl)methyl]-2-{[(2S)- 1,4-dioxan-2-yljmethyl}-4-methyl-8- (trifluoromethyl)-4,5-dihydro-2H-furo[2,3-glindazole-7-carboxamide (48)-N-[(5-chloropyrazin-2-yl)methyl]-2-{[(2S)-1,4-dioxan-2-ylJmethyl}-4-methyl-8- (trifluoromethyl)-4,5-dinydro-2H-furo[2,3-glindazole-7-carboxamide or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

6. A method of preparing a compound of general formula (I) according to any one of claims 1 to 5, said method comprising the step of an intermediate compound of general formula (11): ra R” 7 R Rk NaN r* Il oN N—N Rr? \ 1 \ 0 | I R Oo R R in which R is H, OH, OMe, or OEt and R', R?, R?, R* R"® and R™ are as defined for the compound of general formula (I) according to any one of claims 1 to 4, to react with a compound of general formula (lll): in which R® and R® are as defined for the compound of general formula (I) according to any one of claims 1 to 4, thereby giving a compound of general formula (I): R72 R" 5 w%? R Ne—N rR? 1 a N—R rR N 4 -—N \ 3 \ 0 ; IN R 7 0 N- R R? (0), inwhich R', R R?, R®, R®, R™ and R™ are as defined for the compound of general formula (1) according to any one of claims 1 to 4.

7. A compound of general formula (ll): Rr’ R” 4 R Rk Ne—N Rr: i CN N—N Rr? \ 1 NN 0 | R R oR rR? in which R is H, OH, OMe, or OEt and R', R?, R®, R*, R™ and R™ are as defined for the compound of general formula (I) according to any one of claims 1 to 4, 8. Use of a compound of general formula (11)